netFormulary
 Report : A-Z of formulary items 20/09/2020 02:02:41
[Back]
 
Section Name Details
13.02.01 Emollin® spray 

Only to be prescribed for very painful / fragile skin where "hands on" application of creams or ointments is difficult 

11.08.01 (Cross–linked) sodium hyaluronate, coenzyme Q10 VisuXL®

Consultant Opthalmologist recommendation only - chronic keratitis. 

05.03.01 Abacavir 

Commissioned by NHS England.

05.03.01 Abacavir and Dolutegravir and Lamivudine Triumeq®

Commissioned by NHS England.

05.03.01 Abacavir and Lamivudine Kivexa®

Commissioned by NHS England.

Not first line - see APC HIV protocol

05.03.01 Abacavir and Lamivudine and Zidovudine Trizivir®

Commissioned by NHS England.

10.01.03 Abatacept 

Commissioned by CCGs in line with NICE TA195 (Update of TA36, 126 and 141) and TA375 (replaces TA280)
Subcutaneous abatacept has been approved for its licensed indications in line with NICE criteria for intravenous abatacept
 
In line with NICE TA373-(Commissioned by NHS England)
people 6 years and older whose disease has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs) including at least 1 tumour necrosis factor (TNF) inhibitor.


Funded by NHS England when used for Paediatric Indications where Adult NICE TAs exist.

02.09 Abciximab ReoPro®
08.03.04.02 Abiraterone Zytiga®

Recommended option for metastatic prostate cancer after testosterone reduction therapy and docetaxel in line with NICE TA259.

Abiraterone  is recommended as an option for treating metastatic hormone-relapsed prostate cancer in line with NICE TA387.


Commissioned by NHSE

04.10.01 Acamprosate Calcium 

Prescribing by substance misuse specialists only. This includes GPs with appropriate training / competence who are contracted to provide substance misuse treatment on a shared care basis via a Locally Enhanced Service agreement between GP practices and the substance misuse specialist service provider.

06.01.02.03 Acarbose 
02.08.02 Acenocoumarol 

Only when warfarin, phenindione or DOAC not tolerated / clinically appropriate

11.06 Acetazolamide 250mg tablets  

For glaucoma

 

NOT to be prescribed at NHS expense for altitude sickness.

11.06 Acetazolamide Modified-Release caps 

For glaucoma

 

NOT to be prescribed at NHS expense for mountain sickness.

12.01.01 Acetic Acid 2% Ear Calm ®

  • For acute otitis externa as per antimicrobial guidance.

  • Available Over the Counter. Consider self care.

03.07 Acetylcysteine 

  • For interstitial lung disease/idiopathic pulmonary fibrosis but no longer routinely recommended.

  • Any prescribing for new patients to be retained by secondary care.

  • Primary care prescribing supported for existing patients only, where 600mg effervescent tablets  (NACSYS®)  should be used.

11.08.01 Acetylcysteine 5% with Hypromellose 0.35% eye drops Ilube® Consultant Opthalmologist recommendation only - Severe aqueous tear deficiency e.g Sjögren’s syndrome
05.03.02.01 Aciclovir 
13.10.03 Aciclovir 5% cream 

Patients with conditions appropriate for self-care should be advised to buy over the counter, in line with NHSE&I guidance.

01.01.02 Acidex Advance®  

First choice ’Advance’ alginate preparation

13.05.02 Acitretin capsules Neotigason®

Should only be prescribed within secondary care under the lead of a Consultant Dermatologist

03.01.02 Aclidinium Eklira®Genuair

Approved for the maintenance treatment of COPD; to be considered as a twice daily option when initiating treatment for a new patient.


PRESCRIBE BY BRAND

03.01.04 Aclidinium & formoterol  Duaklir® Genuair

Approved for the maintenance treatment of COPD; to be considered as a twice daily LAMA/LABA option when initiating treatment for a new patient.


PRESCRIBE BY BRAND 

01.05.03 Adalimumab 

In Line With NICE TA187 and TA329

Possible treatment for adults with moderate to severe ulcerative colitis if conventional therapy hasn’t worked or isn’t suitable as per NICE TA329. (See Guidance for further details)

Possible treatment for Crohn's disease as per NICE TA187.
(See Guidance for further details)

10.01.03 Adalimumab 

In Line With NICE TA143, TA146, TA195 (Update of TA36, 126 and 141), TA199 (Update of TA104 and 125) and TA329, TA373, TA375, TA383
  
Use of Adalimumab in Paediatric Uveitis is commissioned by NHS England

13.05.03 Adalimumab 

In line with NICE TA146 and TA199; commissioned by the CCG

NHS England commissioned when used Behcets Sydrome, Hiradenitis Suppurativa and Uveitis - Specialist Centre prescribing only

13.06.01 Adapalene Differin®
13.06.01 Adapalene 0.1%, benzoyl peroxide 2.5% gel Epiduo®
05.03.03.01 Adefovir Dipivoxil Hepsera ®

In Line With NICE TA96
For Hepatitis B in line with NICE guidance

02.03.02 Adenosine 
02.07.03 Adrenaline / Epinephrine Adrenaline / Epinephrine 1 in 10000, dilute
03.04.03 Adrenaline / Epinephrine Adrenaline / Epinephrine 1 in 1000
03.04.03 Adrenaline / Epinephrine 

Epipen® & Jext® auto-injectors


There are shelf life, device and administration differences for the devices, therefore related education and training is required for patients and their carers.


PRESCRIBE BY BRAND


Note that as of 18/5/20 all strengths of Emerade® are unavailable following class 2 MHRA patient level recalls - see MHRA website below:  

14.04 Adsorbed Diphtheria [low dose], Tetanus and Inactivated Poliomyelitis Vaccine Td/IPV

  • May be administered on the NHS for travel if clinically appropriate

  • Use Revaxis® brand for travel.


 



  • When used as part of the national immunisation programme, obtain stock via Immform.

14.04 Adsorbed Diphtheria, Tetanus, Pertussis (Acellular, Component) and Inactivated Poliomyelitis Vaccine DTaP/IPV

  • When used as part of the national immnunisation programme, obtain stock via Immform.

  • Brands to be used: Repevax® and Boostrix-IPV®

08.01.05 Afatinib Giotrif ®

For use in line with NICE TA310: 



Afatinib is recommended as an option, within its marketing authorisation, for treating adults with locally advanced or metastatic non-small-cell lung cancer only if:
the tumour tests positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and
the person has not previously had an EGFR-TK inhibitor and
the manufacturer provides afatinib with the discount agreed in the patient access scheme.


Commissioned by NHSE

11.08.02 Aflibercept Eylea®

In line with NICE TA346 and TA409

NICE TA409:Recommended as an option within its marketing authorisation for treating visual impairment in adults caused by macular oedema after branch retinal vein occlusion, only if the company provides aflibercept with the discount agreed in the patient access scheme

06.01.01.03 Agamatrix® Ultra Thin Lancets 
05.05.01 Albendazole 
09.02.02.02 Albumin Solution Isotonic solutions

From blood bank - contact for information about supply and administration

08.01.05 Alectinib Alecensa®

For untreated ALK-positive advanced non-small-cell lung cancer in line with NICE TA536. 

08.02.03 Alemtuzumab Lemtrada®

In line with NICE TA 312 Alemtuzumab is recommended as an option, within its marketing authorisation, for treating adults with active relapsing–remitting multiple sclerosis in line with NICE TA 312. To be prescribed by specialist centres.


Commissioned by NHS England.


06.06.02 Alendronic acid 

Oral solution (70mg/100mL) is less cost effective; RESTRICTED only to patients unable to take tablets. 


 

09.06.04 Alfacalcidol 

Brand: One-Alpha®



  • Forms available as capsules, drops & injection.

15.01.04.03 Alfentanil 
07.04.01 Alfuzosin Hydrochloride 
07.04.01 Alfuzosin Hydrochloride Modified-Release 

Brands include Besavar XL®

19.08 Alginate dressing Biatain Alginate® dressing

Sizes



  • 5cm x 5cm

  • 10cm x 10cm

  • 15cm x 15cm


Uses



  • Calcium alginate dressing used in moderate to highly exuding wounds with a sloughy or granulating wound bed. 

  • Can also help with haemostasis in wounds with minor bleeding.

  • Is biodegradable and available in flat and rope dressing.

  • Primary dressing only secondary dressing will be required.


Applications



  • 1-4 days depending on exudate level


Cautions



  • Do not use in individuals with a known sensitivity to any of the components of the dressing.

  • Do not use on lightly exuding wounds as adherence is an issue.

  • Extreme caution if used with tumours with friable tissue.


Tips



  • Do not wet before use.


 

02.12 Alirocumab Praluent®

In line with NICE TA393

13.05.01 Alitretinoin capsules Toctino®

In line with NICE TA177; commissioned by the CCG

Should only be prescribed by Consultant Dermatologist or GPSI only

10.01.04 Allopurinol 
06.01.02.03 Alogliptin 

There does not appear to be any significant clinical advantages over other DPP-4 inhibitors but overall it appears that this is the most cost effective option.

06.01.02.03 Alogliptin with metformin  

There does not appear to be any significant clinical advantages over other DPP-4 inhibitors but overall it appears that this is the most cost effective option.

09.06.05 Alpha Tocopheryl Acetate Vitamin E
07.01.01.01 Alprostadil Prostin VR®
07.04.05 Alprostadil 3mg/g Cream 

Vitaros®


Specialist initiation only; prescribing can be continued in primary care.

07.04.05 Alprostadil intracavernosal injection 

Specialist initiation only; prescribing can be continued in Primary Care.

07.04.05 Alprostadil urethral application MUSE®

Specialist initiation only; prescribing can be continued in Primary Care.

02.10.02 Alteplase Actilyse®

In line with NICE TA52 and TA264

01.01.01 Aluminimum Hydroxide 
09.05.02.02 Aluminium Hydroxide Alu-Cap®
01.02 Alverine Citrate 

Use 60mg capsules rather than 120mg

04.09.01 Amantadine Hydrochloride 

Specialist initiation

05.01.04 Amikacin 
02.02.03 Amiloride Hydrochloride 
03.01.03 Aminophylline 

MR tablets


PRESCRIBE BY BRAND

03.01.03 Aminophylline 

IV Injection

02.03.02 Amiodarone (injection) 
02.03.02 Amiodarone (tablets) 

Only following specialist initiation and in line with NHSE&I "Items which should not routinely be prescribed in primary care".


See also HWCCG Amiodarone Prescribing Guidance

04.02.01 Amisulpride 

In Line With NICE CG178 (Replaces TA43)

04.07.03 Amitriptyline Tablets 
02.06.02 Amlodipine 

First choice CCB for hypertension

13.10.02 Amorolfine 5% nail lacquer 

Prescribe by GENERIC NAME

In line with local H&W Guidelines for Primary Care Antimicrobial Prescribing.  Topical treatment is expensive and only appropriate where infection is limited to distal end of nails.

Products may be purchased OTC from community pharmacies according to license

05.01.01.03 Amoxicillin 

Capsules, injection, oral solution and 3g sachets

05.02.03 Amphotericin 



05.02.03 Amphotericin 

Commissioned by NHS England.

08.01.05 Amsacrine Amsidine®
09.01.04 Anagrelide Xagrid®

In tariff (previously CDF) for 2nd line treatment of high-risk essential thrombocytopenia where first line therapy is not effective.

08.03.04.01 Anastrozole 
05.02.04 Anidulafungin  

Commissioned by NHS England.

14.05.03 Anti-D (Rh0) Immunoglobulin 

  • In Line With NICE TA156 

19.14 Antimicrobial Irrigation Fluids Octenilin® Irrigation Solution

Size - 350ml


Use



  • Cleansing, decontamination and moisturising of acute and chronic wounds including 1st and 2nd degree burns


Application



  • At each dressing change

01.07.02 Anusol-HC® 
02.08.02 Apixaban 
04.09.01 Apomorphine Hydrochloride APO-go®

Consultant initiation only - may be continued by GP in line with Shared Care Guideline

11.08.02 Apraclonidine 0.5% eye drops Iopidine® Consultant Opthalmologist recommendation only
11.08.02 Apraclonidine 1% eye drops unit dose Iopidine® Consultant Opthalmologist recommendation only
13.05.03 Apremilast Otezla®

In line with NICE TA419 and TA433; commissioned by the CCG

04.06 Aprepitant 

Prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy after failure of first line anti-emetic options.

13.02.01 Aproderm®  

Cream and gel only

09.04.01 Aptamil®Pepti 1 

Suitable from birth to 6 months

09.04.01 Aptamil®Pepti 2 

Suitable from 6 months onwards

02.08.01 Argatroban 
04.02.02 Aripiprazole long acting injection 

For the maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole in line with the WHCT Antipsychotic Long-Acting Injection (Depot) Choice Pathway; for secondary care prescribing only, i.e. not for primary care prescribing, with an annual audit requested.

04.02.01 Aripiprazole Tablets 

In Line With NICE TA213
Schizophrenia in people aged 15 to 17 years who are intolerant of resperidone, or for who risperidone is contraindicated, or whose schizophrenia has not been adequately controlled with risperidone

In Line With Nice TA292
Aripiprazole as a possible treatment (for up to 12 weeks) for moderate to severe manic episodes in young people aged 13 and older with bipolar I disorder.

05.04.01 Artemether with lumefantrine Riamet®
12.03.05 AS Saliva Orthana® 
09.06.03 Ascorbic Acid 500mg tablets

Treatment of deficiency only (i.e scurvy).

02.09 Aspirin 75mg dispersible tablets 
04.07.01 Aspirin Tablets Dispersible 300mg

  • Available over the counter for some conditions.

  • Consider self care.

05.03.01 Atazanavir 

Commissioned by NHS England.

05.03.01 Atazanavir and Cobicistat Evotaz®

Commissioned by NHS England.

02.04 Atenolol 
04.04 Atomoxetine 

  • Consultant initiation only. 

  • In Line with local shared pathway.

02.12 Atorvastatin chewable tablets 

For patients unable to swallow ordinary tablets who would otherwise need a liquid.

02.12 Atorvastatin Tablets 
07.01.03 Atosiban Tractocile®
15.01.05 Atracurium Besilate 
15.01.03 Atropine Sulphate 
11.05 Atropine Sulphate 0.5% and 1% eye drops 
11.05 Atropine Sulphate 1% single use eye drops Minims® Atropine Sulphate
08.01.05 Avelumab Bavencio®

For treating metastatic Merkel cell carcinoma, in line with NICE TA517.

06.01.06 Aviva blood glucose test strips 

For patients who require a carbohydrate counting function and Accu-Chek insulin pumps.

08.01.05 Axitinib Inlyta®

For treating advanced renal cell carcinoma after failure of prior systemic treatment in line with NICE TA333.


Commissioned by NHSE

A2.02.02.03 Aymes ActaGain 2.4 Complete Maxi 

200ml milkshake style supplement (ready to drink). One bottle daily - see prescribing guidelines and pathway

A2.02.01.02 Aymes Shake Compact powder 

Mix with 100ml whole milk

A2.02.01.02 Aymes Shake Smoothie powder 

Mix with 150ml water (juice drink)

09.04 Aymes® ActaGain 2.4 Complete 

200mls. One a day supplement. Ready to drink. ACBS requirements.

09.04 Aymes® ActaSolve Smoothie® powder 

Mix with 150mls water. ACBS requirements.


 

09.04 Aymes® Complete 

200mls. Ready to drink. ACBS requirements.

09.04 Aymes® Shake Compact powder 

Mix with 100mls of whole milk. ACBS requirements.

09.04 Aymes® Shake powder 

Mix with 200mls of whole milk. ACBS requirements.

08.01.03 Azacitidine Vidaza®

For myelodysplastic syndromes in line with NICE TA 218

Commissioned by NHSE

01.05.03 Azathioprine 
08.02.01 Azathioprine 
10.01.03 Azathioprine 
13.05.03 Azathioprine tablets 

For initiation by Dermatology Specialist only.

13.06.01 Azelaic Acid 15% gel Finacea®

Facial acne vulgaris, papulopustular rosacea

13.06.01 Azelaic acid 20% cream Skinoren®

Acne vulgaris - PRESCRIBE BY BRAND and STRENGTH

Most cost-effective strength

11.04.02 Azelastine Hydrochloride Optilast®
12.02.01 Azelastine Hydrochloride Rhinolast®
05.01.05 Azithromycin 

Do not prescribe azithromycin as a stand-alone medication for the indication of gonorrhoea. Refer to Sexual Health Clinic for IM ceftriaxone as per UK guidelines.

05.01.02.03 Aztreonam Cayston®

Commissioned by NHS England for Cystic Fibrosis

08.02.04 Bacillus Calmette-Guerin (BCG) bladder instillation ImmuCyst® & OncoTICE®
10.02.02 Baclofen 
13.02.01 Balneum® Cream 

Contains urea 5% and ceramide 0.1%

01.05.01 Balsalazide Sodium 

  • Colazide®

10.01.03 Baricitinib 

In line with NICE TA466

08.02.02 Basiliximab Simulect®

Funded by NHS England (NCB)when used for renal transplant. Prescribing at Specialist Centres Only.

In line With NICE TA481 and TA482

14.04 BCG vaccine Intradermal Bacillus Calmette-Guerin Vaccine

  • Do not give on the NHS  for travel.

06.01.01.03 BD AutoShield DuoTM safety pen needles 

Only for patients who have thier insulin administered by healthcare professionals.

06.01.01.03 BD VivaTM pen needles 
03.02.01 Beclometasone & formoterol  Fostair®

Fostair® MDI is a preferred option for asthma (100/6 & 200/6) & COPD (100/6 only)

Fostair Nexthaler® is a preferred fixed dose DPI ICS/LABA option (100/6 & 200/6) for asthma.


DPI and MDI can also be used in asthma MART regime (100/6 only)


PRESCRIBE BY BRAND

12.02.01 Beclometasone Dipropionate Nasal Spray

  • First choice steroid nasal spray.

  • Patients with conditions suitable for self care should be advised to buy over the counter, in line with NHSE&I guidance.

  • Please note that purchase of steroid nasal sprays is restricted to patients aged 18 and over.

03.02.01 Beclometasone inhalers 

QVAR® & Clenil® MDI 


Easyhaler® Beclometasone (DPI) 


All are only licensed for asthma 


PRESCRIBE BY BRAND - devices are not bioequivalent

03.02.03 Beclometasone/formoterol/glycopyrronium  

 Trimbow® MDI 87/5/9 


Patients currently on triple therapy should not automatically be optimised to this device without an assessment to confirm the need for triple therapy to continue.


 


PRESCRIBE BY BRAND

05.01.09 Bedaquiline Sirturo®

Commissioned by NHS England when used for extensively drug resistant TB or multi-drug resistant TB.
Prescribing at Specialist Centres Only i.e. Heartlands 

03.04.02 Bee and Wasp Allergen Extracts Pharmalgen®

In line with NICE TA 246 

10.01.03 Belimumab 

In line with NICE TA397
Commissioned by NHS England

08.01.05 Bendamustine 

 

For the first-line treatment of chronic lymphocytic leukaemia in line wiith NICE TA216

 

In combination with obinutuzumab for treating follicular lymphoma after rituximab, in line with NICE TA629

 

02.02.01 Bendroflumethiazide 
04.02.01 Benperidol 
03.04.02 Benralizumab Fasenra®

Commissioned  by NHS England in line with NICE TA565 for the treatment of severe eosinophilic asthma

13.06.01 Benzoyl Peroxide 5% with Clindamycin 1% Gel Duac®
13.06.01 Benzoyl Peroxide gel  

PREFERRED BRAND: Acnecide

Patients with conditions appropriate for self-care should be advised to buy over the counter, in line with NHSE&I guidance.

12.03.01 Benzydamine Hydrochloride 0.15% Oral Rinse & Spray Difflam®

Patients with conditions suitable for self care should be advised to buy over the counter, in line with NHSE&I guidance. 


 

05.01.01.01 Benzylpenicillin Injection 
04.06 Betahistine Dihydrochloride Tablets 
09.08.01 Betaine 

Commissioned by NHS England when used for homocystinuria. Prescribed at Specialist Centres Only.

06.03.02 Betamethasone 
12.01.01 Betamethasone Sodium Phosphate Ear/Eye/Nose Drops
12.02.01 Betamethasone Sodium Phosphate Ear/eye/nose drops
12.01.01 Betamethasone Sodium Phosphate 0.1% with Neomycin Sulphate 0.5% Ear/Eye/Nose Drops
13.04 Betamethasone valerate 0.025% RD Betnovate RD®

Potency: MODERATE

13.04 Betamethasone valerate 0.1% Betacap®, Betnovate®, Bettamousse®

Potency: POTENT

Cream, ointment, scalp application and cutaneous foam

13.04 Betamethasone valerate medicated plasters Betesil®

Potency: POTENT

11.06 Betaxolol Hydrochloride 0.25% and 0.5% eye drops 
11.04.01 Bethamethasone 0.1% drops 
07.04.01 Bethanechol Chloride Myotonine®
08.01.05 Bevacizumab Avastin®
11.08.02 Bevacizumab Avastin®

The restricted use of intravitreal bevacizumab (Avastin®▼) has been approved in the following off-label indications:



  • Prior to panretinal laser coagulation in patients with proliferative diabetic retinopathy (PDR) who have vitreous haemorrhage, which makes the application of laser difficult.

  • To aid surgical delamination of the fibrovascular membranes when surgery is necessary in patients with PDR.

  • Adjunct treatment of neovascular glaucoma.






02.12 Bezafibrate 
08.03.04.02 Bicalutamide 
11.06 Bimatoprost 0.03% with Timolol 0.5% Ganfort®
11.06 Bimatoprost 0.3mg/ml eye drops 
12.03.05 Biotene Oralbalance® 
06.01.01.02 Biphasic insulin aspart NovoMix® 30

PRESCRIBE BY BRAND

06.01.01.02 Biphasic insulin lispro Humalog® Mix25

PRESCRIBE BY BRAND

06.01.01.02 Biphasic insulin lispro Humalog® Mix50

PRESCRIBE BY BRAND

06.01.01.02 Biphasic isophane insulin Humulin® M3

PRESCRIBE BY BRAND

06.01.01.02 Biphasic isophane insulin Insuman® Comb 15

PRESCRIBE BY BRAND

06.01.01.02 Biphasic isophane insulin Insuman® Comb 25

PRESCRIBE BY BRAND

06.01.01.02 Biphasic isophane insulin Insuman ®Comb 50

PRESCRIBE BY BRAND

01.06.02 Bisacodyl 

Tablets and suppositories

02.04 Bisoprolol Fumarate 
02.08.01 Bivalirudin 

In line with NICE TA 230

08.01.02 Bleomycin 
06.01.06 Blood ketone meters and test strips 

Guideline for the choice of blood glucose meters,test strips, lancets and needles in diabetes

08.01.05 Bortezomib Velcade®

in line with NICE TA129, TA228, TA311 and TA370.


08.01 Bosutinib Bosulif®

In line with NICE TA401 for previously treated chronic myeloid leukaemia.

Commissioned by NHSE

04.09.03 Botulinum Toxin Type A Botox®

In line with NICE TA260. See commissioning statement below.

Second line to local application of diltiazem for anal fissures.

04.09.03 Botulinum Toxin Type A Dysport®

Consultant use only including use in a patient pathway. See commissioning statement below.

Second line to local application of diltiazem for anal fissures.

04.09.03 Botulinum Toxin Type A Xeomin®

Consultant use only including use in a patient pathway. See commissioning statement below.

Second line to local application of diltiazem for anal fissures.

04.09.03 Botulinum Toxin Type B NeuroBloc®

Consultant use only.


Only for use when Botulinum Type A is ineffective.

01.06.05 Bowel Cleansing Solutions 
08.01.05 Brentuximab Adcetris®

 

For relapsed or refractory systemic anaplastic large cell lymphoma in line with NICE TA478

 

For CD30-positive Hodgkin lymphoma in line with NICE TA524 . 

 

For CD30-positive cutaneous T-cell lymphoma in line with NICE TA577 

 

11.06 Brimonidine Tartrate 
11.06 Brinzolamide 
11.06 Brinzolamide 1% with Timolol 0.5%  Azarga®

Use only when dorzolamide + timolol (Cosopt) cannot be tolerated.

04.08.01 Brivaracetam 

Brivaracetam requires specialist initiation by a Consultant Neurologist with appropriate experience in the treatment of epilepsy/Epilepsy CNS prescriber. The initiating consultant/Epilepsy CNS will continue to prescribe brivaracetam until the patient has been reviewed and stabilisation of the patient's dose and condition has been achieved; maintenance prescribing may be requested from GPs whilst giving any supportive monitoring guidance.


MHRA Category 3 - It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors

13.05.03 Brodalumab Kyntheum®

In line with NICE TA511; commissioned by the CCG

04.09.01 Bromocriptine 

Specialist initiation only 


Note: Ergot-derived dopamine receptor agonists have been associated with pulmonary, retroperitoneal and pericardial fibrotic reactions. 

06.07.01 Bromocriptine 

  • Hyperprolactinaemia


 

03.02.01 Budesonide 

Dry powder inhaler (Pulmicort® Turbohaler)


Nebulised solution

03.02.01 Budesonide & formoterol  Symbicort® Turbohaler

Symbicort® Turbohaler Available in 100/6 200/6 400/12 strengths


Fixed dose option for asthma


SMART option for asthma (100/6 & 200/6 only)


Also preferred option for COPD 


PRESCRIBE BY BRAND 

03.02.01 Budesonide & formoterol Duoresp® Spiromax

Duoresp® Spiromax Available in 160/4.5 & 320/9 strengths 


Maintenance treatment of COPD and asthma; to be considered as a twice daily preferred DPI ICS/LABA option.


For asthma, can also be used in MART regime  (160/4.5 strength only)

PRESCRIBE BY BRAND

03.02.01 Budesonide & formoterol  Fobumix® Easyhaler

Fobumix® Easyhaler available in 80/4.5 160/4.5 & 320/9 strengths 


A preferred  fixed dose DPI ICS/LABA option for asthma. 


Can also be used in a MART regime (80/4.5 & 160/4.5 strengths only


PRESCRIBE BY BRAND

01.05.02 Budesonide 3mg M/R capsules 

PRESCRIBE BY BRAND



  • Budenofalk® 

  • Enterocote®

01.05.02 Budesonide 9M/R Granules 

PRESCRIBE BY BRAND


Budenofalk®

01.05.02 Budesonide 9M/R Granules Budenofalk®
01.05.02 Budesonide 9M/R tablets 

PRESCRIBE BY BRAND


Cortiment®

01.05.02 Budesonide Rectal Foam 

Budenofalk®

02.02.02 Bumetanide 
15.02 Bupivacaine and Adrenaline 
15.02 Bupivacaine hydrochloride 
15.02 Bupivacaine with Fentanyl 
04.10.03 Buprenorphine Subutex®

In Line With NICE TA114


Prescribing by substance misuse specialists only. This includes GPs with appropriate training / competence who are contracted to provide substance misuse treatment on a shared care basis via a Locally Enhanced Service agreement between GP practices and the substance misuse specialist service provider.


 

04.10.03 Buprenorphine and Naloxone Suboxone®

Prescribing by substance misuse specialists only. This includes GPs with appropriate training / competence who are contracted to provide substance misuse treatment on a shared care basis via a Locally Enhanced Service agreement between GP practices and the substance misuse specialist service provider.

04.10.03 Buprenorphine oral lyophilisate Espranor®

NOT bioequivalent to buprenorphine sublingual tablets (e.g. Subutex®). 


Prescribing by substance misuse specialists only. This includes GPs with appropriate training / competence who are contracted to provide substance misuse treatment on a shared care basis via a Locally Enhanced Service agreement between GP practices and the substance misuse specialist service provider.


[Patients to be maintained on their normal brand if admitted as an inpatient - Contact Drug and Alcohol Services for further advice]

04.07.02 Buprenorphine patches (twice weekly) Hapoctasin®

  • PRESCRIBE BY BRAND

  • For use in palliative care only where patients unable to swallow.

  • Hapoctasin® is the more cost effective preparation in primary care

  • Remove after no longer than 72 hours.

04.07.02 Buprenorphine patches (twice weekly) Bupease®

  • PRESCRIBE BY BRAND

  • For use in palliative care only where patients unable to swallow.

  • Bupeaze® is the more cost effective preparation in primary care.

  • Remove after no longer than 96 hours.


 

04.07.02 Buprenorphine patches (weekly)  Butec®

  • PRESCRIBE BY BRAND

  • In palliative care for patients unable to swallow.

  • Butec® is the most cost effective preparation in Primary Care.After a dose of 15 micrograms/hour it would be cost effective to consider a change to low dose fentanyl patches.
     



 

04.07.02 Buprenorphine Tablets 

  • For analgesia.

06.07.02 Buserelin Suprecur®
04.01.02 Buspirone Hydrochloride 

Consultant Psychiatrist initiation only

08.01.01 Busulfan 
03.04.03 C1 Esterase Inhibitor 

Berinert® (As of Jan 20, very limited stock available)


Cynrize® 


Commissioned by NHS England

08.01.05 Cabazitaxel Jevtana®

For hormone-refractory metastatic prostate cancer previously treated with docetaxel in line with NICE TA 391

04.09.01 Cabergoline 

Specialist initiation only 


Note: Ergot-derived dopamine receptor agonists have been associated with pulmonary, retroperitoneal and pericardial fibrotic reactions.

06.07.01 Cabergoline 

  • Hyperprolactinaemia


 

08.01.05 Cabozantinib Cabometyx®

For treating Previously treated advanced renal cell carcinoma in line with NICE TA463 and untreated advanced renal cell carcinoma in line with NICE TA542.

08.01.05 Cabozantinib Cometriq®

For treating medullary thyroid cancer in line with NICE TA516.

03.05.01 Caffeine (base) Injection 

  • Unlicensed.

  • Specialist use for neonates only

  • Prescribe as caffeine citrate as per BNF advice

13.05.02 Calcipotriol ointment Dovonex®

First choice topical Vitamin D analogue

13.05.02 Calcipotriol with betamethasone ointment  Dovobet® ointment

First choice combination preparartion of calcipotriol and betamethasone

Review regularly. Max 15g / day.

13.05.02 Calcipotriol with betamethasone scalp gel Xamiol®, Dovobet gel®

Use after failure of first-line treatments.

13.05.02 Calcipotriol with betamethasone topical foam  Enstilar®

Second choice combination preparartion of calcipotriol and betamethasone

• In line with local psoriasis guidance; the use of a combined vitamin D analogue and corticosteroid preparation should be considered for psoriasis affecting large areas of the body.
• Psoriasis affecting smaller areas such as the scalp, face, flexures or genitals should be managed with a short term topical corticosteroid.

06.06.01 Calcitonin (salmon)  
13.05.02 Calcitriol ointment Silkis®

Second choice topical Vitamin D analogue

09.05.02.02 Calcium acetate Renacet®
08.01 Calcium Folinate 
09.02.01.01 Calcium polystyrene sulfonate Calcium Resonium®
09.05.01.01 Calcium Salts Calcium Gluconate
09.05.01.01 Calcium Salts Adcal®
09.05.01.01 Calcium Salts Calcichew®
09.05.02.02 Calcium Salts Phosex®
06.01.02.03 Canagliflozin 

In Line with NICE TA315 and NICE TA390

02.05.05.02 Candesartan Cilexetil 
13.09 Capasal® Shampoo 

Contains distilled coal tar, salicylic acid and coconut oil

08.01.03 Capecitabine Xeloda®

 

For colorectal cancer in line with NICE TA61 and TA100 

 

For gastric cancer in line with NICE TA191

10.03.02 Capsaicin 0.075% cream Axsain®

In line with manufacturer's licence and local guidelines for the management of neuropathic pain.

10.03.02 Capsaicin patches 

For severe post herpetic pain ONLY following lidocaine patch failure (i.e. fifth line within the current local treatment pathway for patients presenting with shingles); for use (following the relevant training) only by a secondary-care physician or health care professional under the supervision of a physician.

02.05.05.01 Captopril 
04.08.01 Carbamazepine 

Only through specialist recommendation (for adults) or specialist initiation(for children).


PRESCRIBE BY BRAND - Tegretol is the preferred brand.



MHRA Category 1 - Doctors are advised to ensure that their patient is maintained on a specific manufacturer’s product 
 

04.07.03 Carbamazepine Tablets 

Trigeminal neuralgia only

06.02.02 Carbimazole 
03.07 Carbocisteine 

Capsules, liquid & SF sachets.


Note: BNF recommendation that mucolytic therapy should be reviewed & stopped if there is no benefit after a 4 week trial.

11.08.01 Carbomer 980 eye gel GelTears® Secondary Care Contract. Clinitas 0.2% Gel® is a more affordable but identical preparation to GelTears® in Primary Care.
11.08.01 Carbomer 980 eye gel Clinitas 0.2% Gel®

Encourage self-care with OTC products for self-limiting short term use/mild dry eye


First choice option for mild dry eye (see local guidelines on the treatment of dry eye)


08.01.05 Carboplatin 
07.01.01 Carboprost Hemabate®
06.01.06 Caresens® N blood glucose test strips 

For patients with visual impairment and gestational diabetes.

06.01.06 CaresensTM PRO blood glucose test strips 

For patients with Type 1 Diabetes

06.01.01.03 CaresensTMLancets 
11.08.01 Carmellose 0.5% eye drops Evolve®

Encourage self-care with OTC products for self-limiting short term use/mild dry eye


First choice option for mild dry eye (see local guidelines on the treatment of dry eye) 

11.08.01 Carmellose 0.5% eye drops Optive®

Encourage self-care with OTC products for self-limiting short term use/mild dry eye


Second choice option for mild dry eye (see local guidelines on the treatment of dry eye)


12.03.01 Carmellose Sodium Orabase®

Patients with conditions suitable for self care should be advised to buy over the counter, in line with NHSE&I guidance.


 

08.01.01 Carmustine 

Implants - In Line With NICE TA121




02.04 Carvedilol 
05.02.04 Caspofungin 

Commissioned by NHS England.

07.04.04 Catheter Patency Solutions Sodium Chloride 0.9%; Solution S

Short term use only. Not to be used as routine for every patient; only to be used as part of a treatment plan

07.04.04 Catheter Patency Solutions Citric Acid 3.23%; Solution G

Short term use only. Not to be used as routine for every patient; only to be used as part of a treatment plan. 

07.04.04 Catheter Patency Solutions Citric Acid 6%; Solution R

Short term use only. Not to be used as routine for every patient; only to be used as part of a treatment plan.

05.01.02.01 Cefalexin 
05.01.02.01 Cefixime 

For treatment of gonorrhoea by Sexual Health Clinics only

05.01.02.01 Cefotaxime 

To be used in line with local Guidelines for Primary Care Antimicrobial Prescribing.

05.01.02.01 Ceftazidime 
05.01.02.01 Ceftazidime with avibactam 2g/0.5g 

Use only for the treatment of serious, multidrug-resistant, ceftazidime-avibactam susceptible Gram-negative pathogens, principally Enterobacteriaceae producing KPC and OXA-48 carbapenemases, on the advice of a medical microbiologist.

05.01.02.01 Ceftriaxone 
05.01.02.01 Cefuroxime 
10.01.01 Celecoxib 

In Line With NICE CG59 and CG79 (Replace TA27)
Second line Cox II inhibitor - prescribing by rheumatologists only

08.01.05 Ceritinib Zykadia®

For previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer in line with NICE TA395

For untreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in adults in line with NICE TA500

 

10.01.03 Certolizumab Pegol 

In line with NICE TA375, TA383 and TA415

13.05.03 Certolizumab pegol Cimzia®

In line with NICE TA445 and TA574; commissioned by the CCG

03.04.01 Cetirizine Hydrochloride 

Patients with conditions appropriate for self-care should be advised to buy over the counter, in line with NHSE&I guidance

13.02.01 Cetraben® 

Lotion and ointment only

08.01.05 Cetuximab Erbitux®

 

For locally advanced squamous cell cancer of the head and neck in line with NICE TA145.

 

For previously untreated metastatic colorectal cancer in combination with panitumumab in line with NICE TA439 . 

 

For recurrent or metastatic squamous cell cancer of the head and neck in line with NICE TA473 

 

04.01.01 Chloral Hydrate Elixir Chloral Elixir®

  • Many strengths are unlicensed "Specials"

  • Preferred preparation is licensed chloral hydrate 143.3mg/5ml (Welldorm) elixir.

08.01.01 Chlorambucil 
11.03.01 Chloramphenicol drops, ointment 

Patients with conditions appropriate for self-care should be advised to buy the preparation over the counter, in line with NHSE&I guidance.


Advise patients/parents to purchase OTC from community pharmacies (licensed for sale 2 years and over).

04.10.01 Chlordiazepoxide Hydrochloride Tablets 

Prescribing by substance misuse specialists only. This includes GPs with appropriate training / competence who are contracted to provide substance misuse treatment on a shared care basis via a Locally Enhanced Service agreement between GP practices and the substance misuse specialist service provider.


 

12.03.04 Chlorhexidine Gluconate 0.2% Mouthwash 

Available over the Counter. Consider self care.


 


 

12.02.03 Chlorhexidine Hydrochloride 0.1%, Neomycin Suphate 0.5% Nasal Cream
05.04.01 Chloroquine 
 

Primary care  - prophylaxis is part of self care

Patients should always consider taking antimalarial medicine when travelling to areas where there's a risk of malaria. Visit your local travel clinic  or GP practice for malaria advice and prescriptions.

RED

Secondary care - malaria treatment is NHS&I commissioned

03.04.01 Chlorphenamine Maleate 

Patients with conditions appropriate for self-care should be advised to buy the preparation over the counter, in line with NHSE&I guidance

04.02.01 Chlorpromazine Hydrochloride 
14.04 Cholera vaccine Dukoral®

  • Available on the NHS for travel but NOT indicated in most travellers.

  • Check the Travel Pro Website for details (NaTHNaC)


 


 

01.05.03 Ciclosporin 

PRESCRIBE BY BRAND

08.02.02 Ciclosporin 

To be prescribed in line With NICE TA481 and TA482

PRESCRIBE BY BRAND

Commissioned by NHS England when used post transplant. All new patients should receive treatment from the Acute Trust provider. GPs can continue to prescribe for any existing patients and this will be commissioned by the CCG.

RED For new post-transplant patients
AMBER SC For existing post-transplant patients

 

10.01.03 Ciclosporin 

For skin conditions to be initiated by Consultant Dermatologist or GPSI but GPs may continue.
For use post transplant see section 8.2.2

11.08.01 Ciclosporin 1 mg/mL eye drops, emulsion Ikervis®

Secondary care Consultant Opthalmologist initiation only in line with NICE TA369

Recommended as an option for treating severe keratitis in adult patients with dry eye disease that has not improved despite treatment with tear substitutes

13.05.03 Ciclosporin capsules Neoral®

For initiation by Dermatology Specialist only.

Note prescribing by brand not necessary for dermatology indications.  For use post transplant see section 8.2.2

05.03.02.02 Cidofovir 

Commissioned by NHS England.
Cytomegalovirus infection

01.03.01 Cimetidine 

Check for interactions

09.05.01.02 Cinacalcet Mimpara®

NHS England commission use in line with NICE TA117(secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy).
Note also commissioned in primary hyperparathyroidism where cinacalcet is not excluded from tariff.

Maintenance prescribing for either indication may be requested from GPs whilst giving any supportive monitoring guidance.

04.06 Cinnarizine Tablets 
05.01.12 Ciprofloxacin 
12.01.01 Ciprofloxacin ear drops Cetraxal®

Licensed ear preparation

11.03.01 Ciprofloxacin eye drops Ciloxan®
08.01.05 Cisplatin 
15.01.05 Cistracurium 
04.03.03 Citalopram 

  • Tablets and oral drops.

  • See Guidance re dose dependent QT prolongation.

  • Note: 4 drops (8 mg) is equivalent in therapeutic effect to 10mg tablet. Mix with water, orange juice, or apple juice before taking


08.01.03 Cladribine Mavenclad®

For treating relapsing–remitting multiple sclerosis in line with NICE TA616.

 

Commissioned by NHSE.

05.01.05 Clarithromycin 
05.01.06 Clindamycin 
07.02.02 Clindamycin 2% Vaginal Cream 
04.08.01 Clobazam  

Specialist recommendation(adults) or initiation(children)

MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history

13.04 Clobetasol propionate 0.05% Dermovate®, Etrivex®

Potency: VERY POTENT

Cream, ointment, scalp application and shampoo

13.04 Clobetasone butyrate 0.05% Eumovate®

Potency: MODERATE

08.01.03 Clofarabine 

For the treatment of relapsed/refractory acute lymphoblastic leukaemia with intent to use treatment to bridge to bone marrow transplant.

04.01.01 Clomethiazole 
06.05.01 Clomifene citrate 
04.08.02 Clonazepam Injection 

Specialist initiation

04.08.01 Clonazepam Tablets 

For specialist recommendation (Adults) or initiation (Children).


MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history

04.07.04.02 Clonidine Hydrochloride Tablets 
02.09 Clopidogrel 
07.02.02 Clotrimazole  

  • Clotrimazole 10% VC cream

  • Clotrimazole 2% cream (Available over the counter. Consider self care)

  • Clotrimazole 100mg pessaries (Available over the counter. Consider self care)

  • Clotrimazole 500mg pessaries (Available over the counter. Consider self care)

12.01.01 Clotrimazole 1% solution
13.10.02 Clotrimazole cream 

Patients with conditions appropriate for self-care should be advised to buy over the counter, in line with NHSE&I guidance.

04.02.01 Clozapine 

Consultant Psychiatrist initiation only. Not for prescribing in primary care.

13.05.02 Coal tar 12%, sulphur 4% & salicylic acid 2% ointment Sebco®

Note: Sebco® same formula as Cocois® but less expensive

13.05.02 Coal Tar 5% Lotion Exorex®
02.02.04 Co-amilofruse (furosemide and amiloride) 
02.02.04 Co-amilozide (amiloride and hydrochlorothiazide) 
05.01.01.03 Co-Amoxiclav 

Injection, oral solution and tablets
Only to be used for specific indications in line with Herefordshire & Worcestershire antimicrobial prescribing guidelines

04.09.01 Co-Beneldopa Madopar®CR

Specialist initiation

04.09.01 Co-Beneldopa Madopar®

Specialist initiation

05.03.01 Cobicistat  

Commissioned by NHS England.

04.09.01 Co-Careldopa Sinemet® CR

50/200 (carbidopa 50 mg & levodopa 200 mg)


Specialist initiation

04.09.01 Co-Careldopa Sinemet®

Specialist initiation

04.09.01 Co-Careldopa Half Sinemet ®CR

25/100 (carbidopa 25 mg & levodopa 100 mg) modified-release capsule


Specialist initiation

04.09.01 Co-Careldopa and Entacapone Stanek®; Sastravi®

Specialist initiation


Sastravi® and Stanek® are the formulary brands of choice.

13.06.02 Co-cyprindiol 2000/35
(Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms)
 

PRESCRIBE BY GENERIC NAME and not brand Dianette®

01.06.02 Co-danthramer 

Only for constipation in terminally ill patients of all ages - see BNF.

01.06.02 Co-danthrusate 

Only for constipation in terminally ill patients of all ages - see BNF.

03.09.01 Codeine Linctus BP 

Patients with conditions appropriate for self-care should be advised to buy the preparation over the counter, in line with NHSE&I guidance

01.04.02 Codeine Phosphate 

Tablets

04.07.02 Codeine Phosphate 

Tablets and injection


10.01.04 Colchicine 
09.06.04 Colecalciferol 10,000 units/ml drops 

Brand: Thorens®



  • 200 units per drop

09.06.04 Colecalciferol 1000 units tablets 

Brand: Stexerol-D3®

09.06.04 Colecalciferol 25,000 units/ml oral solution 

Brand: InVita D3®


Available as:



  • 25,000 units in 1ml ampoules.

  • 50,000 units in 2ml ampoules.

09.06.04 Colecalciferol 400 units and Calcium Carbonate 1.25g 

Brand: Calcichew-D3® Forte

09.06.04 Colecalciferol and Calcium Carbonate 

Brand: Adcal-D3®


Forms available:



  • Caplets (Most cost effective form)

  • Chewable tablets,

  • Effervescent tablets,

09.06.04 Colecalciferol and calcium carbonate Calci-D®

ONCE DAILY formulary preparation option.
(Most affordable Vitamin D and calcium option overall and could facilitate compliance with a once daily regimen)

09.06.04 Colecalciferol capsules 20,000units  

Brands include:



  • Fultium D3® 

  • Plenachol®

09.06.04 Colecalciferol capsules 3,200 units 

Brand : Fultium-D3®

09.06.04 Colecalciferol capsules 40,000 units  

Brand: Plenachol®

09.06.04 Colecalciferol capsules 50,000 units 

 Brand : InVita-D3®



  • available as soft capsules.

09.06.04 Colecalciferol tablets 800 units 

Brand: Desunin®

02.12 Colesevelam Cholestagel®

Consultant initiation in patients with terminal ileal resection where cholestyramine is not tolerated and can be continued by GP if patient shows response beyond one month.

01.09.02 Colestyramine 
02.12 Colestyramine 
05.01.07 Colistimethate Sodium Colomycin®, Promixin®
RED

Commissioned by NHS England in line with NICE TA 276 (Cystic Fibrosis) for new patients.
GPs should continue to prescribe for existing patients until patients are formally repatriated and will be commissioned by the CCG (when delivered via nebulisation/inhalation). GPs should not take on new prescribing of this medicine. 

AMBER

NON-CF BRONCHIECTASIS: Colomycin® brand is specifically available on the formulary for nebulised use in non-CF bronchiectasis with the approved supporting letter/dosing information to be provided to GPs when on-going prescribing of the drug and saline is requested to be undertaken in Primary Care.

01.01.01 Co-magaldrox Maalox®

Low sodium

01.01.01 Co-magaldrox Mucogel®

Low sodium

06.04.01.01 Combined continuous HRT 

For women with uterus - continuous therapy 



  • Femoston® Conti tablets

  • Evorel® Conti patches

  • Elleste-Duet® Conti tablets

  • Kliovance® tablets


 

06.04.01.01 Combined cyclical HRT 

For women with uterus - cyclical therapy



  • Elleste-Duet® tablets

  • Femoston® tablets

  • Evorel® Sequi patches


 

07.03.01 Combined Hormonal Contraceptive Patches Evra® Transdermal Patch

Consider if adherence is an issue with oral formulations despite other interventions


PRESCRIBE BY BRAND 

19.23 Compression bandage K-Lite® bandage, K-Lite Long® bandage

Sizes



  • K-Lite®

    • 5cm x 4.5m

    • 7cm x 4.5m

    • 10cm x 4.5m

    • 15cm x 4.5m



  • K-Lite Long®

    • 10cm x 5.25m




Application



  • 1 to 7 days


Use



  • Layer 2 of multilayer compression

  • Designed for use on sprains/strains.

  • Provides Type 2 light support.

  • Recommend a wadding bandage is applied beneath.


Caution



  • Known allergy to components

19.23 Compression bandage K-ThreeC® bandage

Size



  • 10cm x 3m


Use



  • Type 3C high compression bandage for use with multilayer compression for the treatment of venous leg ulcers.

  • Used for high sized ankles as layer three.


Application



  • 1 to 7 days


Caution



  • Known allergy to components.

19.23 Compression bandage Ko-Flex® bandage, Ko-Flex Long ® bandge

Size



  • Ko-Flex - 10cm x 6m

  • Ko-Flex Long - 10cm x 7m


Use



  • Venous ulceration

  • Oedema

  • Managing straight sprains and strains

  • Following orthopaedic surgery


  • Forms part of the K Four bandage system


Application



  • 1 to 7 days dependent on exudate levels if wound present or oedema management.


Caution



  • Not recommended on those patients with an ankle brachial pressure index lower than 0.8.

  • Contains latex.

19.23 Compression bandage K-Plus® bandage, K-Plus Long® bandage

Size



  • K-Plus® - 10cm x 8.7m

  • K-Plus Long® - 10cm x 10.25m


Application



  • 1 to 7 days


Use



  • Layer 3 of multilayer compression

  • Type 3a light compression bandage for use with multilayer compression for the treatment of venous leg ulcers.


Caution



  • Known allergy to components


 

06.01.06 Contour®Next blood glucose test strips 

For gestational diabetes and Medtronic insulin pumps

01.04.02 Co-Phenotrope 

For use in palliative care only.

07.03.04 Copper Intra-uterine Contraceptive Devices 

Various

05.01.08 Co-trimoxazole 

Restricted indications

08.01.05 Crizotinib Xalkro®

In line with NICE TA406 and TA422

NICE TA406 & NICE TA422:Crizotinib is recommended, within its marketing authorisation, as an option for untreated anaplastic/previously treated lymphoma kinase-positive advanced non-small-cell lung cancer in adults. The drug is recommended only if the company provides it with the discount agreed in the patient access scheme.


13.03 Crotamiton Eurax®
04.06 Cyclizine Tablets & Injections 
11.05 Cyclopentolate Hydrochloride 0.5% and 1% single use eye drops  

Diagnostic use

08.01.01 Cyclophosphamide 
06.04.02 Cyproterone acetate 
08.03.04.02 Cyproterone Acetate 
08.01.03 Cytarabine 
02.08.02 Dabigatran 
08.01.05 Dabrafenib Tafinlar®

Specialist centre prescribing only in line with NICE TA321

08.01.05 Dacarbazine 
08.01.02 Dactinomycin 
02.08.01 Dalteparin Sodium 
10.02.02 Dantrolene Sodium Capsules 
15.01.08 Dantrolene Sodium Injection 
06.01.02.03 Dapagliflozin 










GREEEN

In line with NICE TA288 for patients with type 2 diabetes.(Please note TA288 has been partially updated - see TA418), TA390 and TA418.


AMBER In line with NICE TA 597 for patients with type 1 diabetes: Initiation and prescribing of dapagliflozin with insulin in T1DM patients to be retained by secondary care for the first six months, with the request for GPs to take over maintenance prescribing if the specialist deems there to be the required improvement in HbA1c (i.e. at least 0.3%) and the patient has received any additional monitoring guidance and education about increased risk of DKA.

 


 

06.01.02.03 Dapagliflozin with metformin  

In line with NICE TA288 'Dapagliflozin in Combination Therapy for Treating Type 2 Diabetes'.

05.01.10 Dapsone 

For skin conditions to be initiated by Dermatology Specialist or GPSI.  May be continued in primary care in line with shared care guidelines. 


 


 

05.01.07 Daptomycin 

Consultant microbiologist initiation only

09.01.03 Darbepoetin Alfa Aranesp®

Commissioned by NHS England

05.03.01 Darunavir 

Commissioned by NHS England.
Third or fourth line to other HIV therapy

05.03.01 Darunavir and Cobicistat Rezolsta®

Commissioned by NHS England.

08.01.05 Dasatinib Sprycel®

In line with NICE TA425 and NICE TA426

NICE TA425:
Dasatinib and nilotinib are recommended as options for treating only chronic- or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults, if:
•they cannot have imatinib, or their disease is imatinib-resistant and
•the companies provide the drugs with the discounts agreed in the relevant patient access schemes.


NICE TA426:
Dasatinib and nilotinib are recommended, within their marketing authorisations, as options for untreated chronic-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults. The drugs are recommended only if the companies provide them with the discounts agreed in the relevant patient access schemes

Commissioned by NHSE

08.01.02 Daunorubicin 
19.17 Debrisoft® Lolly 

Use



  • Acute or chronic wounds with surface debris eg. pressure ulcers, leg ulcers, diabetic foot ulcers, hyperkeratosis.

  • Thick hyperkeratosis may take more than one treatment.


Application



  • At each dressing change or as required.


Caution



  • Known sensitivity to polyester. 

  • Heavy slough and necrotic tissue may require automatic autolytic debridement to soften prior to use.


Tips



  • Must be wet with clean warm water prior to use.

  • Do not get an emollient on the pad as this blocks the monofilaments.

19.17 Debrisoft® pad 

Sizes



  • 10cm x 10cm

  • 13cm x 20cm


Use



  • Acute or chronic wounds with surface debris eg. pressure ulcers, leg ulcers, diabetic foot ulcers and hyperkeratosis.

  • Thick hyperkeratosis may take more than one treatment.


Application



  • At each dressing change or as required.


Caution



  • Known sensitivity to polyester.

  • Heavy slough and necrotic tissue may require automatic autolytic debridement to soften prior to use.


Tips



  • Must be wet with clean warm water prior to use.

  • Do not get an emollient on the pad as this blocks the monofilaments.

09.01.03 Deferasirox Exjade®

For the treatment of iron overload for transfused and non transfused patients with chronic inherited anaemias as per NHSE Policy 1670/P. Funded by specialised commissioning 

20 Defibrotide capsules 400 mg 

Commissioned by NHS England

20 Defibrotide Injection 200 mg 

Commissioned by NHS England

08.03.04.02 Degarelix Firmagon®

In line with NICE TA404

NICE TA404: Degarelix is recommended as an option for treating advanced hormone-dependent prostate cancer in people with spinal metastases


In tariff (i.e NOT FOR PRIMARY CARE PRESCRIBING) for the treatment of newly diagnosed advanced prostate cancer for a subgroup of patients with areas of critical metastases including those with established or incipient spinal cord compression who are at risk of urinary retention using standard LHRH analogues & those where there is need to avoid pro-thrombotic risk of streroidal anti-androgens.

05.01.03 Demeclocycline Hydrochloride 

For SIADH and hyponatraemia only

06.06.02 Denosumab XGEVA®

In line with NICE TA265 

06.06.02 Denosumab Prolia®

In line with NICE TA204 and  local guidelines for the initiation and on-going treatment of osteoporosis in men and postmenopausal women.


In line with recommendations within NICE Clinical Guideline ng131 on the diagnosis and care of men with prostate cancer and managing adverse effects of hormone treatment, which states that:



  • Do not routinely offer bisphosphonates to prevent osteoporosis in men with prostate cancer having ADT.

  • Consider assessing fracture risk in men with prostate cancer who are having ADT, in line with NICE guidance on osteoporosis fragility fracture (NICE CG 146)

  • Offer bisphosphonates to men who are having ADT and have osteoporosis, and

  • Consider denosumab if bisphosphonates are contraindicated or not tolerated.

13.02.01 Dermatonics Once Heel Balm® 

Contains 25% urea

13.02.01 Dermol 500® Lotion 

Contains benzalkonium chloride 0.1% & chlorhexidine hydrochloride 0.1%

13.02.01 Dermol® Cream 

Contains benzalkonium chloride 0.1% & chlorhexidine hydrochloride 0.1%

09.01.03 Desferrioxamine Mesilate Desferal®
06.05.02 Desmopressin 

  • Tablets

  • Melts (60mcg, 120mcg and 240mcg only) £££

  • Nasal spray (10mcg/dose)

  • Nasal solution


 

06.05.02 Desmopressin 

  • Solution for injection


 

07.03.02.01 Desogestrel (Oral progestogen-only contraceptive) 

To be prescribed generically

06.03.02 Dexamethasone 

  • Tablets

  • Oral solution


 

11.04.01 Dexamethasone 0.1% eye drops single use Minims® Dexamethasone
11.04.01 Dexamethasone 0.1% eye drops Maxidex®
11.04.01 Dexamethasone 700micrograms intravitreal implant Ozurdex®

In line with NICE TA229 and TA349

NICE TA349: Only if the implant is to be used in an eye with an intraocular (pseudophakic) lens and the diabetic macular oedema does not respond to non-corticosteroid treatment, or such treatment is unsuitable.

10.01.02.02 Dexamethasone Phosphate 
12.01.01 Dexamethasone with Antibacterial Sofradex® eardrops
12.01.01 Dexamethasone with Neomycin Otomize®
11.04.01 Dexamethasone with Neomycin and Polymyxin B sulphate eye drops, ointment Maxitrol®

Only for use following ocular surgery

04.04 Dexamfetamine Sulphate 
15.01.04.04 Dexmedetomidine 

Approved by APC January 2013 for use by anaesthetists ONLY.

08.01 Dexrazoxane 

For anthracycline induced toxicity

09.02.02.02 Dextran 40® 
09.02.02.02 Dextran 70® 
04.07.02 Diamorphine Hydrochloride Injection 

  • For palliative care

04.01.02 Diazepam 
04.08.02 Diazepam 

Injection and rectal solution

10.02.02 Diazepam 
15.01.04.01 Diazepam 
17 Dibotermin Alfa, rhBMP-2 Inductos®
10.01.01 Diclofenac Sodium Tablets

Available for as a third line treatment for short term acute pain where ibuprofen and naproxen are not clinically suitable alternatives.

10.01.01 Diclofenac Sodium Modified-Release 

Available for as a third line treatment for short term acute pain where ibuprofen and naproxen are not clinically suitable alternatives.

10.01.01 Diclofenac Sodium with Misoprostol Arthrotec 50 and 75®

Not recommended for new patients


Restricted: Second line agent in patients with criteria to support the use of Misoprostol

01.02 Dicycloverine Hydrochloride  Kolanticon®Suspension

PRESCRIBE BY BRAND AND FORMULATION


Also contains aluminium hydroxide,magnesium oxide & simeticone

05.03.01 Didanosine 

Commissioned by NHS England.

08.03.01 Diethylstilbestrol 

For Oncology indications

02.01.01 Digibind 
02.01.01 Digoxin 
04.07.02 Dihydrocodeine 
01.07.04 Diltiazem 2% rectal ointment 

To be used as second line choice only in patients intolerant of or unresponsive to GTN ointment.


 

02.06.02 Diltiazem Hydrochloride 

60 mg tablet formulations are safely interchangeable but should be prescribed as Tildiem® brand as it is more cost effective.


Other strengths are NOT interchangeable and should always be prescribed by brand name.


Preferred once daily modified-release brand:



  • Zemtard XL® capsules

  • Viazem XL®capsules for 360mg strength


Preferred twice daily modified release brand:



  • Angitil SR® capsules


 

08.02.04 Dimethyl fumarate 

 For the treatment of relapsing-remitting multiple sclerosis in line with NICE TA320.


Commissioned by NHSE

13.05.03 Dimethyl fumarate Skilarence®

In line with NICE TA475; commissioned by the CCG

NHS England is responsible commissioner for Multiple Sclerosis

07.01.01 Dinoprostone Propess®
07.01.01 Dinoprostone Prostin E2®

WVT Consultant use of vaginal tablets only.

14.04 Diptheria, tetanus,pertussis( whooping cough),polio,Haemophilus influenza type B(Hib),and hepatitis B. Infanrix hexa®

  • When used as part of the national immunisation programme, obtain stock via Immform.

02.09 Dipyridamole M/R Capsules 
02.03.02 Disopyramide 
10.02.01 Distigmine Bromide 
04.10.01 Disulfiram 

Prescribing by substance misuse specialists only. This includes GPs with appropriate training / competence who are contracted to provide substance misuse treatment on a shared care basis via a Locally Enhanced Service agreement between GP practices and the substance misuse specialist service provider.


 

02.07.01 Dobutamine Injection 
08.01.05 Docetaxel Taxotere®

In line With NICE TA101 & NICE TA109 

01.06.02 Docusate Sodium  

Capsules and solution.

05.03.01 Dolutegravir 

Commissioned by NHS England.

04.06 Domperidone 

Domperidone is now contraindicated in people:




    • With conditions where cardiac conduction is, or could be, impaired

    • With underlying cardiac diseases such as congestive heart failure

    • Receiving other medications known to prolong QT interval or potent CYP3A4 inhibitors

    • With severe hepatic impairment



 


 MHRA/CHM advice (updated December 2019): Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents

04.11 Donepezil Hydrochloride 

In Line With NICE TA217 (Replaces TA19 and TA111)
 

02.07.01 Dopamine Hydrochloride Injection 
02.07.01 Dopexamine Hydrochloride Injection 
03.07 Dornase Alfa 










AMBER GPs can continue to prescribe for existing patients & will be commissioned  by the CCG (when delivered via nebulisation/inhalation).
RED New patients to receive from Acute Trust Provider. Commissioned by NHS England for Cystic Fibrosis only.

 GPs should not take on any new prescribing of this drug.


 

11.06 Dorzolomide 
11.06 Dorzolomide 2% with Timolol 0.5% Cosopt®
13.02.01 DoubleBase Dayleve® 
03.05.01 Doxapram Hydrochloride 

Consultant use only

15.01.07 Doxapram Hydrochloride 
02.05.04 Doxazosin 

EXCLUDING modified-release tablets

07.04.01 Doxazosin 

  • Immediate release tablets

08.01.02 Doxorubicin Hydrochloride 
08.01.02 Doxorubicin Pegylated Liposomal Infusion Caelyx®

For  recurrent ovarian cancer in line with NICE TA389

05.01.03 Doxycycline 
13.06.02 Doxycycline  
19.19 Dressing pack Nurse It® Sterile dressing pack

Use



  • PRIMARY CARE ONLY

  • To be used for all wounds requiring aseptic dressing procedures.


Application



  • Single use

19.19 Dressing packs Softdrape® sterile dressing pack

Use



  • NHS supplies fro INPATIENT USE ONLY

  • To be used for all wounds requiring aseptic dressing procedures.


Application



  • Single use

02.11 Dried Prothrombin Complex Beriplex®
02.03.02 Dronedarone 

Only following specialist initiation and in line with NHSE&I "Items which should not routinely be prescribed in primary care" and NICE TA197.


See also HWCCG Dronedarone Prescribing Guidelines and MHRA guidance on cardiovascular, hepatic and pulmonary toxicity.

03.01.05 Drug Delivery Device(Spacer) 

  • AeroChamber Plus®

  • Volumatic®

06.01.02.03 Dulaglutide 

 

 GREEN  
 AMBER

When administration is with insulin: In line with NICE NG28, diabetes specialist initiation advice/recommendation should be sought when initiating GLP1 agonists in combination with insulin. 

04.03.04 Duloxetine  Cymbalta®

Step 3 for diabetic neuropathy - discontinue if inadequate response after 2 months.

07.04.02 Duloxetine Yentreve®

Second line for stress incontinence only, after physio and pelvic floor exercises

13.05.03 Dupilumab Dupixent®

In line with NICE TA534; commissioned by the CCG

NHS England is the responsible commissioner for use in asthma through the IFR process - Specialist Centre prescribing only

02.08.02 Edoxaban 

Edoxaban should be prescribed as first line DOAC in the treatment of non-valvular AF.

05.03.01 Efavirenz 

Commissioned by NHS England.

19.23 Elasticated tubular bandage Acti-Fast® 2 way stretch stockinette

Various sizes


Use



  • Two way stretch tubular bandage to be used under compression or retention bandaging if needed.

  • Can be used as a garment to retain dressing in hard to dress areas such as the head.


Application



  • As required.


Tip



  • Ensure correct size for limb is selected.

05.03.03.02 Elbasvir and grazoprevir Zepatier®

In line with NICE TA413

Commissioned by NHS England

09.01.04 Eltrombopag Revolade®

SECONDARY CARE PRESCRIBING ONLY

Approved for its licensed indication to be stopped if no improvement is seen within 2 of months of initiation of treatment.
In accordance with NICE TA 293 for ITP.

05.03.01 Elvitegravir 

Commissioned by NHS England.

06.01.02.03 Empagliflozin 

In line with NICE TA336 and TA390

05.03.01 Emtricitabine 

Commissioned by NHS England.

05.03.01 Emtricitabine, Rilpivirine and Tenofovir Eviplera®

Commissioned by NHS England

 

For the treatment of HIV 1 infection for those adult patients with a viral load of less than 100,000 RNA copies/ml unsuitable or unable to tolerate efavirenz or the combination product Atripla. 

05.03.01 Emtricitabine, Tenofovir, Cobicistat, Elvitegravir Stribild®

Commissioned by NHS England

13.02.01 Emulsifying ointment 
02.05.05.01 Enalapril 
05.03.01 Enfuvirtide 

Commissioned by NHS England.
Second line to other HIV therapy as per protocol

02.08.01 Enoxaparin sodium Clexane®Inhixa®

PRESCRIBE BY BRAND

Please ensure all prescribers are aware of the specific instructions relating to the prescribing of enoxaparin and ensure relevant staff understand the administration differences between Clexane® and Inhixa® and can counsel patients accordingly.

A2.02.02.01 Ensure ® Plus Milkshake style 

only use when first line supplements are not suitable or via PEG

A2.02.02.01 Ensure ® Plus Yoghurt style 

only use when first line supplements are not suitable or via PEG

09.04 Ensure® Plus Yoghurt & Milkshake Style

200mls. Ready to drink. ACBS requirements.

09.04 Ensure® Shake 

Mix with 200mls of whole milk. ACBS requirements

04.09.01 Entacapone 

Specialist initiation

05.03.03.01 Entecavir Baraclude ®

In line with NICE TA153
Commissioned by NHS England

08.03.03 Enzalutamide Xtandi®

For metastatic hormone-relapsed prostate cancer previously treated with a docetaxel containing regimen in line with NICE TA316.

Metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in line with NICE TA377.

12.02.02 Ephedrine Hydrochloride Nasal Drops

  • Short term use only. 

  • Patients with conditions suitable for self care should be advised to buy over the counter, in line with NHSE&I guidance.


 

02.07.02 Ephedrine Hydrocloride 
13.02.01 Epimax® ExCetra Cream 

Equivalent to Cetraben®

13.02.01 Epimax® Isomol Gel 

First choice emollient gel

Less excipients than Doublebase® gel

13.02.01 Epimax® Oatmeal Cream 
13.02.01 Epimax® Ointment 

First choice emollient ointment

Equivalent to Epaderm® ointment and similar to Hydromol® ointment

13.02.01 Epimax® Original Cream 

First choice emollient cream

Equivalent to Diprobase®

13.02.01 Epimax® Paraffin-Free Ointment 
08.01.02 Epirubicin hydrochloride 
02.02.03 Eplerenone 

Second-line to spironolactone for heart failure after acute MI with ejection fraction of 40% or less.

09.01.03 Epoetin alfa 

Commissioned by NHS England

09.01.03 Epoetin beta NeoRecormon®

Commissioned by NHS England

09.01.03 Epoetin Theta Eporatio®

Commissioned by NHS England

02.08.01 Epoprostenol Flolan®

ITU use only in haemofiltration

02.09 Eptifibatide Integrilin®
17 Eptotermin Alfa  Osigraft®
17 Erectile Dysfunction Vacuum Pump 

Can be prescribed in primary care following Consultant Urology recommendation; patient must be advised how to use the appliance by secondary care.

09.06.04 Ergocalciferol Injection 

Hospital use only for patients with high stoma output/ severe malabsorption.

07.01.01 Ergometrine Maleate Ergometrine
07.01.01 Ergometrine Maleate and Oxytocin Syntometrine®
08.01.05 Eribulin Halaven®

In line with NICE TA423

Eribulin is recommended as an option for treating locally advanced or metastatic breast cancer in adults, only when:
•it has progressed after at least 2 chemotherapy regimens (which may include an anthracycline or a taxane, and capecitabine)
•the company provides eribulin with the discount agreed in the patient access scheme

08.01.05 Erlotinib Tarceva®

First-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer in line with NICE TA258 


Non-small-cell lung cancer that has progressed after prior chemotherapy if EGFR-TK POSITIVE (or likely to be) in line with NICE TA374 



Commissioned by NHSE

05.01.02.02 Ertapenem 

To prescribe on microbiologist advice only.

06.01.02.03 Ertugliflozin 

In line with NICE TA572

05.01.05 Erythromycin 

To be prescribed as erythromycin 250mg gastro-resistant tablets.

05.01.05 Erythromycin Lactobionate Injection 

For use in pregnancy only

04.03.03 Escitalopram  
04.08.01 Eslicarbazepine acetate  

Following tertiary provider consultant recommendation in line with provider Shared Care Agreement.
 
MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history

02.04 Esmolol (injection) 
01.03.05 Esomeprazole tablets/capsules 
07.02.01 Estradiol 10mcg Pessaries Vagifem®
08.01.01 Estramustine Phosphate 
07.02.01 Estriol Cream 0.01%  
07.02.01 Estriol Cream 0.1% Ovestin®
10.01.03 Etanercept 

Biosimilar etanercept is available on the formulary in line with its licence.

CCGs commission in line with NICE TA35, TA36, TA103, TA195 (Update of TA36, 126 and 141),TA199(Update of TA 104), TA373, TA375 and TA383 (replaces TA143)

Paediatric use commissioned by NHS England
 

13.05.03 Etanercept 

In line with NICE TA103 and TA199; commissioned by the CCG

09.05.01.02 Etelcalcetide 

In line with NICE TA448.


NHSE/I commissioned. 

05.01.09 Ethambutol Hydrochloride 
02.13 Ethanolamine Oleate 
06.04.01.01 Ethinylestradiol 
08.03.01 Ethinylestradiol 

For Oncology indications

07.03.01 Ethinylestradiol / levonorgestrel phased pill  Triregol®, Logynon®

Phasic standard strength


Triregol® is preferred brand as more cost effective than Logynon® 


PRESCRIBE BY BRAND

07.03.01 Ethinylestradiol /etonogestrol vaginal delivery system NuvaRing® SyreniRing®

PRESCRIBE BY BRAND.

To be considered when all other options have been declined or are not suitable

07.03.01 Ethinylestradiol 20mcg / desogestrel 150mcg Gedarel® 20/150,Mercilon®

Monophasic low strength


Gedarel® 20/150 is preferred brand as more cost effective than Mercilon®


PRESCRIBE BY BRAND

07.03.01 Ethinylestradiol 20mcg / gestodene 75 mcg  Millinette® 20/75, Juliperla®, Femodette®

Monophasic low strength


Millinette®20/75 and Juliperla® are preferred brands as more cost effective than Femodette®


PRESCRIBE BY BRAND

07.03.01 Ethinylestradiol 30mcg / desogestrel 150mcg Gedarel®30/150, Cimizt®

Monophasic standard strength


Gedarel® 30/150 & Cimizt® are preferred brands as more cost effective than Marvelon®


PRESCRIBE BY BRAND

07.03.01 Ethinylestradiol 30mcg / gestodene 75 mcg Millinette®30/75, Sofiperla®, Femodene®

Monophasic standard strength


Millinette® 30/75 and Sofiperla®  are preferred brands as more cost effective than Femodene®


PRESCRIBE BY BRAND

07.03.01 Ethinylestradiol 30mcg / levonorgestrel 150mcg Rigevidon®,Levest®,Microgynon®

Monophasic standard strength


Rigevidon® & Levest® are preferred brands as are more cost-effective than Microgynon 30®


PRESCRIBE BY BRAND

07.03.01 Ethinylestradiol 30mcg / levonorgestrel 150mcg  Microgynon 30 ED®

Monophasic standard strength 'Every day' preparation


PRESCRIBE BY BRAND


 

07.03.01 Ethinylestradiol 35 mcg / noresthisterone 1mg Norimin®

Monophasic standard strength

07.03.01 Ethinylestradiol 35 mcg / noresthisterone 500mcg Brevinor®

Monophasic standard strength


PRESCRIBE BY BRAND

07.03.01 Ethinylestradiol 35 mcg / norgestimate 250 mcg (Cilique®, Lizinna®) 

Monophasic standard strength


PRESCRIBE BY BRAND


Note Cilest® was discontinued in July 2019

04.08.01 Ethosuximide 

Only through specialist recommendation (Adults) or Initiation (children).
 
MHRA Category 3 - It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors

10.01.01 Etodolac 

In Line With NICE CG59 and CG79 (Replace TA27)

15.01.01 Etomidate 
07.03.02.02 Etonogestrel implant Nexplanon®
08.01.04 Etoposide 
10.01.01 Etoricoxib 

First line Cox II inhibitor - prescribing by rheumatologists only

05.03.01 Etravirine 

Commissioned by NHS England.
Second line where other antiretrovirals within NNRTI class have failed.

08.01.05 Everolimus Afinitor®

Treating advanced breast cancer in combination with exemestane after endocrine therapy in line with NICE TA421

Commissioned by NHSE


02.12 Evolocumab Repatha®

In line with NICE TA394

08.03.04.01 Exemestane 
06.01.02.03 Exenatide 

The only formulation approved for use is the powder and solvent for prolonged-release suspension for injection (Bydureon®).


 













 GREEN  
 AMBER

When administration is with insulin: In line with NICE NG28, diabetes specialist initiation advice/recommendation should be sought when initiating GLP1 agonists in combination with insulin. 



 

02.12 Ezetimibe 

In line with NICE TA385

06.01.01.03 Fastclix Lancets 

A drum of 6 lancets for use with the Fastclix Lancing device only.

10.01.04 Febuxostat 

In Line With NICE TA164

02.12 Fenofibrate 
04.07.02 Fentanyl Abstral®

Approved for initiation and ongoing prescribing by palliative care clinicians ONLY.

04.07.02 Fentanyl Effentora®

Approved for initiation and ongoing prescribing by palliative care clinicians ONLY.

04.07.02 Fentanyl Instanyl®

Approved for initiation and ongoing prescribing by palliative care clinicians ONLY.

04.07.02 Fentanyl Actiq®

Approved for initiation and ongoing prescribing by palliative care clinicians ONLY.

15.01.04.03 Fentanyl 

In Primary Care for Palliative Care ONLY

04.07.02 Fentanyl Patches 

  • PRESCRIBE BY BRAND

  • Matrifen® is the brand of choice.

  • For patients unable to tolerate or swallow strong oral opioid morphine preparations.

  • Standardisation of opioid products is required to be prescribed solely by brand across the Herefordshire and Worcestershire Health Economy.
     




Occasionally some problems have been identified with adhesion of the patch with certain patients, although it is not obvious why. For these patients Fencino® is available as a second line option.
Durogesic DTrans® are also available as a third choice.


09.01.01.02 Ferric Carboxymaltose Ferinject®
09.01.01.01 Ferrous Fumarate 
09.01.01.01 Ferrous Gluconate 

Second line to ferrous fumarate and ferrous sulphate.

09.01.01.01 Ferrous Sulphate 
03.04.01 Fexofenadine Hydrochloride 

Prescribing to be considered only when alternative, more readily available OTC antihistamines have failed.

17 Fibrin Sealant Tisseel®
05.01.07 Fidaxomicin® 

For Consultant Microbiologist or Infectious Diseases Physician approval only for relapsing Clostridium difficile infection in patients where vancomycin treatment is not appropriate; or in patients with second or further antibiotic relapse of Clostridium difficile infection.

09.01.06 Filgrastim 
06.04.02 Finasteride 
08.02.04 Fingolimod Gilenya®

For the treatment of relapsing-remitting multiple sclerosis in line with NICE TA 254.


Commissioned by NHSE 

06.01.06 Flash glucose monitoring system 

Currently the only approved product is FreeStyle Libre.


March 2019: RESTRICTED TO SECONDARY CARE INITIATION in line with:



  • Flash Glucose Monitoring in Adults Commissioning Policy (link below)


 

02.03.02 Flecainide Acetate 
13.02.01 Flexitol® 10% Urea Cream 

Contains urea 10%

05.01.01.02 Flucloxacillin 

Capsules, injection and oral solution

05.02.01 Fluconazole 
08.01.03 Fludarabine Phosphate 

For the treatment of B-cell chronic lymphocytic leukaemia in line with NICE TA29.

As per NICE guidance OR with cyclophosphamide for CLL inpatients

06.03.01 Fludrocortisone acetate 
13.04 Fludroxycortide tape 

Potency: MODERATE

The brand Haelan® has been discontinued.

PRESCRIBE BY GENERIC NAME

15.01.07 Flumazenil 
12.01.01 Flumetasone Pivalate 0.02% with Clioquinol 1% Locorten-Vioform®
11.04.01 fluocinolone acetonide Iluvien®

In line with NICE TA 301:
Fluocinolone acetonide intravitreal implant is recommended as an option for treating chronic diabetic macular oedema that is insufficiently responsive to available therapies only if:
- the implant is to be used in an eye with an intraocular (pseudophakic) lens
and
- the manufacturer provides fluocinolone acetonide intravitreal implant with the discount agreed in the patient access scheme.

13.04 Fluocinolone acetonide 0.025% Synalar®

Potency: POTENT

13.04 Fluocinonide 0.05% Metosyn®

Potency: POTENT

11.08.02 Fluorescein Sodium Minims®

Diagnostic use

11.04.01 Fluorometholone eye drops FML®
08.01.03 Fluorouracil  

For oncology indications

13.08.01 Fluorouracil 0.5%, salicylic acid 10% solution Actikerall®
13.08.01 Fluorouracil 5% cream Efudix®
04.03.03 Fluoxetine 

  • Capsules, dispersible tablets, and oral solution.

  • (N.B. Dispersible tablets are more cost effective than the oral solution)

04.02.01 Flupentixol 
04.02.02 Flupentixol Decanoate Depixol® Conc.
04.02.02 Flupentixol Decanoate Depixol® Low Volume
04.02.02 Fluphenazine Decanoate Modecate®
08.03.04.02 Flutamide 
03.02.01 Fluticasone & formoterol Flutiform®

Flutiform® MDI, available in 50/5, 125/5 & 250/10 strengths


A preferred MDI option for asthma


PRESCRIBE BY BRAND

03.02.01 Fluticasone & salmeterol  Seretide®

Seretide®Accuhaler and MDI inhalers available for existing asthma patients only. 

Seretide®500 Accuhaler also available for existing COPD patients only 


PRESCRIBE BY BRAND

03.02.01 Fluticasone & salmeterol  Sirdupla® , Airfusal®

MDIs available in 125/25 & 250/25 strengths only 


Formulary options for asthma 

PRESCRIBE BY BRAND

03.02.01 Fluticasone & salmeterol  Airflusal® Forspiro

Airflusal® Forspiro 500 device for existing COPD patients only


PRESCRIBE BY BRAND

12.02.01 Fluticasone Furoate Nasal Spray

  • Treatment of allergic rhinitis, both seasonal and perennial, in people aged 6 years and over.

  • Patients with conditions suitable for self care should be advised to buy over the counter, in line with NHSE&I guidance.

  • Please note that purchase of steroid nasal sprays is restricted to patients aged 18 and over.


 

03.02.01 Fluticasone furoate & vilanterol  Relvar® Ellipta

Relvar® Ellipta 92/22  a preferred device for asthma (medium dose) and COPD 


Relvar® Ellipta 184/22  a preferred device for asthma only (high dose) 


PRESCRIBE BY BRAND

03.02.03 Fluticasone furoate/umeclidinium/vilanterol  Trelegy® Ellipta

Trelegy® Ellipta (DPI) 92/5/22


Patients currently on triple therapy should not automatically be optimised to this device without an assessment to confirm the need for triple therapy to continue


PRESCRIBE BY BRAND 


 

03.02.01 Fluticasone inhalers 

Inhaler devices (MDI, Accuhaler)

12.02.01 Fluticasone Propionate Nasal Spray

  • Treatment of allergic rhinitis, both seasonal and perennial, in people aged 6 years and over.

  • Patients with conditions suitable for self care should be advised to buy over the counter, in line with NHSE&I guidance.

  • Please note that purchase of steroid nasal sprays is restricted to patients aged 18 and over.


 

12.02.01 Fluticasone Propionate Nasal Drops®
12.02.01 Fluticasone propionate/azelastine hydrochloride Dymista®

For moderate to severe persistent allergic rhinitis where optimum response, following initial treatment failure with oral/topical antihistamines, has not been shown with a high dose intranasal corticosteroid alone and in combination with a separate oral/topical antihistamine and other lines of therapy; i.e. leukotriene receptor antagonist, allergan immunotherapy are being considered. This places Dymista® effectively fourth line in the British Society for Allergy and Clinical Immunology (BSACI) guidelines for the management of allergic and non-allergic rhinitis.

02.12 Fluvastatin 
19.07 Foam adhesive dressing Allevyn Adhesive® dressing

Sizes



  • 7.5cm x 7.5cm

  • 10cm x 10cm

  • 12.5cm x 12.5cm

  • Other sizes are available where needed but not routinely used.


Uses



  • Acute chronic full thickness or partial thickness or shallow granulating wounds 

  • Including pressure ulcers, leg ulcers, diabetic foot ulcers, malignant wounds, surgical wounds, donor sites and fungating ulcers

  • Can be used as primary or secondary dressing.


Applications



  • 3-7 days depending on exudate level


Cautions



  • Care with fragile skin.

19.07 Foam adhesive dressing Biatain Adhesive® dressing

Sizes



  • 7.5cm x 7.5cm

  • 10cm x 10cm

  • 12.5cm x 12.5cm

  • Other sizes are available where needed but are not routinely used.


Uses



  • Acute chronic full thickness or partial thickness or shallow granulating wounds

  • Including pressure ulcers, leg ulcers, diabetic foot ulcers, malignant wounds, surgical wounds, donor sites and fungating ulcers 

  • Can be used as primary or secondary dressing.


Applications



  • 3-7 days depending on exudate level


Cautions



  • Care with fragile skin

19.07 Foam adhesive dressing Tegaderm Foam® adhesive dressing

ONLY WHERE SHAPE IS CLINICALLY NECESSARY


Sizes



  • Oval - 6.9cm x 7.6cm

  • Oval - 10cm x 11cm

  • Oval - 14.3cm x 15.6cm

  • Oval - 19cm x 22.2cm

  • Circular - 13.9cm x 13.9cm


Uses



  • Acute chronic full thickness or partial thickness or shallow granulating wounds

  • Including pressure ulcers, leg ulcers, diabetic foot ulcers, malignant wounds, surgical wounds, donor sites and fungating ulcers 

  • Can be used as primary or secondary dressing.

  • Film border increases adherence

  • More expensive than square or rectangular foam dressings and should only be used where oval size is necessary for example heels and elbows


Applications



  • 3-7 days depending on exudate level


Cautions



  • Care with fragile skin


Tips



  • Their shape is also useful where patients pull at their dressings because the clear border is harder to see and pull

19.07 Foam non-adhesive dressing Allevyn® non-adhesive dressing

Sizes



  • 5cm x 5cm

  • 10cm x 10cm

  • 10.5cm x 13.5cm (heel)

  • Other sizes are available where needed but are not routinely used.


Uses



  • Wound management by secondary intention on acute, chronic, full thickness or partial thickness or shallow granulating wounds 

  • Including pressure ulcers, leg ulcers, diabetic foot ulcers, malignant wounds, surgical wounds, donor sites and fungating ulcers.

  • Can be used as a primary or secondary dressing


Applications



  • 3-7 days depending on exudate level


Cautions



  • If redness or sensitisation occur, discontinue use.

  • Caution under compression when exudate levels are moderate to high

19.07 Foam non-adhesive dressing Biatain Non-Adhesive® dressing

PODIATRY USE ONLY


Sizes



  • 10cm x 10cm

  • 15cm x 15cm

  • 5cm x 7cm

  • 10cm x 20cm


Uses



  • Wound management by secondary intention on acute, chronic, full thickness or partial thickness or shallow granulating wounds


Applications



  • 3-7 days depending on exudate level


Cautions



  • If redness or sensitisation occur, discontinue use.

  • Caution under compression when exudate levels are moderate to high.

09.01.02 Folic Acid 

400 microgram tablets considered to be self care.

17 Fomepizole 

Specialist use only for treatment of ethylene glycol and methanol poisoning.

02.08.01 Fondaparinux Sodium Arixtra®
09.04 Foodlink CompleteTM powder 

Mix with 200mls of whole milk. ACBS requirements

09.04 Foodlink CompleteTM with Fibre powder 

Mix with 200mls of whole milk. ACBS requirements

A2.02.01.02 Foodlink® Complete with Fibre  

mix with 200ml whole milk

09.06.07 Forceval® soluble tablets 

Dietitian recommendation only for tube-fed patients.

03.01.01.01 Formoterol Fumarate 

Inhaler devices (Easyhaler®,Oxis® Atimos®)


PRESCRIBE BY BRAND


Not to be used in asthma without an inhaled corticosteroid

A2.02.02.01 Fortisip ® Bottle 

only use when first line supplements are not suitable or via PEG

05.03.01 Fosamprenavir 

Commissioned by NHS England.

05.03.02.02 Foscarnet Sodium 

Commissioned by NHS England.
Cytomegalovirus infection

05.01.13 Fosfomycin Sachets 3g 

For the treatment of uncomplicated UTI in patients in whom nitrofurantoin and trimethoprim is not suitable AND pivmecillinam is contraindicated due to allergy.

06.01.06 Freestyle Lite 

For patients using Freestyle InsuLinx

06.01.06 FreeStyle Optium blood glucose test strips 

For use when patients have a history of DKA or very labile blood sugars.

02.11 Fresh Frozen Plasma 
02.02.02 Furosemide 
13.10.01.01 Fusidic Acid 2% Fucidin®

To be used in line with local H&W Guidelines for Primary Care Antimicrobial Prescribing.

Not for repeated use

04.08.01 Gabapentin  

Only through specialist recommendation (for adults) or specialist initiation(for children)

MHRA Category 3 - It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors

04.07.03 Gabapentin Capsules 

For Step 2 use in neuropathic pain. 

04.11 Galantamine 

In Line With NICE TA217
 Preferred brand GATALIN XL

05.03.02.02 Ganciclovir 

Commissioned by NHS England.
Cytomegalovirus infection

11.03.03 Ganciclovir 0.15% Virgan®
01.01.02 Gaviscon Infant 
08.01.05 Gefitinib Iressa®


In line With NICE TA192 and NICE TA374


Commissioned by NHSE

09.02.02.02 Gelatin 
12.03.01 Gelclair® concentrated oral rinse gel  

  • Gelclair concentrated oral rinse gel is available for secondary care prescribing ONLY for the prevention and treatment of oral mucositis in head and neck cancer patients undergoing radiotherapy and or chemotherapy treatment.

  • Stock is held on the required units at Worcestershire Royal Hospital.


08.01.03 Gemcitabine Gemzar®

 

For pancreatic cancer and metastatic breast cancer in line with NICE TA25 and NICE TA116 

For untreated metastatic pancreatic cancer in combination with paclitaxel as albumin-bound nanoparticles in line with NICE TA476

05.01.04 Gentamicin 

Nebulised gentamicin is supported as a second line option for eradication of Pseudomonas aeruginosa in patients with non-CF bronchiectasis who have ≥3 exacerbations per year who are colonised with Pseudomonas aeruginosa and are resistant to or cannot tolerate colistimethate sodium; with Microbiology approval. 

12.01.01 Gentamicin  Eardrops
11.03.01 Gentamicin drops 
12.01.01 Gentamicin 0.3% with Hydrocortisone Acetate 1% Gentisone® HC
12.03.05 Glandosane® Spray 
08.02.04 Glatiramer Acetate Copaxone®

For treating multiple sclerosis in line with NICE TA527.


Commissioned by NHSE

06.01.02.01 Gliclazide 
06.01.02.01 Glipizide 
06.01.04 Glucagon GlucaGen® HypoKit
06.01.04 GlucoGel® 

Formally known as Hypostop®

06.01.06 GlucoMen Areo® Sensor blood glucose test strips 

For patients with Type 1 Diabetes

06.01.03 Glucomen® Areo blood ketone test strips 

For patients who require ketone testing.

06.01.01.03 GlucoRx Safety Lancets 

Only for patients having blood glucose tests by a Health Care Professional.

09.02.02.01 Glucose Intravenous 
01.06.02 Glycerol (Glycerin) suppositories 
02.06.01 Glyceryl Trinitrate 

SL spray and SL tablets

01.07.04 Glyceryl Trinitrate 0.4% Rectogesic®

Only licensed GTN rectal ointment available in the UK

03.01.02 Glycopyrronium  

Approved for the maintenance treatment of COPD; to be considered as a daily option when initiating treatment for a new patient.


PRESCRIBE BY BRAND

03.01.04 Glycopyrronium & indacaterol 

Approved for  the maintenance treatment of COPD; to be considered as a once daily LAMA/LABA option when initiating treatment for a new patient


PRESCRIBE BY BRAND

15.01.03 Glycopyrronium 320 micrograms/ml oral solution 

Restricted to specialist initiation in the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged ≥3 years with chronic neurological disorders and the off-label use in adults for this indication.  In both scenarios Sialanar® should not be a 1st line option but considered after treatment failure with other antimuscarinics; noting the prescribing recommendations and cautions within the SPC. 


Once titrated to a maintenance dose in line with the SPC and deemed effective, requests can be made to Primary Care to take over prescribing; for paediatrics, it is stated in the SPC that following the dose titration period, the child's sialorrhoea should be monitored, in conjunction with the carer at no longer than 3 monthly intervals, to assess changes in efficacy and/or tolerability over time, and the dose adjusted accordingly.

15.01.03 Glycopyrronium bromide Injection

In Primary Care for Palliative Care ONLY

10.01.03 Golimumab 

In line with NICE TAs 220, 225, 233, 329,375 (Guidance replaces NICE TA224 and partially updates TA225)
and TA383 (Guidance replaces NICE TA233)

06.07.02 Goserelin Zoladex®

  • Zoladex - 3.6mg (monthly)

  • Zoladex L.A. - 10.8mg (3 monthly)

08.03.04.01 Goserelin Zoladex®

Early and advanced breast cancer - specialist initation only

08.03.04.02 Goserelin Zoladex®

Monthly injection

08.03.04.02 Goserelin Zoladex® LA

12-weekly injection 

04.06 Granisetron 
05.02.05 Griseofulvin tablets 
13.10.02 Griseofulvin tablets 

Tinea Capitis on specialist advice only

04.04 Guanfacine  

  • Consultant initiation only. 

  • In Line with local shared pathway.

  • M/R tablets 1mg/2mg/3mg/4mg

13.05.03 Guselkumab Tremfya®

In line with NICE TA521; commissioned by the CCG

14.04 Haemophilus influenzae type B / Menigitis Combined Vaccine Menitorix®

  • When given as part of the national immunisation programme, obtain stock via Immform.

04.02.01 Haloperidol 
04.02.02 Haloperidol Haldol Decanoate®
04.09.03 Haloperidol 
02.08.01 Heparin Calcium Subcutaneous 

On Consultant advice only

02.08.01 Heparin Sodium Flushes 

For use in long line and central lines only

02.08.01 Heparin Sodium IV 
14.04 Hepatitis A vaccine 

  • Available as an NHS service for travel.

14.04 Hepatitis A vaccine with Hepatitis B vaccine  

Combined Hepatitis A and B vaccine should not be prescribed for travel because Hepatatis B is not available on the NHS for purposes of travel. If required Hepatitis B can be offered to patients as a private service.


There are limited specific clinical circumstances listed in the Green Book where both Hepatitis A and B are indicated and where a combined product may be prescribed. In such circumstances the indication for the NHS indication should be recorded in the GP clinical system.

14.04 Hepatitis B vaccine 

  • Not available as an NHS service for travel.

  • Not to be prescribed on the NHS for occupational health purposes.


 


There are limited specific circumstances as listed in the Green Book where Hepatitis B vaccine is indicated. In such circumstances the indication for the NHS indication should be documented in the GP clinical record.

05.04.05 Hexadecylphosphocholine Miltefosine®

Infectious Diseases Consultant request only for patients who have not responded to first-line treatment with sodium stibogluconate or who have a high risk of toxicity to first-line treatment.

09.06.02 High Potency Vitamin B & C Injection Pabrinex®
19.11 Honey based topical application Activon® Medical Grade Manuka honey dressing

Size - 25g


Uses



  • Burns, chronic wounds, necrotic/sloughy wounds, donor sites, fungating wounds


Application



  • 3-7 dyas depending on exudate level


Cautions



  • Known sensitivity to the dressing or any of its components

  • Known allergy to bee venom and honey products.

  • Not suitable for full thickness burns or deep narrow cavities.


Tips



  • Blood sugars should be monitored in diabetic patients

19.11 Honey dressings sheet Activon Tulle® gauze dressing

Sizes



  • 5cm x 5cm

  • 10cm x 10cm


Uses



  • Infected wounds that need debriding. 

  • Creates a moist healing environment effectively eliminates odour.

  • Provides antimicrobial action.

  • Debrides and de-sloughs wounds.

  • Requires a secondary dressing


Application



  • Daily in acute infection

  • Up to 4 days in chronic infection dependent on exudate.


Cautions



  • Wounds with active blood loss. 

  • Known allergies to bee venom and honey products

  • Stinging sensation may be experienced on immediate contact especially in leg wounds. Discontinue and irrigate the wound if this occurs.


Tips



  • Blood sugars should be monitored in diabetic patients


 

19.11 Honey dressings sheet Algivon® dressing

Sizes



  • 5cm x 5cm

  • 10cm x 10cm


Uses



  • Primary dressing for infected, shallow cavity wounds, particularly if necrotic or malodorous with moderate exudate. 

  • Requires secondary dressing.  


Application



  • Daily in acute infection.

  • Up to 4 days in chronic infection dependent on exudate


Cautions



  • Wounds with active blood loss.

  • Known allergies to bee venom and honey products. 

  • Stinging sensation may be experienced on immediate contact especially in leg wounds. Discontinue and irrigate the wound if this occurs.


Tips



  • Blood sugars should be monitored in diabetic patients.

14.04 Human papilloma virus vaccine Gardasil®










RED

For men who have sex with men( MSM)- to be prescribed by the specialist sexual health services and HIV clinics . NHSE / PHE funded.


Green

When provided as part of the national immunisation programme, obtain stock via Immform.


02.05.01 Hydralazine Hydrochloride 
19.06 Hydrocolloid dressing Comfeel Plus® dressing

Sizes



  • 4 x 6cm

  • 10cm x 10cm

  • 15cm x 15cm

  • 20cm x 20cm

  • 17cm x 17cm


Uses



  • An absorbent hydrocolloid with waterproof top film. 

  • For moderately exuding wounds.

  • For the removal of superficial slough.


Applications



  • 1-7 days


Cautions



  • Not suitable for infected wounds, diabetic foot ulcers or ischaemic wounds.

  • Avoid if known product or component sensitivity.

19.06 Hydrocolloid dressing Comfeel Plus Contour® dressing

Sizes



  • 6cm x 8cm

  • 9 x 11cm


Uses



  • An absorbent hydrocolloid with waterproof top film. 

  •  For moderately exuding wounds.

  • For the removal of superficial slough.


Applications



  • 1-7 days


Cautions



  • Not suitable for infected wounds, diabetic foot ulcers or ischaemic wounds. 

  • Avoid if known product or component sensitivity.


 

19.06 Hydrocolloid dressing DuoDERM Extra Thin® dressing

Specialist use only - for making fixation tapes for paediatric use only


Sizes



  • 5cm x 10cm

  • 7.5cm x 7.5cm

  • 10cm x 10cm

  • 9cm x 15cm

  • 9cm x 25cm

  • 9cm x 35cm

  • 15cm x 15cm


Uses



  • In paediatrics to make fixation tapes for tubing. 


Applications



  • 3-7 days


Cautions



  • Not suitable for infected wounds, full thickness burns, all wounds with exposed bone, muscle or tendon or wounds that are likely to macerate. 

  • Known product or component sensitivity

19.06 Hydrocolloid fibrous dressing Durafiber® dressing

Sizes



  • 5cm x 5cm

  • 10cm x 10cm

  • 15cm x 15cm

  • 4cm x 10cm

  • 4cm x 20cm

  • 4cm x 30cm


Uses



  • Moderate to heavy exudate, sloughy, necrotic or granulating wounds.

  • Available as rope for cavities.


Applications



  • 1-7 days depending on clinical need


Cautions



  • Not suitable for dry wounds. 

  • Non-dissolvable.

  • Do not use in blind cavities.

  • Avoid if known product or component sensitivity


Tips



  • Do not cut


 

06.03.02 Hydrocortisone 
13.04 Hydrocortisone 0.5% or 1% 

Potency: MILD

Patients with conditions appropriate for self-care should be advised to buy over the counter, in line with NHSE&I guidance.

10.01.02.02 Hydrocortisone acetate Hydrocortistab®
13.04 Hydrocortisone butyrate Locoid®

Potency: POTENT

12.03.01 Hydrocortisone pellets 
01.05.02 Hydrocortisone Rectal Foam 

Colifoam®

11.04.01 Hydrocortisone sodium phosphate 3.35mg/ml Softacort®

Restricted for secondary care prescribing only for those patients who may benefit from a low corticosteroid potency, preservative-free formulation; longer-term off-label prescribing may occasionally be requested of primary care if duration of recommended treatment exceeds a month.     

19.03 Hydrogel dressing Intrasite Gel 8g

ONLY UNLESS DIRECTED BY SPECIALIST


Size - 8g


Use



  • Aids auto debridement and removal of devitalised tissue.

  • Use in low exuding, necrotic or sloughy wounds.


Application  - 1 to 3 days


Cautions



  • Not suitable for heavily exuding wounds, known product or component sensitivity, full-thickness burns or infected wounds.

  • Do not apply to ischaemic wounds.

19.03 Hydrogel dressing Intrasite Conformable ® dressing

Size



  • 10cm x 10cm

  • 10cm x 20cm


Use



  • Management of shallow and deep wounds healing by secondary intent, debridement and removal of devitalised tissue. 


Application - 1 to 3 days


Cautions



  • Not suitable for heavily exuding wounds, known product or component sensitivity, full-thickness burns or infected wounds.

  • Do not apply to ischaemic wounds.


Tips 



  • Do not allow to dry out

19.03 Hydrogel dressings ActiFormCool® sheet

Sizes



  • 5cm x 5.6cm

  • 10cm x 10cm


Use



  • Necrotic or sloughy wounds that require debridement and can aid pain relief.

  • Can be layered.

  • Ensure blue dotted side is upper most.

  • Requires a secondary dressing.


Application



  • 1-3 days or if dressing becomes discoloured or opaque or at first signs of exudate strikethrough.


Cautions



  • Should not be used as a covering for deep narrow cavities or sinuses.

  • Do not use on infected wounds.

  • Not suitable for heavily exuding wounds, known product or component sensitivity.

  • Do not apply to ischaemic wounds.


Tips



  • Can aid pain relief.


 

05.01.07 Hydrogen Peroxide 1% cream Crystacide®

To be used in line with local Guidelines for Primary Care Antimicrobial Prescribing for the treatment of local non-bullous impetigo.

13.02.01 Hydromol® Ointment 
09.01.02 Hydroxocobalamin 
08.01.05 Hydroxycarbamide 

For oncology indications

09.01.03 Hydroxycarbamide 
10.01.03 Hydroxychloroquine Sulphate 
03.04.01 Hydroxyzine Hydrochloride 
01.02 Hyoscine Butylbromide 

Injection and tablets though tablets are poorly absorbed

15.01.03 Hyoscine Hydrobromide  

In Primary Care for Palliative Care ONLY

03.07 Hypertonic sodium chloride solution 7% 

For nebulisation

06.06.02 Ibandronic acid  solution for injection

  • Treatment of osteoporosis in postmenopausal women at increased risk of fracture

  • Treatment of osteoporosis in men at increased risk of fracture (unlicensed use)

  • Solution for injection 1mg per 1ml

06.06.02 Ibandronic acid 150mg tablets 

  • Treatment of osteoporosis in postmenopausal women at increased risk of fracture

  • Treatment of osteoporosis in men at increased risk of fracture (unlicensed use)

06.06.02 Ibandronic acid 50mg tablets 

Indicated in adults for the prevention of skeletal events in patients with breast cancer and bone metastases.

08.01.05 Ibrutinib Imbruvica®

In line with NICE TA429
Ibrutinib alone is recommended within its marketing authorisation as an option for treating chronic lymphocytic leukaemia in adults:
•who have had at least 1 prior therapy or
•who have a 17p deletion or TP53 mutation, and in whom chemo-immunotherapy is unsuitable and
•only when the company provides Ibrutinib with the discount agreed in the patient access scheme

07.01.01.01 Ibuprofen Injection
10.01.01 Ibuprofen 
10.03.02 Ibuprofen 5% Gel  

Prescribe by brand name FENBID in primary care

100g is more affordable than 50g presentation

10.01.01 Ibuprofen Modified-Release 
03.04.03 Icatibant 

Firazyr®


Commissioned by NHS England

08.01.02 Idarubicin Hydrochloride 
02.08 Idarucizumab Praxbind®
08.01.05 Idelalisib Zydelig®

In line with NICE TA359 
Recommended for untreated CLL in adults with a 17p deletion or TP53 mutation, or for previously-treated CLL when relapsed within 24 months. Idelalisib is recommended only if the company provides the drug with the discount agreed in the simple discount agreement.

08.01.01 Ifosfamide 
02.05.01 Iloprost 

Unlicensed use in vascular patients. Manufacturer form must be completed by prescribing consultant and pharmacist.

08.01.05 Imatinib Gilvec®

In line with NICE TA86 & NICE TA326:

Adjuvant treatment of gastro-intestinal stromal tumours (GIST), in patients considered at high risk of relapse (based on risk criteria or mutation analysis), for up to 3 years. 

NICE TA209 specifies doses above 400mg not recommended.

NICE TA70 & TA426:
Imatinib is recommended as an option for untreated, chronic-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults.

Commissioned by NHSE

05.01.02.02 Imipenem with cilastatin (IM Injection) 

To prescribe on microbiologist advice only; for all other patients where a carbapenem is indicated while supply problems with meropenem.

04.03.01 Imipramine Hydrochloride 
13.07 Imiquimod 5% cream Aldara®
RED Secondary care use only for patients with external anogenital warts
AMBER For use in basal cell carcinoma
GREEN For use in actinic keratosis
13.08.01 Imiquimod 5% cream Aldara®
RED Secondary care use only for patients with external anogenital warts
AMBER For use in basal cell carcinoma
GREEN For use in actinic keratosis
13.02.01 ImuDERM®  

First choice emollient containing urea

Contains urea 5% and glycerol 5%

02.02.01 Indapamide 

2.5mg immediate release tablets

05.03.01 Indinavir 

Commissioned by NHS England.

07.01.01.01 Indometacin Injection
10.01.01 Indometacin 

Not to be used first line.
Suppositories permitted for pancreatitis.

10.01.01 Indometacin Modified-Release 

Not to be used first line

09.04.01 Infatrini®Peptisorb 

Suitable from birth. See Prescribing Guidleines.

01.05.03 Infliximab 

In Line With NICE TA163, TA329 and TA187 (Replaces TA40)
For use in Crohns and Ulcerative Colitis as per NICE guidance

Inflectra is the biosimilar preparation of choice in gastroenterology

10.01.03 Infliximab 

In line with NICE TA134, TA195 (Update of TA36, 126 and 141),TA199, 329,TA375 (replaces NICE TA130) and TA383 (replaces NICE TA143)


13.05.03 Infliximab infusion 

In line with NICE TA134 and TA199; commissioned by the CCG

  • NHS England is responsible commissioner for JIA and Crohn's disease in children. 
  • NHS England is responsible commissioner for uveitis, connective tissue disease - interstital lung disease, graft versus host disease, renal, pulmonary sarcoidosis, hidradenitis suppurativa and Behcet's syndrome use through the IFR process - Specialist Centre Prescribing Only.
14.04 Influenza vaccine  

  • In line with current NHSE guidance.


 



  • If stock is obtained via Immform for the national immunsation programme it should not be claimed on FP34PD.

06.01.01.01 Insulin Actrapid®

PRESCRIBE BY BRAND

06.01.01.01 Insulin Humulin® S

PRESCRIBE BY BRAND

06.01.01.01 Insulin Insuman® Rapid

PRESCRIBE BY BRAND

20 INSULIN 500 units in 1mL Humulin R®

UNLICENSED [Vials - (being discontinued); Kwikpen]


 


When managing diabetes with Humulin®R U-500, important steps must be taken to reduce the risk of prescribing and administration errors. It is extremely important that healthcare professionals prescribing or administering Humulin®R U-500 understand the strength is different to standard insulin currently available. 

06.01.01.01 Insulin 500 units/ml Humulin R ®

PRESCRIBE BY BRAND


Kwikpen - available (vial discontinued)


Imported unlicensed from United States.


HUMULIN R IS 5 TIMES THE STRENGTH OF STANDARD INSULINS - TAKE GREAT CARE WHEN PRESCRIBING OR ADMINISTERING.


 


 

06.01.01.01 Insulin aspart Fiasp®

PRESCRIBE BY BRAND


Worcestershire APC - FEBRUARY 2019:


 For restricted use only if:



  • First line use of conventional insulin aspart or insulin lispro has been tried and failed and ONLY on initiation and prescribing by a secondary care diabetic specialist. Primary care maintenance prescribing is supported only if the secondary care diabetic specialist determines significant benefit is evident by 3 months (reduction in hypoglycaemia/post prandial spikes) and HbA1c has not increased by > 5mmols:

  • Type 1 Diabetes Mellitus patients on insulin pumps who experience persistent problems with postprandial hypoglycaemia despite appropriate education and dose adjustment with their usual analogue soluble insulin.

  •  Type 1 Diabetes Mellitus patients on basal bolus insulin, who, despite optimisation of all other factors including correction of background or basal insulin, timing of bolus injections, optimised carbohydrate counting and improved injection technique/site still require tighter control (e.g. in patients where postprandial hyperglycaemia could be contributing to sub-optimal control of blood glucose and the patient is experiencing regular postprandial glucose ‘spikes’ of > 8mmol/mol 1 to 3 hours after eating) and are being considered for an insulin pump.

  • If first line use of conventional insulin aspart or insulin lispro has been tried and failed and ONLY on the initiation of a secondary care diabetic specialist with prescribing and monitoring maintained in secondary care:



  • Pregnant patients (Type 1, Type 2 or gestational diabetes mellitus) on insulin.


 

06.01.01.01 Insulin aspart NovoRapid®

PRESCRIBE BY BRAND

06.01.01.02 Insulin degludec Tresiba®

PRESCRIBE BY BRAND


 


MPC July 2020: Suitable for GP initiation following specialist recommendation, with advice.

Type 1 diabetes: Insulin degludec should be reserved for the following groups of patients with Type 1 diabetes:
• Difficult hypoglycaemia, particularly with loss of warning.
• Recurrent DKA.
• People who do shift work, particularly with a variable shift pattern.
• Patients being considered for pump therapy – would look to try insulin degludec first.
• Patients who are struggling with a pump and are looking for an alternative insulin regimen.

Type 2 diabetes: Insulin degludec should not be needed for Type 2 diabetes, unless there is very difficult hypoglycaemia that does not resolve with other measures. It has been agreed that Toujeo® is now the most appropriate long-acting insulin for insulin-resistant patients with Type 2 diabetes who need large doses.

06.01.01.02 Insulin detemir Levemir®

PRESCRIBE BY BRAND


Second line to insulin glargine 100units/ml

06.01.01.02 Insulin glargine  Lantus®

PRESCRIBE BY BRAND


06.01.01.02 Insulin glargine  Semglee®

PRESCRIBE BY BRAND. 


Semglee® (biosimilar insulin) is the first line insulin glargine 100units/ml preparation.



Semglee® has been shown to be equivalent to Lantus® in its pharmacokinetic and pharmacodynamic properties.  However, as with other biosimilar medicines, some dose adjustment may be needed if a switch is agreed through a face-face review. 


 This is a more cost effective preparation than Lantus® and Abasaglar® and is available as a 100 units/mL solution for injection in a pre-filled pen in the same device as Lantus®.

06.01.01.02 Insulin glargine  Abasaglar®

PRESCRIBE BY BRAND



06.01.01.02 Insulin glargine 300 units/mL Toujeo®

PRESCRIBE BY BRAND


High strength insulin glargine - 300 units/ml

Toujeo® is now the most appropriate long-acting insulin for insulin-resistant patients with Type 2 diabetes who need large doses.

Prescribing can be started and maintained in Primary Care as long as it has been discussed and endorsed by a Secondary Care Diabetology Specialist (including Secondary Care DSNs).

Insulin glargine formulations Semglee®/Lantus®/Abasaglar® (glargine 100units/ml) and Toujeo® (glargine 300units/ml) are not bioequivalent and therefore not interchangeable without dose adjustment. Please see Manufacturer's Prescribing Guidance

06.01.01.01 Insulin glulisine Apidra®

PRESCRIBE BY BRAND

06.01.01.01 Insulin lispro Humalog®

PRESCRIBE BY BRAND

06.01.01.01 Insulin lispro  Insulin Lispro Sanofi®

PRESCRIBE BY BRAND


Insulin Lispro Sanofi® (biosimilar insulin) is the first line insulin lispro 100 units/ml product for new patient initiations.


Insulin Lispro Sanofi® has been shown to be equivalent to Humalog® 100 units/ml in its pharmacokinetic and pharmacodynamic properties. However, as with other biosimilar medicines, some adjustment may be needed if a switch is agreed through a face-face review.


This is a more cost effective preparation than Humalog® 100 units/ml.

06.01.01.01 Insulin lispro 200 units/mL Humalog® KwikPen

PRESCRIBE BY BRAND


Bioequivalent to Humalog 100units/ml and the cost per unit is the same.
This double strength preparation could be useful for patients on large doses of soluble insulin - with associated reduction in waste.

08.02.04 Interferon Alfa 

For Hepatitis C in line with TA75


Commissioned by NHSE

08.02.04 Interferon Beta Avonex®

For treating multiple sclerosis in line with NICE TA527. 


Commissioned by NHSE

08.02.04 Interferon Beta Betaferon®

For treating multiple sclerosis in line with NICE TA527. 


Commissioned by NHSE

08.02.04 Interferon Beta Proleukin®

For treating multiple sclerosis in line with NICE TA527.


Commissioned by NHSE

08.02.04 Interferon beta Extavia®

For treating multiple sclerosis in line with NICE TA527.


Commissioned by NHSE

06.02.02 Iodide with iodine 
19.12 Iodine dressing Inadine® dressing

Sizes



  • 5cm x 5cm

  • 9.5cm x 9.5cm


Uses



  • Non-adherent dressing impregnated with povidone- iodine (10%). 

  • Mild local infection where there are low exudate levels.

  • Broad spectrum of antimicrobial activity.


Application



  • 1-3 days depending on uptake of iodine from dressing. 

  • The dressing will change colour from orange to white indicating when it needs to be changed


Cautions



  • Iodine allergy or sensitivity, thyroid disorders, renal impairment. 

  • Not suitable for children, pregnant or lactating women.

  • Do not use on large wounds or for prolonged periods of time due to possible systemic absorption.


 

19.12 Iodine dressing Iodoflex® paste dressing

Sizes



  • 5g

  • 10g


Uses



  • Iodine paste in gauze mesh for chronic infected sloughy wounds with moderate exudate

  • Including pressure ulcers, leg ulcers, diabetic foot ulcers

  • Can be used under compression bandaging.

  • Is an alternative to honey products for patients with bee allergy


Application



  • Daily for acute infection

  • Up to 3 days for chronic wounds and infection depending on exudate levels


Cautions



  • Allergy or sensitivity to iodine.

  • Precaution with large wounds due to absorption.

  • Not suitable for dry necrotic wounds, thyroid disorders, renal impairment

  • Not suitable for children, pregnant or lactating mothers or concurrent lithium therapy.


Tips



  • Do not use more than 50 g in a single application and no more than 150 g in 7 days

  • Do not use for more than three months if used constantly.

19.12 Iodine dressing Iodosorb ointment dressing, Iosdosorb powder dressing sachets

Sizes



  • Ointment dressing - 10g

  • Powder dressing sacht - 3g


Uses



  • Chronic exuding sloughy wounds 

  • Including leg ulcers, pressure ulcers, diabetic foot ulcers

  • Can be used under compression bandaging


Application



  • Daily for acute infection

  • Up to 3 days for chronic infection


Cautions



  • Allergy or sensitivity to iodine products

  • Not suitable for dry necrotic tissue

  • Not suitable for children, pregnant or lactating mothers, thyroid disorders or renal impairment


Tips



  • Needs at least twice weekly dressings for iodine to be effective

  • Do not use more than 50g in a single application and no more than 150g in 7 days.

  • Do not use for more than 3 months if used constantly

08.01.05 Ipilimumab Yervoy®

Recommended for previously treated advanced (unresectable or metastatic) melanoma as an option for treating advanced (unresectable or metastatic) melanoma in people who have received prior therapy, only if the manufacturer provides ipilimumab with the discount scheme agreed in the patient access scheme in line with NICE TA 268.

Ipilimumab is recommended as a possible treatment for adults with advanced (unresectable or metastatic) melanoma that has not been treated before in line with NICE TA319.

03.01.02 Ipratropium Bromide 

Inhaler devices and nebules

12.02.02 Ipratropium Bromide Nasal Spray
03.01.04 Ipratropium bromide & salbutamol Combivent® Nebules
02.05.05.02 Irbesartan 
09.01.01.02 Iron Dextran CosmoFer®
09.01.01.02 Iron Sucrose Venofer
15.01.02 Isoflurane 
05.01.09 Isoniazid 
06.01.01.02 Isophane insulin Insulatard®

PRESCRIBE BY BRAND

06.01.01.02 Isophane insulin Humulin® I

PRESCRIBE BY BRAND

06.01.01.02 Isophane insulin Insuman® Basal

PRESCRIBE BY BRAND



  • For Type 2 diabetes

  • Use human isophane insulin first before insulin analogues

02.07.01 Isoprenaline Sulphate Injection 
02.06.01 Isosorbide Dinitrate intravenous infusion Isoket®
02.06.01 Isosorbide Mononitrate 
02.06.01 Isosorbide Mononitrate Modified Release 

Preferred modified-release brands:



  • Chenydur XL® 60mg tablets

  • Monomil XL® 60mg tablets

  • Elantan LA® 25mg capsules

  • Elantan LA® 50mg capsules



13.06.02 Isotretinoin Roaccutane®

Should only be prescribed within secondary care under the lead of a Consultant Dermatologist.

13.06.01 Isotretinoin 0.05%, erythromycin 2% gel Isotrexin®
01.06.01 Ispaghula Husk 
05.02.01 Itraconazole oral
02.06.03 Ivabradine 














AMBER Chronic Heart Failure: In line with NICE TA 267.
AMBER Angina: In line with SPC
RED Prior to planned CT angiogram in asthmatic patients (Specialist initiation only): Ivabradine 5mg bd for 3 days. This off-label, non-formulary indication is used in patients who cannot have beta blockers, as they must have a heart rate less than 60 for the CT to give good enough images. Full 3 day supply must be prescribed and dispensed to patients by secondary care  i.e. not for primary care prescribing.
13.06.03 Ivermectin cream Soolantra®

Only consider as an option in patients where topical metronidazole and/or azelaic acid gel are ineffective or not tolerated.

08.01.05 Ixazomib Ninlaro®

With lenalidomide and dexamethasone for relapsed or refractory multiple myeloma in adults in line with NICE TA505.

13.05.03 Ixekizumab Taltz®

In line with NICE TA442 and TA537; commissioned by the CCG

A2.01.01.01 Jevity ®  
A2.01.02.01 Jevity ® 1.5 kcal 

for tube fed patients under care of dietitian team

04.07.03 Ketamine Oral Solution

Palliative Care Use ONLY

15.01.01 Ketamine 
10.03.02 Ketoprofen 2.5% Gel 

Second formulary option

15.01.04.02 Ketorolac Trometamol 
11.08.02 Ketorolac Trometamol 0.5% eye drops Acular®
06.01.03 KetosensTM blood ketone test strips 

For patients who require ketone testing.

11.04.02 Ketotifen Preservative Free unit dose Eye Drops Ketofall®

An option for the treatment of seasonal allergic conjunctivitis refractory to over the counter treatments and where a preservative-free option is desirable.

03.04.01 Ketotifen Tablets and Syrup 

Zaditen® -  Paediatrics only

02.04 Labetalol Hydrochloride 
04.08.01 Lacosamide 

MHRA Category 3 - It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors

01.06.04 Lactulose solution 
05.03.01 Lamivudine 

Commissioned by NHS England.

04.08.01 Lamotrigine 

Only through specialist recommendation (for adults) or specialist initiation(for children)

MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history

08.03.04.03 Lanreotide Somatuline LA® Autogel®

 

 

AMBER SC For neuroendocrine tumours only: Maintenance prescribing may be requested from GPs by specialists whilst giving supportive monitoring guidance.
RED For all other indications, including acromegaly
01.03.05 Lansoprazole Orodispersiible

For patients with swallowing difficulties

01.03.05 Lansoprazole capsules  
09.05.02.02 Lanthanum 

In line with NICE Clinical Guideline CG157 'Hyperphosphataemia in Chronic Kidney Disease' following initiation by a Renal Consultant.

Commissioned by NHS England. Maintenance prescribing may be requested from GPs whilst giving any supportive monitoring guidance.

11.06 Latanoprost 
11.06 Latanoprost 0.005% with Timolol 0.5% 
02.13 Lauromacrogol 400 / polidocanol  Aethoxysklerol®

APC MAR 20: Alternative sclerotherapy treatment option of varicose veins of the lower extremities (in line with commissioning policy), for a specific cohort of patients where the efficacy and safety profile makes it a preferred treatment choice over sodium tetradecyl sulfate

05.03.03.02 Ledipasvir and sofosbuvir  Harvoni®

In line with NICE TA363

Commissioned by NHS England

10.01.03 Leflunomide 
08.02.04 Lenalidomide Revlimid®

For multiple myeloma in adults who have had at least 2 prior therapies in line with NICE TA171

This drug is a possible treatment for people with transfusion-dependent anaemia, caused by low- or intermediate-1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality, when other treatments haven’t worked well enough in line with NICE TA322


Commissioned by NHSE

09.01.06 Lenograstim 
08.01.05 Lenvatinib Lenvima®

For treating differentiated thyroid cancer after radioactive iodine as per NICE TA535 


For untreated advanced hepatocellular carcinoma as per NICE TA551 

02.06.02 Lercanidipine 

HWMPC July 2020: Added to the formulary as an alternative to amlodipine where it may be of benefit for patients who experience ankle oedema.

08.03.04.01 Letrozole 
06.07.02 Leuprorelin Acetate Prostap DCS®

  • Prostap SR DCS - 3.75mg (monthly)

  • Prostap 3 DCS - 11.25mg (3 monthly)

08.03.04.02 Leuprorelin acetate Prostap® SR DCS

Monthly injection

08.03.04.02 Leuprorelin acetate Prostap® 3 DCS

3-monthly injection

04.08.01 Levetiracetam 

Only through specialist recommendation (for adults) or specialist initiation(for children).
 
MHRA Category 3 - It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors

11.06 Levobunolol Hydrochloride 0.5% eye drops 
15.02 Levobupivacaine 
15.02 Levobupivacaine with Fentanyl 
04.09.01 Levodopa 

Specialist initiation

05.01.12 Levofloxacin 

For severe CAP in patients with severe penicillin allergy in secondary care only. Not supported for the treatment of CAP or bronchiectasis exacerbations in primary care.

04.02.01 Levomepromazine Injection 

Palliative Care

07.03.05 Levonorgestrel Levonelle® 1500

Available in most pharmacies following consultation with a pharmacist

07.03.02.03 Levonorgestrel 13.5mg per 24 hour intra-uterine progestogen-only system Jaydess®

As an option; for its licensed indication i.e. contraception for up to 3 years.


PRESCRIBE BY BRAND

07.03.02.03 Levonorgestrel 19.5 microgram per 24 hour intra-uterine progestogen-only system Kyleena®

As an option; for its licensed indication i.e. contraception for up to 5 years. 


PRESCRIBE BY BRAND

07.03.02.03 Levonorgestrel 20 microgram per 24 hour intra-uterine progestogen-only system  Levosert®

PLEASE NOTE - Different fitting technique to Mirena.
A management option for heavy menstrual bleeding and a more affordable option for contraception than Mirena. 


PRESCRIBE BY BRAND

07.03.02.03 Levonorgestrel 20 microgram per 24 hour intra-uterine progestogen-only system  Mirena®

PRESCRIBE BY BRAND

07.03.02.01 Levonorgestrel 30mcg (Oral Progestogen Only Contraceptive) Norgeston®
06.02.01 Levothyroxine sodium 
15.02 Lidocaine 2.5% with Prilocaine 2.5% Emla
15.02 Lidocaine 5% plasters (700mg/medicated plaster) 

Forth line option for severe Post-Herpetic Neuralgia (PHN) pain which is not responsive to, or where the patient cannot tolerate, other agents.

Prescribe as Ralvo® brand

15.02 Lidocaine and chlorhexidine Hydro-Caine

CE Medical device - Lubricating gel for catheterisation.

15.02 Lidocaine HCl 2% with chlorhexidine gluconate 0.25% Instillagel®
15.02 Lidocaine HCl with Adrenaline 
02.03.02 Lidocaine Hydrochloride 
15.02 Lidocaine Hydrochloride 
15.02 Lidocaine hydrochloride LMX 4®

Approved as an alternative to EMLA by APC 6/12/11

11.07 Lidocaine Hydrochloride 4% with Fluorescein 0.25% Minims®

Diagnostic use

19.23 Lightweight conforming bandage K-Band® bandage,

Sizes



  • 5cm x 4m

  • 7cm x 4m

  • 10cm x 4m

  • 15cm x 4m


Use



  • Light weight conforming bandage used for retention of non-adhesive dressing products. 

  • Always use a primary dressing


Application



  • Change in line with dressing change.


Caution

05.01.07 Linezolid 
06.02.01 Liothyronine Sodium 

LIOTHYRONINE SHOULD ONLY BE PRESCRIBED BY AN NHS ENDOCRINE SPECIALIST















AMBER  TABLETS

Liothyronine has a similar action to levothyroxine but is more rapidly metabolised and has a more rapid effect; 20–25 micrograms is equivalent to 100 micrograms of levothyroxine. Its effects develop after a few hours and disappear within 24 to 48 hours of discontinuing treatment.


RED INJECTION

It may be used in severe hypothyroid states such as hypothyroid coma when a rapid response is desired.


08.01.02 Liposomal cytarabine–daunorubicin Vyxeos®

For untreated acute myeloid leukaemia in line with NICE TA552.


Commissioned by NHSE

13.02.01 Liquid and White Soft Paraffin Ointment (50:50) 
11.08.01 Liquid paraffin eye ointment Hylo-Night® formerly known as VitA-POS®

6 month post opening sterility, NOT suitable with contact lenses; 300 applications per tube.
This is the recommended alternative option to the non-formulary product Lacri-Lube® which has a 1 month expiry once opened; 210 applications per 3.5g tube and is a more expensive alternative.


 


Blinking enables eyes to renew a thin film of tears and keep them lubricated. It is because of the lack of blinking at night that this thin film of tears may not refresh itself properly and the majority of ocular damage can occur. A nightly application of ocular lubricant ointment e.g. VitA-POS® eye ointment can be of great benefit to dry eye patients and used regularly may reduce the need for daytime administration of ocular lubricants.

11.08.01 Liquid Paraffin Eye Ointment (Xailin Night) 

2 month post opening sterility.  This is a recommended alternative option to the non-formulary product Lacri-Lube® which has a 1 month expiry once opened; 210 applications per 3.5g tube and is a more expensive alternative.



Blinking enables eyes to renew a thin film of tears and keep them lubricated. It is because of the lack of blinking at night that this thin film of tears may not refresh itself properly and the majority of ocular damage can occur. A nightly application of ocular lubricant ointment eye ointment can be of great benefit to dry eye patients and used regularly may reduce the need for daytime administration of ocular lubricants.

06.01.02.03 Liraglutide 

1.8mg dose not recommended.













 GREEN  
 AMBER

When administration is with insulin: In line with NICE NG28, diabetes specialist initiation advice/recommendation should be sought when initiating GLP1 agonists in combination with insulin. 


04.04 Lisdexamfetamine 

  • Consultant initiation only. 

  • In Line with local shared pathway.

02.05.05.01 Lisinopril 
04.02.03 Lithium Carbonate Camcolit®
04.02.03 Lithium Carbonate Modified-Release Tablets Priadel®
04.02.03 Lithium Citrate Liquid Priadel®
06.01.02.03 Lixisenatide 

 













GREEN LIXISENATIDE SHOULD BE THE PRODUCT OF CHOICE WHEN A DAILY GLP-1 AGONIST IS TO BE USED.

 AMBER


 



When administration is with insulin: In line with NICE NG28, diabetes specialist initiation advice/recommendation should be sought when initiating GLP1 agonists in combination with insulin. 


04.03.01 Lofepramine 
04.10.03 Lofexidine Hydrochloride 

Prescribing by substance misuse specialists only. This includes GPs with appropriate training / competence who are contracted to provide substance misuse treatment on a shared care basis via a Locally Enhanced Service agreement between GP practices and the substance misuse specialist service provider.


 

08.01.01 Lomustine 
01.04.02 Loperamide  
05.03.01 Lopinavir and Ritonavir Kaletra®

Commissioned by NHS England.

03.04.01 Loratadine 

Patients with conditions appropriate for self-care should be advised to buy over the counter, in line with NHSE&I guidance

04.01.02 Lorazepam 
15.01.04.01 Lorazepam 
04.08.02 Lorazepam Injection 
02.05.05.02 Losartan Potassium 
19.01 Low adherent dressings – knitted polyester primary dressing Atrauman® dressing

Sizes



  • 5cm x 5cm

  • 7.5cm x 10cm

  • 10cm x 20cm

  • 20cm x 30cm


Use



  • Granulating and epithelializing wounds

  • Non to heavy exudate where adherence may occur

  • It's a primary dressing with a secondary for absorption


Application




  • Up to 7 days depending on levels of exudate




Cautions




  • Known product or component sensitivity



03.01.05 Low range peak flow meter 
05.01.03 Lymecycline 
  • Dermatology use, including acne (see guidance)
  • Used by oncology for the prevention of skin reactions due to cetuximab/ panitumumab therapy based on Christie Hospital protocol (instead of doxycyline)

 

13.06.02 Lymecycline 
01.06.04 Macrogol 
09.05.01.03 Magnesium aspartate Magnaspartate 243 mg powder for oral solution

Each 6.5g sachet of powder contains magnesium aspartate dihydrate equivilent to 243mg (10mmol) of magnesium.

09.05.01.03 Magnesium Hydroxide 5.5% Suspension 

Magnesium hydroxide suspension contains 7.12mmol/5mls of magnesium.

09.05.01.03 Magnesium Sulphate Injection 
20 magnesium sulphate injection 10%,50%  
01.01.01 Magnesium Trisilicate Mixture BP 
13.10.04 Malathion 0.5% Derbac-M®

Second choice

Patients with conditions appropriate for self-care i.e. headlice should be advised to buy over the counter, in line with NHSE&I guidance.

 

 

02.02.05 Mannitol 

Commissioned by NHSE as a contrast media in radiography.

03.07 Mannitol dry powder for inhalation 

In line with NICE TA266. Dry powder inhalation for treating cystic fibrosis 


Commissioned by NHSE

05.03.01 Maraviroc 

Commissioned by NHS England.
Second line where there are problems with adherence or toxicity to current anti-retroviral treatent.

14.04 Measles, Mumps and Rubella Vaccine, Live (MMR) 

  • When used as part of the national immunisation programme, obtain via Immform

05.05.01 Mebendazole 
01.02 Mebeverine Hydrochloride 
01.02 Mebeverine Hydrochloride Modified Release Colofac® MR

Second line to standard release tablets

13.02.02 Medi Derma-S® barrier cream 
13.02.02 MediHoney® barrier cream 
06.04.01.02 Medroxyprogesterone acetate 

  • Climanor®

  • Provera®


For the off-label indication of postponement of menstruation specifically for those women that are contraindicated to receive norethisterone due to VTE risk factors - see FSRH guidance.

08.03.02 Medroxyprogesterone Acetate 

For Oncology indications

07.03.02.02 Medroxyprogesterone acetate 104mg/0.65ml susp. in pre-filled injector Sayana Press®

LARC option: A subcutaneously injected formulation of medroxyprogesterone providing contraceptive cover for 13 weeks.

07.03.02.02 Medroxyprogesterone acetate 150mg/ml susp. pre-filled syringe Depo-Provera®

LARC option: Administered by deep intramuscuar injection, providing contraceptive cover for 12 weeks.

08.03.02 Megestrol Acetate 

For Oncology indications

04.01.01 Melatonin Modified-Release Tablets Circadin ®

  • Approved for the treatment of sleep disorders in children and adults associated with neurological and/or behavioural problems, including ADHD and autism, and in older adults with dementia where alternative hypnotics have failed.

  • Treatment should be specialist-initiated with transfer to primary care under shared care if specialist and GP in agreement.

10.01.01 Meloxicam 

In line with NICE CG59 and CG79 (Replaces TA27)

08.01.01 Melphalan 
04.11 Memantine Hydrochloride 

In line with NICE TA 217 (Replaces TA111)

09.06.06 Menadiol Sodium Phosphate 
14.04 Meningococcal A, C, W135, and Y conjugate vaccine Menveo®

  • Not to be given on the NHS as a service for travel.

  • When provided as part of the national immunisation programme, obtain stock via Immform.

14.04 Meningococcal group B vaccine Bexsero®

  • Not to be given as an NHS service for travel.


 



  • When provided as part of the national immunsation programme, obtain stock via Immform.


 



  • Bexsero® vaccine is restricted for children and adults with asplenia or splenic dysfunction or complement disorder in line with the up-to-date recommendations/schedules of the Public Health England - Green Book.

13.03 Menthol in aqueous cream Dermacool®, Menthoderm®

PRESCRIBE BY BRAND

Strengths available by brand:

  • Dermacool®: 0.5%, 1%, 2%
  • Menthoderm®: 1%, 3%, 5%

 

03.04.02 Mepolizumab Nucala®

Commissioned  by NHS England in line with NICE TA431 for the treatment of severe eosinophilic asthma

04.07.02 Meptazinol Injection 

Obstetrics use only

01.05 Mercaptopurine 

For initiation by Gastroenterology Specialist only. 

05.01.02.02 Meropenem 

To prescribe on microbiologist advice only.

01.05.01 Mesalazine Modified Release Tablets

PRESCRIBE BY BRAND.



  • Octasa® (currently the preferred brand)

  • Asacol® 

  • Pentasa®

  • Mezavant®- Once daily preparation.

01.05.01 Mesalazine Granules

PRESCRIBE BY BRAND



  • Salofalk® (currently referred brand)

  • Pentasa®

01.05.01 Mesalazine  Foam Enema

PRESCRIBE BY BRAND.



  • Asacol®

01.05.01 Mesalazine  retention enema

PRESCRIBE BY BRAND



  • Pentasa®

08.01 Mesna 
02.07.02 Metaraminol 
06.01.02.02 Metformin hydrochloride 
06.01.02.02 Metformin hydrochloride modified release 

Second line if intolerant to minimum effective dose of immediate release tablets


Modified release metformin preparations of choice on the formulary.



  • Sukkarto® SR

  • Yaltormin® SR 

04.07.02 Methadone Hydrochloride 
04.10.03 Methadone Hydrochloride preparations 

In Line With NICE TA114


Prescribing by substance misuse specialists only. This includes GPs with appropriate training / competence who are contracted to provide substance misuse treatment on a shared care basis via a Locally Enhanced Service agreement between GP practices and the substance misuse specialist service provider.

01.05.03 Methotrexate 
08.01.03 Methotrexate 

For oncology indications

10.01.03 Methotrexate Injection Metoject
13.05.03 Methotrexate subcutaneous / tablets 

For initiation by Dermatology Specialist only.

10.01.03 Methotrexate Tablets 

 


 


 


 


 

09.01.03 Methoxy Polyethylene Glycol-Epoetin Beta Micera®

Commissioned by NHS England


 

01.06.01 Methycellulose tablets Celevac®
02.05.02 Methyldopa 
04.04 Methylphenidate Hydrochloride MR caps 

PRESCRIBE BY BRAND



  • Brands include Medikinet® and Equasym®

04.04 Methylphenidate Hydrochloride MR tabs 

PRESCRIBE BY BRAND



  • Product of choice - Xaggitin® XL 

  • Other brands include: Concerta XL® and Matoride XL®

  • NB. Concerta XL® & Xaggitin XL® are bioequivalent and can be interchanged.

06.03.02 Methylprednisolone 

In line with NICE CG186.

10.01.02.02 Methylprednisolone Acetate Depo-Medrone®
06.03.02 Methylprednisolone acetate depot injection 
04.06 Metoclopramide Hydrochloride 

Note: Not for use in patients under 20 years old

02.02.01 Metolazone 

Metolazone 5mg tablets are now discontinued. 2.5mg tablets are available as an unlicensed 'special'.

02.04 Metoprolol Tartrate 
05.01.11 Metronidazole 
13.10.01.01 Metronidazole 0.75% cream Rozex®

Most cost effective choice of topical metronidazole for the treatment of  Rosacea.

13.10.01.01 Metronidazole 0.75% gel Anabact®

PRESCRIBE ONLY 15g

Only licensed indication(s) fungating tumours, gravitational ulcers and decubitus ulcers.

13.10.01.01 Metronidazole 0.75% gel Metrogel®

Quantity available 40g

Licensed indications are:

    • For the treatment of acute inflammatory exacerbation of rosacea.
    • For fungating tumours.

 

02.03.02 Mexiletine Hydrochloride 
05.02.04 Micafungin 

Commissioned by NHS England.

05.02.02 Miconazole oral gel
05.02.02 Miconazole 2% vaginal cream
07.02.02 Miconazole 2% vaginal cream 

  • 2% vaginal cream

13.10.02 Miconazole nitrate cream 

Patients with conditions appropriate for self-care should be advised to buy over the counter, in line with NHSE&I guidance.

12.03.02 Miconazole Oral Gel Daktarin®

Available over the counter in pharmacies. Consider self care.

06.04.01.02 Micronised progesterone (oral capsule) 

  • Utrogestan®


OCT 19: Due to HRT stock availability issues, Utrogestan® is available on the formulary, recommended as an option if combination patches are not available; i.e. enabling the option of oestrogen as a patch or gel with an oral progesterone.  

15.01.04.01 Midazolam 10mg/2mL 

In Primary Care for Palliative Care ONLY

04.08.02 Midazolam Buccal 

Specialist initiation.


PRESCRIBE BY BRAND - Buccolam® is the preferred brand


Buccolam® and Epistatus® are not interchangeable and there is high risk of harm if patients receive the incorrect brand and strength of buccal midazolam.

02.07.02 Midodrine Tablets  
08.02.04 Mifamurtide Mepact®

In combination with postoperative multi-agent chemotherapy is recommended within its licensed indication as an option for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection in children, adolescents and young adults in line with NICE TA235.

07.01.02 Mifepristone Mifegyne®
02.01.02 Milrinone 
07.04.02 Mirabegron 

For use in line with NICE TA 290 as an option for treating symptoms of overactive bladder when at least two antimuscarinics are contra-indicated, clinically ineffective or have unacceptable side effects.

04.03.04 Mirtazapine 
01.03.04 Misoprostol 

Misoprostol can prevent NSAID-associated ulcers. 

07.01.01 Misoprostol 

Misoprostol can be used orally, vaginally or rectally in the management of post partum haemorrhage and with mifepristone for medical terminations and induction of labour following intra-uterine fetal death.

08.01.02 Mitomycin 
08.01.02 Mitoxantrone (Mitozantrone) 
15.01.05 Mivacurium Chloride 
06.01.06 Mobile blood glucose test cassette 

For patients with needle phobia, paediatrics, visual impairments, dexterity issues with test strip insertion or sharps disposal issues.

04.03.02 Moclobemide 
04.04 Modafinil 

In line with licensed indication:


"Modafinil is indicated in adults for the treatment of excessive sleepiness associated with narcolepsy with or without cataplexy."

12.02.01 Mometasone Furoate Nasal Spray
13.04 Mometasone furoate 0.1% 

Potency: POTENT

PRESCRIBE BY GENERIC NAME

03.03.02 Montelukast 

Adjunctive therapy in asthma, to be added if required after introduction of inhaled LABA in a combination inhaler.

04.07.02 Morphine Sulfate (standard release) tablets Sevredol®

  • PRESCRIBE BY BRAND

  • Sevredol® is the standard release morphine sulfate preparation of choice.

  • Sevredol is a standard preparation and required to be prescribed solely by brand across the Herefordshire & Worcestershire Health Economy.

04.07.02 Morphine Sulfate 10mg/5mL oral solution Oramorph®

  • PRESCRIBE BY BRAND

  • Standardisation of opioid products is required to be prescribed solely by brand across the Herefordshire and Worcestershire Health Economy.

04.07.02 Morphine Sulfate modified release capsules 

  • PRESCRIBE BY BRAND

  • Zomorph® is the brand of choice for modified release morphine sulfate.

  • Standardisation of opioid products is required to be prescribed solely by brand across the Herefordshire and Worcestershire Health Economy.

04.07.02 Morphine Sulfate suspension (= sachet of granules to mix with water) MST Continus®

Available on the formulary for Percutaneous endoscopic gastrostomy (PEG) and nasogastric (NG) tube administration ONLY

05.01.12 Moxifloxacin 

MDR-TB under specialist supervision or otherwise under ID/micro recommendation only

02.05.02 Moxonidine 
12.03.01 Mucosamin® topical oral solution/spray 

  • Mucosamin® topical oral solution and spray are available for secondary care prescribing ONLY for the prevention and treatment of oral mucositis in head and neck cancer patients undergoing radiotherapy and or chemotherapy treatment.

  • Stock is held on the required units at Worcestershire Royal Hospital.


09.06.07 Multivitamin preparations Abidec®

For use in premature babies up to 6 months of age only and patients with cystic fibrosis where there is malabsorption

12.02.03 Mupirocin nasal ointment 

For eradication of MRSA nasal carriage

13.10.01.01 Mupirocin ointment/cream Bactroban®

To be used in line with local H&W Guidelines for Primary Care Antimicrobial Prescribing.

08.02.01 Mycophenolate Mofetil 

To be prescribed in line with NICE TA481 and TA482

Commissioned by NHSE when used post transplant. All new patients should receive treatment from the Acute Trust provider. GPs can continue to prescribe for any existing patients and this will be commissioned by the CCG.

RED For new post-transplant patients
AMBER SC For existing post-transplant patients



13.05.03 Mycophenolate mofetil tablets / capsules 

For initiation by Dermatology Specialist only.

For dermatomyocitis, polymyocitis, psoriasis, atopic dermatitis, autoimmune bullous dermatoses incl pemphigus - all unlicensed indications.  For use post transplant see section 8.2.1.

06.01.01.03 Mylife Safety Lancets 

Only for patients having blood glucose tests by a Health Care Professional.

04.06 Nabilone 

As an anti-emetic during systemic anti-cancer therapy if unresponsive to conventional treatments; in line with Network/Trust guidelines (WAHT MSC Aug 2020)

10.01.01 Nabumetone 

Consultant use only

02.06.04 Naftidrofuryl Oxalate 

In line with NICE TA223.

04.10.01 Nalmefene 

In line with NICE TA325


Prescribing by substance misuse specialists only. This includes GPs with appropriate training / competence who are contracted to provide substance misuse treatment on a shared care basis via a Locally Enhanced Service agreement between GP practices and the substance misuse specialist service provider.


 

01.06 Naloxegol Moventig®

In line with NICE TA345

15.01.07 Naloxone Hydrochloride 
04.10.03 Naloxone hydrochloride 1mg/mL Prenoxad®

Prescribing by substance misuse specialists only. This includes GPs with appropriate training / competence who are contracted to provide substance misuse treatment on a shared care basis via a Locally Enhanced Service agreement between GP practices and the substance misuse specialist service provider.


 

04.10.03 Naltrexone Hydrochloride Nalorex® & Opizone®,

In Line With NICE TA115


Prescribing by substance misuse specialists only. This includes GPs with appropriate training / competence who are contracted to provide substance misuse treatment on a shared care basis via a Locally Enhanced Service agreement between GP practices and the substance misuse specialist service provider.


 

10.01.01 Naproxen 
08.02.04 Natalizumab Tysabri®

For the treatment of adults with highly active relapsing–remitting multiple sclerosis in line with NICE TA127.


This is via other specialist secondary care providers

Commissioned by NHSE

 

02.04 Nebivolol 
03.01.05 Nebuliser diluent Sodium chloride 0.9%
04.07.01 Nefopam Hydrochloride 

Tablets and injection

08.01.03 Nelarabine 

Treatment of refractory T-cell lymphoblastic non-Hodgkin’s lymphoma or refractory T cell acute lymphoblastic leukaemia as a bridge to bone marrow transplantation.

05.03.01 Nelfinavir 

Commissioned by NHS England.

A2.03.01 Neocate Active 

For infants over 12 months

A2.03.01 Neocate LCP 
09.04.01 Neocate®Junior 

Suitable from 1 year onwards. (Flavoured & Unflavoured). See Prescribing Guidelines.

09.04.01 Neocate®LCP 

Suitable from birth

09.04.01 Neocate®Syneo 

Suitable from birth. See Prescribing Guidelines.

05.01.04 Neomycin Sulphate 
12.01.01 Neomycin Sulphate with Dexamethasone Otomize®

In line with the antimicrobial guidance.

10.02.01 Neostigmine 
15.01.06 Neostigmine Metilsulfate 
15.01.06 Neostigmine Metilsulfate with Glycopyrronium 
11.08.02 Nepafenac  Nevanac® SECONDARY CARE PRESCRIBING ONLY, including supply of a second bottle where required.

05.03.01 Nevirapine 

Commissioned by NHS England.

02.06.03 Nicorandil 
04.10.02 Nicotine preparations Nicorette Invisi®, Nicotinell®, NiQuitin® CQ

No behavioural support program associated with FP10 prescribing of NRT is currently available. Evidence shows a greater quit rate when smoking cessation products are combined with a support service.  GPs are therefore advised not to prescribe NRT on FP10. 


Refer all Herefordshire patients to Herefordshire Council Healthy Lifestyle Trainer Service (HLTS) for behavioural support and access to NRT pharmacotherapy. 01432 383567 healthylifestyle.trainerservice@nhs.net


Worcestershire patients who are pregnant can access NRT pharmacotherapy & behavioural support, contact: 


wah-tr.smokingcessationteam@nhs.net for more information. 


 

02.06.02 Nifedipine Modified Release 

Modified release nifedipine should be prescribed by brand because different versions may not have the same clinical effect.


Preferred once daily modified-release brands:



  • Coracten XL® capsules

  • Adipine XL® tablets


Preferred twice daily modified release brands:



  • Coracten SR® capsules

  • Adipine MR® tablets


 

08.01.05 Nilotinib Tasigna®

In line with NICE TA425 and TA426.

NICE TA426:
Dasatinib and nilotinib are recommended, within their marketing authorisations, as options for untreated chronic-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults. The drugs are recommended only if the companies provide them with the discounts agreed in the relevant patient access schemes
(NHSE is the responsible commissioner)

NICE TA425:
Dasatinib and nilotinib are recommended as options for treating only chronic- or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults, if:
•they cannot have imatinib, or their disease is imatinib-resistant and
•the companies provide the drugs with the discounts agreed in the relevant patient access schemes.

Commissioned by NHSE

02.06.02 Nimodipine 

See BNF for restricted indications.

03.11 Nintedanib Ofev®

  • Commissioned  by NHS England.

  • In line with NICE TA379 for the use in idiopathic pulmonary fibrosis

08.01.05 Nintedanib Vargatef®

In line with NICE TA347
-when given in combination with docetaxel (please see guidance for further details)
Funded by NHS England when used for Non-Small Cell Lung Cancer


Commissioned by NHSE

04.01.01 Nitrazepam 
05.01.13 Nitrofurantoin 
15.01.02 Nitrous oxide 
08.01.05 Nivolumab Opdivo®

Nivolumab as monotherapy is recommended, within its marketing authorisation, as an option for treating advanced (unresectable or metastatic) melanoma in adults in line with NICE TA384

Nivolumab in combination with ipilimumab is recommended, within its marketing authorisation, as an option for treating advanced (unresectable or metastatic) melanoma in adults in line with NICE TA400

Recommended, within its marketing authorisation, as an option for previously treated advanced renal cell carcinoma in adults in line with NICE TA417 

13.09 Nizoral® Shampoo 

For pityriasis versicolor in line with local H&W Guidelines for Primary Care Antimicrobial Prescribing.

Contains ketoconazole

02.07.02 Noradrenaline / Norepinephrine  
06.04.01.02 Norethisterone 
08.03.02 Norethisterone 

For Oncology indications

07.03.02.02 Norethisterone enantate Noristerat®

LARC option: Administered by deep intramuscular injection providing contraceptive cover for eight weeks.

14.05.01 Normal Immunoglobulin 

  • Brands include: Gammaplex®, Octagam® and Viagam®.


 

04.03.01 Nortriptyline 
A2.03.01 Nutramigen Puramino 
09.04.01 Nutramigen® PurAmino(Previously Nutramigen®AA) 

Suitable from birth to 6 months then as part of a mixed diet from 6 months onwards.

A2.02.02.01 Nutricrem®  

specialist supplements for patients with dysphagia, recommended by dietitian / SALT team

05.02.03 Nystatin 
12.03.02 Nystatin 100,000 units/ml suspension 
01.09.01 Obeticholic acid  Ocaliva®

In line with NICE TA443

Commissioned by NHSE

08.02.03 Obinutuzumab Gazyvaro®

In line with NICE TA343-
Obinutuzumab, given with chlorambucil, is recommendeded as a possible treatment for adults with untreated chronic lymphocytic leukaemia only if:
-they have other conditions that make full-dose fludarabine unsuitable for them,
-bendamustine is not suitable for them,
-the company provides obinutuzumab with the discount agreed in the patient access scheme
(see guidance for further information)

11.08.02 Ocriplasmin Jetrea®

In line with NICE TA 297
Ocriplasmin for treating vitreomacular traction states that:
Ocriplasmin is recommended as an option for treating vitreomacular traction in adults, only if:
an epiretinal membrane is not present
and
they have a stage II full-thickness macular hole with a diameter of 400 micrometres or less and/or they have severe symptoms.

12.02.03 Octenidine nasal gel Octenisan®
13.11.02 Octenisan® 

In line with local H&W Guidelines for Primary Care Antimicrobial Prescribing:

    • Antimicrobial wash lotion for MRSA skin carriage for 5 days.
    • MD nasal gel for use as a first line alternative option at times there is a national shortage of Bactroban® (mupirocin) 2% nasal ointment.
08.03.04.03 Octreotide Sandostatin®& Sandostatin Lar®

 

 

 

AMBER SC For neuroendocrine tumours only: Maintenance prescribing may be requested from GPs by specialists whilst giving supportive monitoring guidance.
RED For all other indications, including acromegaly
19.10 Odour absorbing dressing Clinisorb® dressing

Sizes



  • 10cm x 10cm

  • 10cm x 20cm

  • 15cm x 25cm


Uses



  • Odour absorbent charcoal dressing for malodorous wounds such as fungating wounds


Applications



  • 1-7 days dependent on exudate levels


Cautions



  • Do not use as a primary dressing in wounds

  • Exudate levels will reduce the effectiveness of the charcoal


 

06.04.01.01 Oestrogen only HRT 

For women without uterus - unopposed oestrogen



  • Elleste solo® tablets

  • Evorel® patches

  • Femseven®

  • Oestrogel®

08.01.05 Ofatumumab Arzerra®


Recommended in combination with chlorambucil as an option for untreated chronic lymphocytic leukaemia in line with NICE TA344.

05.01.12 Ofloxacin 
11.03.01 Ofloxacin eye drops Exocin®
13.02.01 Oilatum® Cream 
04.02.01 Olanzapine Tablets 

In Line With NICE CG185 and CG178 (Replaces TA43)

08.01.05 Olaparib  Lynparza®
12.01.03 Olive Oil Ear Drops

Patients with conditions appropriate for self care should be advised to buy over the counter, in line with NHSE&I guidance.

01.05.01 Olsalazine Tablets / Capsules
03.04.02 Omalizumab Xolair®

Commissioned  by NHS England in line with NICE TA278 (Updates of TA133 and 201) via designated specialist centres.

CCG commissioned in line with NICE TA339: Recommended as an option as add-on therapy for treating severe chronic spontaneous urticaria in adults and young people aged 12 years and over.

05.03.03.02 Ombitasvir, Paritaprevir and Ritonavir Viekirax®

In line with NICE TA365

Commissioned by NHS England

02.12 Omega-3-acid ethyl esters Omacor®

Following consultant lipidologist initiation for refractory hypertriglyceridaemia only.


Should not be routinely be prescribed in primary care, in line with national NHSE&I guidance.

01.03.05 Omeprazole Dispersible tablets

For patients with swallowing difficulties and where lansoprazole orodispersible is not appropriate/ tolerated.

01.03.05 Omeprazole capsules 
01.03.05 Omeprazole IV 
04.06 Ondansetron 
09.02.01.02 Oral Rehydration Salts Dioralyte®

Subject to contract

04.05.01 Orlistat 

NICE Pathway

04.09.02 Orphenadrine Hydrochloride 

Specialist initiation.

03.01.05 Oscillating positive expiratory pressure device 

The prescribing committee supported the addition of the Flutter® valve device (Clement Clarke) to the formulary, when required as an adjunct to Active Cycle of Breathing Techniques (ACBT) in patients with bronchiectasis, COPD bronchiectasis and Cystic Fibrosis and as an addition to ACBT in patients who need extra techniques to clear effectively or who are having repeated infections; ONLY following recommendation, training and supply by competent, qualified NHS respiratory physiotherapists as part of the MDT process; i.e. GP prescribing is NOT supported.


 


Acapella® device also supported in line with provider site preference with same restrictions.

05.03.04 Oseltamivir Tamiflu®

In line with NICE TA158 (Replaces TA67) and TA168 (Replaces TA58)

08.01.05 Osimertinib Tagresso ®

Osimertinib is recommended as an option for use within the Cancer Drugs Fund for treating locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer in adults whose disease has progressed only:
-after first-line treatment with an EGFR tyrosine kinase inhibitor and
-if the conditions in the managed access agreement for osimertinib are followed


in line with NICE TA416

08.01.05 Oxaliplatin 

In combination with capecitabine in the adjuvant treatment of stage III (Dukes' C) colon cancer in Line With NICE TA100 

04.01.02 Oxazepam 
04.08.01 Oxcarbazepine 

Only through specialist recommendation (for adults) or specialist initiation(for children)

MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history

07.04.02 Oxybutynin Hydrochloride 
07.04.02 Oxybutynin Hydrochloride Modified-Release 
07.04.02 Oxybutynin Hydrochloride Patches 

For patients unable to swallow tablets

04.07.02 Oxycodone hydrochloride modified-release tablets 

Second line option after morphine


PRESCRIBE BY BRAND
 


 

04.07.02 Oxycodone hydrochloride standard-release 

Second line option after morphine
 
PRESCRIBE BY BRAND

04.07.02 Oxycodone injection 

Second line option after morphine

04.07.02 Oxycodone oral solution 

Second line option after morphine

05.01.03 Oxytetracycline 
13.06.02 Oxytetracycline 
07.01.01 Oxytocin Syntocinon®
08.01.05 Paclitaxel 

In Line With NICE TA55  and TA389 


NICE TA389- The appraisal committee was unable to make recommendations on the use of these technologies for treating platinum-sensitive ovarian cancer beyond the first recurrence.

08.01.05 Palbociclib Ibrance®

With an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in line with NICE TA495 


With fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer in line with NICE TA619 

04.02.02 Paliperidone 3 monthly injection Trevicta®

PRESCRIBE BY BRAND


For the maintenance treatment of schizophrenia in adult patients who are clinically stable on (formulary) monthly paliperidone palmitate injectable product (Xeplion®).




04.02.02 Paliperidone monthly injection Xeplion®

 PRESCRIBE BY BRAND

05.03.05 Palivizumab Synagis®

In line with Public Health England advice; commissioned by NHS England
See Green Book - Immunisation Against Infectious Diseases

04.06 Palonosetron with netupitant  Akynzeo®
06.06.02 Pamidronate disodium 
01.09.04 Pancreatin 

  • Creon® 10000

  • Creon® 25000

  • Creon® 40000

  • Creon® Micro

  • Nutrizym® 22

  • Pancrex® V

15.01.05 Pancuronium Bromide 
08.01.05 Panitumumab  Vectibix®

In line with NICE TA439
Panitumumab is recommended, within its marketing authorisation, as an option for previously untreated RAS wild-type metastatic colorectal cancer in adults in combination with:
-FOLFOX or
-FOLFIRI 
The drugs are recommended only when the companies provide them with the discounts agreed in their patient access schemes.

08.01.05 Panobinostat  Farydak®

In line with NICE TA380
in combination with bortezomib and dexamethasone is recommended, within its marketing authorisation, as an option for treating multiple myeloma, that is, for ’adult patients with relapsed and/or refractory multiple myeloma who have received at least 2 prior regimens including bortezomib and an immunomodulatory agent’ when the company provides panobinostat with the discount agreed in the patient access scheme.

01.03.05 Pantoprazole tablets 
04.07.01 Paracetamol 

  • Availble over the counter.

  • Consider self care.

04.07.01 Paracetamol and codeine Co-codamol® 8/500
04.07.01 Paracetamol and codeine Co-codamol® 30/500




04.07.01 Paracetamol and dihydrocodeine Co-dydramol®
04.08.02 Paraldehyde Enema 

Specialist initiation

04.03.03 Paroxetine 
09.02.01.01 Patiromer calcium 
08.01.05 Pazopanib Votrient®

For first-line treatment of advanced renal cell carcinoma in line with NICE TA215


Commissioned by NHSE

17 Pegaspargase Oncaspar®

In line with NICE TA408

Commissioned by NHSE

09.01.06 Pegfilgrastim 
08.02.04 Peginterferon Alfa 

For Hepatitis B in line with NICE TA96


For Hepatitis C in line with TA75, TA106, TA200 and TA300.


Commissioned by NHSE

08.02.04 Peginterferon Beta Plegridy®

For treating relapsing–remitting multiple sclerosis in line with NICE TA624

Commissioned by NHSE

08.01.05 Pembrolizumab  Keytruda®

In line with NICE TA357, TA366 and TA428

 


Commissioned by NHSE

08.01.03 Pemetrexed Alimta®

For the treatment of



For the treatment of mesothelioma in line with NICE TA135

 

For the treatment of non small-cell lung cancer in line with NICE TA124, NICE TA181, NICE TA190 

 

For the treatment of non-squamous non-small-cell lung cancer after pemetrexed and cisplatin in line with NICE TA402 

 

10.01.03 Penicillamine 
05.04.08 Pentamidine Isetionate Pantacarinat®

Consultant request only

01.02 Peppermint Oil Enteric Coated 0.2ml 
01.02 Peppermint Oil Modified-Release 0.2ml caps Colpermin®

Second line to standard release capsules

01.02 Peppermint water 

Unlicensed 

01.01.02 Peptac 
04.08.01 Perampanel 

MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history

06.01.06 Performa Nano blood glucose test strips 

For patients with Type 2 Diabetes

04.09.01 Pergolide 

Specialist initiation only 


Note: Ergot-derived dopamine receptor agonists have been associated with pulmonary, retroperitoneal and pericardial fibrotic reactions. 

04.02.01 Pericyazine 
02.05.05.01 Perindopril Erbumine 
13.10.04 Permethrin 5% Lyclear® Dermal Cream

First choice

08.01.05 Pertuzumab Perjeta®

In line with NICE TA424
Pertuzumab, in combination with trastuzumab and chemotherapy, is recommended, within its marketing authorisation, as an option for the neoadjuvant treatment of adults with human epidermal growth factor receptor 2 (HER2) positive breast cancer; that is, in patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer at high risk of recurrence.
It is recommended only if the company provides pertuzumab with the discount agreed in the patient access scheme.


04.07.02 Pethidine Hydrochloride  
02.08.02 Phenindione 

Only when warfarin or DOAC not tolerated / clinically appropriate

04.08.01 Phenobarbital phenobarbitone

PRESCRIBE BY BRAND
 
MHRA Category 1 - Doctors are advised to ensure that their patient is maintained on a specific manufacturer’s product.

02.05.04 Phenoxybenzamine Hydrochloride 
05.01.01.01 Phenoxymethylpenicillin 

Oral solution and tablets

02.05.04 Phentolamine 
02.07.02 Phenylephrine Hydrochloride 
11.05 Phenylephrine Hydrochloride eye drops 

Diagnostic use

04.08.01 Phenytoin 

PRESCRIBE BY BRAND
 
MHRA Category 1 - Doctors are advised to ensure that their patient is maintained on a specific manufacturer’s product 



Note: Dose adjustment necessary when changing formulations

04.08.02 Phenytoin Sodium Epanutin® Ready Mixed Parenteral
04.08.02 Phenytoin Sodium Injection 
A2.07 Phlexy-Vits ® 

Sachets - Under Dietician advice for tube fed patients. Can be used in phenylketonuria and similar amino acid disorders

03.09.01 Pholcodine Linctus, BP 

Patients with conditions appropriate for self-care should be advised to buy the preparation over the counter, in line with NHSE&I guidance

09.05.02.01 Phosphate supplements Phosphate-Sandoz®
01.06.04 Phosphates (Rectal) 

  •  Fleet Ready to use Enema®

09.05.02.01 Phosphates Polyfusor 
09.06.06 Phytomenadione Konakion® MM

Secondary care staff: For intravenous or oral use. Follow the guidance on the reverse of warfarin charts.


 Not licensed for oral use but widely used

09.06.06 Phytomenadione Konakion® MM Paediatric

Licensed for intramuscular, intravenous or oral use

11.06 Pilocarpine 1%, 2% and 4% eye drops 
13.05.03 Pimecrolimus cream Elidel® cream

In line with NICE TA82; commissioned by the CCG
On recommendation of Dermatology Specialist only; GPs may issue first prescription.

06.01.02.03 Pioglitazone 
05.01.01.04 Piperacillin and Tazobactam  

Contains penicillin

04.09.03 Piracetam 

Specialist initiation

03.11 Pirfenidone Esbriet®

  • Commissioned by NHS England.

  • In line with NICE TA504 for use in idiopathic pulmonary fibrosis

10.01.05 Pirfenidone 

Funded by NHS England in line with NICE TA282 via designated specialist centres.
Recommended as possible treatment for patients with FVC between 50% and 80% of expected. Stop if disease worsens.

05.01.13 Pivmecillinam  

If first line options nitrofurantoin/trimethoprim are unsuitable for the treatment of acute UTIs in adult patients; only to be used for specific indication(s) in line with Herefordshire & Worcestershire antimicrobial prescribing guidelines.

Contains penicillin

08.01.02 Pixantrone Pixuvri®

For the treatment of lymphoma (non-Hodgkin’s, relapsed, refractory) in line with NICE TA306


Commissioned by NHSE

04.07.04.02 Pizotifen 
14.04 Pneumococcal polysaccharide conjugate vaccine (13-valent adsorbed) PCV

  • When provided as part of the national immunisation programme, obtain stock via Immform.


 



  • Brand to be used: Prevenar13®

14.04 Pneumococcal polysaccharide vaccine PPV

  • When provided as part of the national immunisation scheme, obtain stock via Immform.


 



  • There are limited specific clinical circumstances listed in the Green Book where pneumococcal vaccine is indicated. In such circumstances the reason for the NHS service should be noted in the GP clinical record.

13.07 Podophyllotoxin Warticon®

For the topical treatment of anogenital warts affecting the penis or the external female genitalia only.  Refer to Sexual Health Clinic for advice.

14.04 Polysaccharide Typhoid Vaccine Typhim Vi®

  • Available as an NHS service for travel.

08.02.04 Pomalidomide Imnovid®



Pomalidomide, in combination with low‑dose dexamethasone, is recommended as an option for treating multiple myeloma in adults previously treated with lenalidomide and bortezomib in line with NICE TA427.

Commissioned by NHS England

03.05.02 Poractant Alfa Curosurf®

  • For Neonates only

  • Approved for use for Respiratory distress syndrome 

19.18 Portable negative wound pressure therapy Pico® dressing kit

TVN advice ONLY


Sizes - Various


Use



  • Disposable and portable system designed to encourage granulation of the wound bed to kick start wound healing.

  • Can be used on various wounds including incision wounds to help strengthen the suture line.

  • Consider standard interactive dressing first.


Application



  • Twice a week dressing change.

  • PICO® device weekly change.


Caution



  • It should not be used on;

  • Confirmed and untreated osteomyelitis

  • Malignancy in wound bed or wound margins

  • Exposed blood vessels,

  • Organs

  • Unexplored fistulae

  • Necrotic wounds

  • Anastomotic sites

  • Emergency airway aspiration

  • Plueral, mediastinal or chest tube drainage.

  • Surgical suction


 


 

05.02.01 Posaconazole (intravenous and oral) 

Commissioned by NHS England.

09.02.01.01 Potasium Chloride Sando-K®
09.02.01.01 Potasium Chloride Kay-Cee-L®
09.02.02.01 Potassium Chloride and Glucose Intravenous Infusion  
09.02.02.01 Potassium Chloride and Sodium Chloride Intravenous Infusion 
09.02.02.01 Potassium Chloride Concentrate (Sterile) 

Only to be used by specialist staff in crtitical care areas in line with trust policy.

09.02.02.01 Potassium Chloride, Sodium Chloride and Glucose Intravenous Infusion 
07.04.03 Potassium Citrate 

Available Over the Counter.  Consider Self Care


If prescribing potassium citrate mixture most cost effective

13.11.06 Potassium Permanganate Permitabs®

For potassium permanganate soaks for weeping hand and/or foot eczema only. Maximum use 1-2 weeks

04.09.01 Pramipexole 

Specialist initiation only

Preferred modified release brand is Pipexus®
 

02.09 Prasugrel 
02.12 Pravastatin Sodium 
02.05.04 Prazosin 
07.04.01 Prazosin 
01.05.02 Prednisolone 

Plain tablets (2.5mg, 5mg, 10mg, 20mg, 25mg), soluble tablets (5mg) and (5mg/5ml) oral solution unit dose vials are formulary approved. However 25mg tablets and 5mg soluble tablets are less cost effective options in primary care so alternatives should be prescribed if possible. Enteric-coated are no longer approved following an APC decision in February 2010.

06.03.02 Prednisolone 

  • Plain tablets (2.5mg, 5mg, 10mg, 20mg, 25mg), soluble tablets (5mg) and (5mg/5ml) oral solution unit dose vials are formulary approved.

  • 25mg tablets and 5mg soluble tablets are less cost effective options in primary care so alternatives should be prescribed if possible.

  • Enteric-coated tablets are no longer approved following an APC decision in February 2010.

01.05.02 Prednisolone Suppositories 

Predsol®

11.04.01 Prednisolone acetate 1% eye drops Pred Forte®
01.05.02 Prednisolone Rectal Foam 
01.05.02 Prednisolone Rectal Solution 

Predsol®

11.04.01 Prednisolone sodium phosphate 0.5% single use eye drops  Minims® Prednisolone Sodium Phosphate
11.04.01 Prednisolone sodium phosphate 0.5% drops Predsol®
04.03 Pregabalin 
04.08.01 Pregabalin 

MHRA Category 3 - It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors

04.07.03 Pregabalin Capsules 

For Step 2 use in neuropathic pain
 

15.02 Prilocaine Hydrochloride Prilotekal®
02.03.02 Procainamide Hydrochloride 
08.01.05 Procarbazine 
04.06 Prochlorperazine 
04.09.02 Procyclidine Hydrochloride 

Specialist initiation.

06.01.01.03 PROFine pen needles 
04.02.01 Promazine Hydrochloride 
03.04.01 Promethazine Hydrochloride 
04.01.01 Promethazine Hydrochloride 
04.06 Promethazine Hydrochloride Injection 
04.06 Promethazine Teoclate 

For hyperemesis gravidarum

02.03.02 Propafenone Hydrochloride 
11.03.01 Propamidine Isetionate Brolene®

Of little use in bacterial infections. Only for Specialist use for treatment of acanthamoeba keratitis.

07.04.02 Propantheline Bromide 

May 2020: Current stock shortages

07.04.02 Propiverine Hydrochloride Immediate Release 
07.04.02 Propiverine Hydrochloride Modified-Release 
15.01.01 Propofol 
04.01.02 Propranolol 
06.02.02 Propranolol 
02.04 Propranolol Hydrochloride 
11.08.01 Propylene glycol 0.6% Systane Balance®

For meibomian gland dysfunction

06.02.02 Propylthiouracil 
02.08.03 Protamine Sulphate Injection 
11.07 Proxymetacaine Hydrochloride Minims®

Diagnostic use

11.07 Proxymetacaine Hydrochloride 0.5% with Fluorescein Sodium 0.25% Minims®

Diagnostic use

01.06 Prucalopride Resolor ®

In Line With NICE TA211

13.05.02 Psoralen 
05.01.09 Pyrazinamide 
10.02.01 Pyridostigmine Bromide 
09.06.02 Pyridoxine Hydrochloride 
04.02.01 Quetiapine 

In Line With NICE CG178 (Replaces TA43)

04.02.01 Quetiapine Modified Release 

In Line With NICE CG178 (Replaces TA43)


If a modified release preparation is required, then preferred brands are:



  • Sondate® XL (1st line choice)

  • Mintreleq®

  • Biquelle® XL
     

05.04.01 Quinine Sulphate 
10.02.02 Quinine sulphate 
13.02.01 QV® Cream 
13.02.01 QV® Intensive Ointment 
13.02.01 QV® Lotion  

First choice emollient lotion

14.05 Rabies immunoglobulin 

  • Post exposure vaccine should be obtained from Public Health England.

  • Not obtained via FP10 or claimed on FP34.

08.03.04.02 Radium-223 dichloride Xofigo®

In line with NICE TA412 


NICE TA412:Recommended as an option for treating hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases in adults, only if:
•they have already had docetaxel or
•docetaxel is contraindicated or is not suitable for them.
The drug is only recommended if the company provides radium‑223 dichloride with the discount agreed in the patient access scheme.

Commissioned by NHSE

06.04.01.01 Raloxifene hydrochloride 

In line With NICE TA160 and TA161 (Replaces TA87)

05.03.01 Raltegravir 

Commissioned by NHS England.
An option for the third line treatment, in combination with optimised background therapy, following failure of 1st and 2nd line antiretroviral tratment of HIV infection in adults, based on genotypic resistance profiling. Raltegravir may have advantages in those patients with cardiovascular risks.

08.01.03 Raltitrexed 
02.05.05.01 Ramipril 
11.08.02 Ranibizumab Lucentis® In Line With NICE Technology Appraisals for relevant indications (please see corresponding links).
01.03.01 Ranitidine 

Note: All formulations currently have little to no availability due to ongoing regulatory investigations as described in DHSC Medicine Supply Notification, below. Which also gives advice about alternatives (see tables at end of document). The CCG acknowledges that it may be necessary to prescribe H2-receptor antagonists which are not in the formulary (when a PPI is not clinically appropriate) while ranitidine stock issues persist. Prescribers are advised to liaise with community pharmacies about stock availability of alternatives and to be mindful of comparative costs.

02.06.03 Ranolazine 
04.09.01 Rasagiline 

Specialist initiation

10.01.04 Rasburicase 

For consultant use in acute hyperuricaemia

08.01.05 Regorafenib Stivarga®

For previously treated unresectable or metastatic gastrointestinal stromal tumours in line with NICE TA488 


For previously treated advanced hepatocellular carcinoma in line with NICE TA555 

05.03 Remdesivir 
15.01.04.03 Remifentanil 
09.06.07 Renavit 

On-going prescribing in dialysis patients on the recommendation of a Renal Dietician or Physician.

06.01.02.03 Repaglinide 

Second line add-on therapy to metformin for patients with irregular eating habits where HbA1c <8.5% 

OR

As an alternative to adding a glitazone in patients failing targets on metformin/sulfonylurea treatments (or on metformin alone where standard sulfonylureas have been problematic, where HbA1c <8.5%)

OR

Occasionally as monotherapy in lean type 2 patients where standard sulfonylureas have resulted in preprandial hypoglycaemia.

03.04.02 Reslizumab Cinqaero®

Commissioned by NHS England in line with NICE TA479 for the treatment of severe eosinophilic asthma

A2.05.02 Resource ® ThickenUp Clear 

See guidance

02.10.02 Reteplase Rapilysin®

In line With NICE TA52

04.08.01 Retigabine 

In line with NICE TA232.
 
MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history

05.03.05 Ribavirin 

In line with NICE TAs 75, 106, 200 and 300; commissioned by NHS England


Note: NICE TA75 has been extended by TA106 and partially updated by TA200 and TA300. TA106 has been partially updated by TA200 and TA300.

08.01.05 Ribociclib Kisqali®

With an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in line with NICE TA496.


Commissioned by NHSE

05.01.09 Rifampicin 
RED For use in the treatment of tuberculosis only
AMBER

For cellulitis associated with lymphoedema only and patient is known to be colonised with MRSA; on the advice of the consultant microbiologist, in line with Guidelines for Primary Care Antimicrobial Prescribing.

 AMBER

For chemoprophylaxis for close contacts (only when advised by PHE) in line with Guidelines for Primary Care Antimicrobial Prescribing only.

05.01.09 Rifampicin and Isoniazid Rifinah® 150, Rifinah® 300
05.01.09 Rifampicin and Isoniazid and Pyrazinamide Rifater®
05.01.09 Rifampicin, isoniazid, pyrazinamide and ethambutol  Voractiv®
05.01.07 Rifaximin Targaxan®

In line with NICE TA337; commissioned by the CCG.

05.03.01 Rilpivirine 

Commissioned by NHS England.
For the treatment of HIV 1 infection for those adult patients with a viral load of less than 100,000 RNA copies/ml unsuitable or unable to tolerate efavirenz or the combination product Atripla

04.09.03 Riluzole 

In line with NICE TA20


GPs can prescribe where there is appropriate shared care arrangements in place.

13.05.03 Risankizumab Skyrizi®

In line with NICE TA596; commissioned by the CCG

06.06.02 Risedronate sodium  
04.02.01 Risperidone 

In Line With NICE CG178 (Replaces TA43)

04.02.02 Risperidone Risperdal Consta®

In Line With NICE CG82 (Replaces TA43)

05.03.01 Ritonavir 

Commissioned by NHS England.

08.02.03 Rituximab 

For anti-neutrophil cytoplasmic - Antibody-associated vasculitis in line with NICE TA308.


For chronic lymphocytic leukaemia in line with NICE TA174 and TA193. 


For follicular lymphoma (first-line treatment of stage III-IV) in line with NICE TA243. 


For Non-Hodgkin's lymphoma in line with TA137 and TA226


Commisioned by NHSE



10.01.03 Rituximab 

Commissioned by CCG for Rheumatological conditions in line with NICE TA195 (Update of TA36, 126 and 141) and TA 308.

For anti-TNF treatment failure patients only; specialist rheumatologist only.
 
 Commissioned by NHS England for ITP.

02.08.02 Rivaroxaban 
04.11 Rivastigmine 

In Line With NICE TA 217 (Replaces TA19 and TA111)
 
Preferred brand for 4.6mg & 9.5mg patches is ALZEST

15.01.05 Rocuronium Bromide 
03.03.03 Roflumilast Daxas®

In line with NICE TA 461.

09.01.04 Romiplostim Nplate®

Funded by CCG in line with NICE TA221

04.09.01 Ropinirole 

Specialist initiation only
 

04.09.01 Ropinirole modified release 

For specialist initiation only
Primary care - prescibe by brand name REPINEX XL

15.02 Ropivacaine Hydrochloride 
02.12 Rosuvastatin 

Not for primary prevention; only for secondary prevention in those whose response is not considered adequate for other statins, despite maximum tolerated doses; or where there is contraindication to other statins due to interactions. 

04.09.01 Rotigotine 

In PD specialist initiation 
 
In Restless Leg Syndrome consultant recommendation only in patients with severe RLS where treatment with pramipexole and ropinirole has failed.

08.01.05 Ruxolitinib Jakavi®


In line with NICE TA386:


Ruxolitinib is recommended as an option for treating disease-related splenomegaly or symptoms in adults with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only:
-in people with intermediate-2 or high-risk disease,
-and if the company provides ruxolitinib with the discount agreed in the patient access scheme

Commissioned by NHSE

02.05 Sacubitril/valsartan  Entresto®

In line with NICE TA388

03.01.01.01 Salbutamol 

Inhaler devices, tablets, solution & nebules


 

07.01.03 Salbutamol 
03.01.01.01 Salbutamol IV 
12.03.05 Salivix® Pastilles 
03.01.01.01 Salmeterol 

Inhaler devices


PRESCRIBE BY BRAND - Be aware of differences in excipients among thr different MDI brands


Not be used in asthma without an inhaled corticosteroid.

05.03.01 Saquinavir 

Commissioned by NHS England.

10.01.03 Sarilumab 

In line with NICE TA485

06.01.02.03 Saxagliptin 
01.07.02 Scheriproct® 
13.05.03 Secukinumab Cosentyx®

In line with NICE TA350 and TA445; commissioned by the CCG

04.09.01 Selegiline Hydrochloride 

Specialist initiation

13.09 Selsun® Shampoo 

Contains selenium sulphide

06.01.02.03 Semaglutide 










 GREEN

SEMAGLUTIDE SHOULD BE THE PRODUCT OF CHOICE WHEN A ONCE WEEKLY GLP-1 AGONIST IS TO BE USED.


 AMBER

When administration is with insulin: In line with NICE NG28, diabetes specialist initiation advice/recommendation should be sought when initiating GLP1 agonists in combination with insulin. 


In line with the SPC, caution should be exercised when considering use in patients with diabetic retinopathy treated with insulin.


01.06.02 Senna 

Tablets and syrup

04.03.03 Sertraline 
09.05.02.02 Sevelamer 

In line with NICE Clinical Guideline CG157 'Hyperphosphataemia in Chronic Kidney Disease' following initiation by a Renal Consultant.

Commissioned by NHS England. Maintenance prescribing may be requested from GPs whilst giving any supportive monitoring guidance.

15.01.02 Sevoflurane 
19.23 Short stretch compression bandage Actico® bandage

Sizes



  • 4cm x 6m

  • 6cm x 6m

  • 8cm x 6m

  • 10cm x 6m

  • 12cm x 6m


Use



  • Venous leg ulceration

  • Lymphoedema

  • Management of chronic oedema.


Application



  • Daily to 7 days dependent on exudate levels if wound present or oedema management and bandage slipping as oedema is reduced.


Caution



  • Not recommended on those patients with ABPI lower than 0.8

  • Caution in diabetic patients

  • Caution when cardiac overload or renal failure present or suspected.


Tips



  • This is an  adhesive inelastic high compression bandage (short stretch bandage)


 

07.04.05 Sildenafil  

Formulary Dose: One tablet weekly prn

FIRST LINE OPTION. With evidence reviews showing no real benefit of one PDE-5 inhibitor over another, sildenafil coming off patent with the associated reduced cost and the revised DoH guidance removing the SLS criteria for sildenafil, sildenafil is the first-line PDE-5 inhibitor available on the formulary.


Prescribe generically

The use of a PDE-5 inhibitor after radical prostatectomy is not supported in this unlicensed indication.

19.13 Silver - topical Flamazine® (sulfadiazine silver 1%) cream

Sizes



  • 50g

  • 250

  • 500g


Use



  • For use on infected leg ulcers


Applications



  • Daily – occasionally alternate days 


Cautions



  • DO NOT USE FOR BURNS

  • Known product sensitivity.

  • Caution in patients with G6PD deficiency

19.13 Silver alginate dressing Biatain Alginate Ag® dressing

Sizes



  • 5cm x 5cm

  • 10cm x 10cm

  • 15cm x 15cm

  • 3cm x 44cm


Uses



  • Calcium alginate dressing with silver used in moderate to highly exuding wounds with a sloughy or granulating wound bed. 

  • Can also help haemostasis in wounds with minor bleeding.

  • Is biodegradable

  • Primary dressing only secondary dressing will be required.


Application



  • 1-4 days dependent on exudate levels.


Cautions



  • Do not use in individuals with a known sensitivity to any of the components of the dressing. 

  • Do not use on lightly exuding wounds as adherence is an issue

  • Extreme caution if used to tumours with friable tissue


Tips



  • Do not wet before use.


 

19.13 Silver dressing - low adherent 

Sizes



  • 5cm x 5cm

  • 10cm x 10cm

  • 10cm x 20xm


Uses



  • Clinically infected shallow, granulating wounds with low exudate. 

  • To be used as a primary dressing with a secondary for absorption.


Application



  • 1-7 days depending on levels of exudate


Cautions



  • Known product or component sensitivity. 

  • Must be removed prior to x-ray, ultrasound, diathermy and MRI

19.13 Silver dressing - low adherent Acticoat Flex 7® dressing

Sizes



  • 5cm x 5cm

  • 10cm x 12.5cm

  • 15cm x 15cm


Uses



  • Clinically infected shallow, granulating wounds with low exudate. 

  • To be used as a primary dressing with a secondary for absorption.


Application



  • 1-7 dys depending on levels of exudate


Cautions



  • Known product or component sensitivity. 

  • Must be removed prior to x-ray, ultrasound, diathermy and MRI

19.13 Silver dressings - low adherent Atrauman Ag® dressing

Sizes



  • 5cm x 5cm

  • 10cm x 10cm

  • 10cm x 20cm


Uses



  • Wound contact layer for clinically infected wounds. 

  • To be used as a primary dressing with a secondary for absorption.


Application



  • 1-7 days depending on levels of exudate


Cautions



  • Known product or component sensitivity

  • Must be removed prior to x-ray, ultrasound, diathermy and MRI

09.04.01 Similac® Alimentum®  

Suitable from birth onwards

03.09.02 Simple Linctus, BP 

Patients with conditions appropriate for self-care should be advised to buy the preparation over the counter

03.09.02 Simple Linctus, Paediatric BP 

Patients with conditions appropriate for self-care should be advised to buy the preparation over the counter

02.12 Simvastatin 
08.02.02 Sirolimus Rapamune®

 

To be prescribed in line With NICE TA481 and TA482

PRESCRIBE BY BRANDPE

Commissioned by NHS England when used post transplant. All new patients should receive treatment from the Acute Trust provider. GPs can continue to prescribe for any existing patients and this will be commissioned by the CCG.

RED For new post-transplant patients
AMBER SC For existing post-transplant patients

 

06.01.02.03 Sitagliptin 

25mg and 50mg doses are available on the formulary to enable dosage adjustment according to renal function.

06.01.02.03 Sitagliptin with metformin 
A2.03.01 SMA Alfamino 
09.04.01 SMA® Alfamino®  

Suitable from birth

09.04.01 SMA®Althera® 

Suitable from birth to 6 months

19.18 Snap cartridge device, Snap foam dressing kit 

PRESCRIBED SEPARATELY


Various sizes


Use



  • Disposable and portable system that can be used to encourage granulation of a wound bed or kick tart wound healing in a chronic wound.

  • As a step down from non-portable NWPT


Application



  • Can be left in place for up to seven days.


Caution



  • It should not be used on:

    • Confirmed and untreated osteomyelitis.

    • Malignancy in wound bed or wound margins

    • Exposed blood vessels

    • Organs

    • Unexplored fistulae

    • Necrotic wounds

    • Anastomotic sites

    • Emergency airway aspiration

    • Pleural, mediastinal or chest tube drainiage

    • Surgical suction




 

10.01.03 Sodium Aurothiomalate [Gold] Myocrisin®
09.02.01.03 Sodium Bicarbonate oral

Capsules most cost effective form.

09.02.02.01 Sodium Bicarbonate Injection / Intravenous Infusion
09.02.02.01 Sodium Bicarbonate Min-I-Jet® Sodium Bicarbonate
12.01.03 Sodium Bicarbonate Ear Drops

  • For removal of ear wax.

  • Patients with conditions suitable for self care should be advised to buy over the counter, in line with NHSE&I guidance. 


 


 

09.02.01.02 Sodium Chloride Slow Sodium®
09.02.02.01 Sodium Chloride Ringer's Solution for Injection
09.02.02.01 Sodium Chloride Sodium Lactate Intravenous Infusion (Compound)
12.02.02 Sodium Chloride 0.9% Normal Saline Nasal Drops

  • Treatment of allergic rhinitis, both seasonal and perennial, in people aged 6 years and over.

  • Patients with conditions suitable for self care should be advised to buy over the counter, in line with NHSE&I guidance. 


 


 

09.02.02.01 Sodium Chloride 0.9% Intravenous 
11.08.01 Sodium Chloride 0.9% unit dose Minims® saline
11.08.01 Sodium Chloride 5% eye drops  Consultant Opthalmologist prescribing only - Corneal oedema
11.08.01 Sodium chloride 5% eye ointment SPECIAL order product Consultant Opthalmologist prescribing only-corneal oedema. Unlicensed product
09.02.02.01 Sodium Chloride and Glucose Intravenous Infusion 
01.06.04 Sodium Citrate (Rectal) 
06.06.02 Sodium clodronate 
12.02.01 Sodium Cromoglicate Nasal Spray

  • Treatment of allergic rhinitis, both seasonal and perennial, in people aged 6 years and over.

  • Patients with conditions suitable for self care should be advised to buy over the counter, in line with NHSE&I guidance. 

11.04.02 Sodium Cromoglicate 2% eye drops 

Patients with conditions appropriate for self-care should be advised to buy the preparation over the counter, in line with NHSE&I guidance.


If prescribed issue 13.5ml pack size (smaller packs for OTC use are more expensive per dose).

03.03.01 Sodium Cromoglicate Inhaler Devices 
09.01.01.01 Sodium Feredetate Sytron®

April 2020: There is currently a supply problem with Sytron oral solution.


Worcestershire Acute Hospitals NHS Trust and Birmingham Children’s Hospital are therefore prescribing SodiFer oral solution instead for premature babies who need to be prescribed an iron preparation.


Note : SodiFer does not appear on the Emis picking list so it will need to be prescribed as “Sodium feredetate (iron 27.5mg/5ml) oral solution sugar free” and, if necessary, the dispenser advised SodiFer could be supplied.

05.01.07 Sodium fusidate 
11.08.01 Sodium hyaluronate 0.1% & Dexpanthenol 2% Hylo-Care®

Ophthalmology Specialist recommendation.  For limited duration following injury/surgery to the outside layer of the cornea. 

11.08.01 Sodium hyaluronate 0.15% Hyabak®

First line option for moderate dry eye (See local Guidelines on the Treatment of Dry Eye)
Soft shell bottle ,ay make it easier to aim and squeeze and subsequently improve compliance  
Recommended swap from Celluvisc® 0.5% single use eye drops (carmellose).

11.08.01 Sodium hyaluronate 0.15%; trehalose 3% Thealoz® Duo

Second line choice for moderate dry eye (See local Guidelines on the Treatment of Dry Eye)

11.08.01 Sodium hyaluronate 0.2% eye drops Hylo-Forte®

First line choice for moderate dry eye (See local Guidelines on the Treatment of Dry Eye)
(Easier to correctly administer than non-formulary Hylo®-Tear).  
Recommended swap from Celluvisc® 0.5% single use eye drops (carmellose).

11.08.01 Sodium hyaluronate 0.4% eye drops  Clinitas® Multi (Fresh)

Third line choice for moderate dry eye (See local guidelines on the treatment of dry eye)


09.02.02.01 Sodium Lactate Intravenous Infusion, Compound 
02.05.01 Sodium Nitroprusside 
09.08.01 Sodium Phenybutyrate Ammonaps®
01.06.02 Sodium Picosulfate liquid 

Used in paediatrics

05.04.05 Sodium Stibogluconate Pentostam®
02.13 Sodium tetradecyl sulphate 
04.08.01 Sodium Valproate 

Only through specialist initiation and specialist annual review

MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history

09.02.01.01 Sodium zirconium cyclosilicate 
05.03.03.02 Sofosbuvir Sovaldi ®

In line with NICE TA330


Commissioned by NHS England

05.03.03.02 Sofosbuvir and Velpatasvir  Epclusa®

In line with NICE TA430



Commissioned by NHS England

19.05 Soft polymer dressing with absorbent pad Allevyn Life® dressing

Sizes



  • 10.3cm x 10.3cm

  • 12.9cm x 12.9cm

  • 15.4cm x 15.4cm

  • 21cm x 21cm


Uses



  • Wound management by secondary intention on acute, chronic, full-thickness or partial-thickness or shallow granulating wounds. 

  • Including pressure ulcers, leg ulcers, diabetic foot ulcers, surgical wounds, malignant wounds, donor sites and fungating ulcers

  • Can be used as a primary or secondary dressing


Application



  • 3-7 days depending on exudate level.

  • Too frequent dressing changes particularly in patients of fragile skin can result in skin stripping.

  • If redness or sensation occurred discontinue use


Cautions



  • Caution under compression when exudate levels are moderate to high.


Tips



  • In common with all adhesive products, some cases of irritation and maceration of the skin may occur.  

19.05 Soft polymer dressing with absorbent pad Biatain Silicone® dressing

Sizes



  • 7.5cm x 7.5cm

  • 10cm x 10cm

  • 10cm x 20cm

  • 12.5cm x 12.5cm

  • 15cm x 15cm

  • 17.5cm x 17.5cm

  • 18cm x 18cm (heel)

  • 14cm x 19.5cm

  • 15cm x 19cm

  • 25cm x 25cm (sacral)


Uses



  • Wound management by secondary intention on acute, chronic, full-thickness or partial-thickness or shallow granulating wounds. 

  • Including pressure ulcers, leg ulcers, diabetic foot ulcers, surgical wounds, malignant wounds, donor sites and fungating ulcers.

  • Can be used as a primary or secondary dressing.


Applications



  • 3-7 days depending on exudate level.

  • Too frequent dressing changes particularly in patients of fragile skin can result in skin stripping.

  • If redness or sensation occurred discontinue use.


Cautions



  • Caution under compression when exudate levels are moderate to high.


Tips



  • In common with all adhesive products, some cases of irritation and maceration of the skin may occur.  

19.05 Soft polymer dressing with absorbent pad Biatain Silicone Lite ® dressing

Sizes



  • 5cm x 5cm

  • 5cm x 12.5cm

  • 7.5cm x 7.5cm

  • 10cm x 10cm

  • 12.5cm x 12.5cm


Uses



  • Wound management by secondary intention on acute, chronic, full-thickness or partial-thickness or shallow granulating wounds.

  • Including pressure ulcers, leg ulcers, diabetic foot ulcers, surgical wounds, malignant wounds, donor sites and fungating ulcers.

  • Can be used as a primary or secondary dressing.


Application



  • 3-7 days depending on exudate level.

  • Too frequent dressing changes particularly in patients of fragile skin can result in skin stripping.

  • If redness or sensation occurred discontinue use.


Cautions



  • Caution under compression when exudate levels are moderate to high.


Tips



  • In common with all adhesive products, some cases of irritation and maceration of the skin may occur.  

19.05 Soft polymer dressing without absorbent pad Adaptic Touch® dressing

Sizes



  • 5cm x 7.6cm

  • 7.6cm x 11cm

  • 12.7cm x 15cm

  • 20 x 32cm


Uses



  • Primary wound contact layer. 

  • Can be used in dry to heavily exuding wounds, to protect the fragile wound bed.


Application



  • Up to 7 days depending on clinical need 


Cautions



  • Avoid for patients with known sensitivity to silicone or cellulose acetate fabric.


 

19.05 Soft polymer dressing without absorbent pad Urgotul® dressing

SECONDARY CARE ONLY


Sizes



  • 5cm x 5cm

  • 10cm x 10cm


Uses



  • A non-adherent flexible soft silicone wound contact layer. 

  • Non to low exuding wounds, traumatic, superficial blistering.

  • Can be used as a contact layer in cavity wounds with secondary absorbent dressing.


Applications



  • Up to 7 days


Cautions



  • Known sensitivity to any components

19.05 Soft polymer dressing without absorbent pad Mepitel One® dressing

TVN ADVICE ONLY


Sizes



  • 6cm x 7cm

  • 9cm x 10cm

  • 13cm x 15cm

  • 24cm x 27.5cm

  • 27.5cm x 50cm


Uses



  • Soft polymer non adherent dressing. 

  • A primary wound contact layer, non-adherent, traumatic and chronic wounds.

  • Requires a secondary dressing  


Applications



  • 1-7 days


Cautions



  • Heavily bleeding wounds. 

  • Any sensitivity to silicone.


 

07.04.02 Solifenacin Succinate 
06.05.01 Somatropin 

Omnitrope® is the first line product of choice for those patients deemed suitable after assessment, in line with NICE TA64/ NICE TA188(Update of TA42)

08.01.05 Sorafenib Nexavar®

Commissioned by NHSE

02.04 Sotalol Hydrochloride 

For anti-arrythmic use only

02.02.03 Spironolactone 
03.01.05 Standard range peak flow meter 
05.03.01 Stavudine 

Commissioned by NHS England.

01.06.01 Sterculia Normacol®
02.10.02 Streptokinase 

In line With NICE TA52

19.23 Sub compression wadding bandage Cellona Undercast® padding bandage

Size



  • 5cm x 2.75m

  • 7.5cm x 2.75m

  • 10cm x 2.75m

  • 15cm x 2.75m


Use



  • Lymphoedema and under casts use only.

  • Provides padding for larger limbs under compression


Application



  • Daily up to weekly dependent on exudate levels and oedema management.


Caution



  • Do not apply directly to skin as it can cause irritation.


 


 

19.23 Sub compression wadding bandage K-Soft® bandage, K-Soft Long bandage

Size



  • K-Soft® - 10cm x 3.5m

  • K-Soft Long - 10cm x 4.5m


Use



  • Provides padding, shaping and protection of the limb prior to the application of compression bandage therapy.


Application



  • Daily up to weekly dependent on exudate levels and oedema management.


Caution



  • Do not apply directly to skinas it can cause irritation.

03.04.02 Sublingual Allergen Immunotherapy (SLIT)  

The availability of the SLIT armoury is supported as deemed appropriate both clinically and financially by the Specialist Division within WAHT; with consultant initiation and prescribing retained in secondary care. 


An annual update in relation to SLIT and noted outcomes will be received.

01.03.03 Sucralfate 

Tablets and suspension


Note:  unlicensed

15.01.06 Sugammadex 

For the reversal of neuromuscular block in anaesthesia induced by rocuronium or vecuronium, when suxamethonium is contra-indicated.

01.05.01 Sulfasalazine 
10.01.03 Sulfasalazine Enteric-Coated Tablets 
04.02.01 Sulpiride 
04.07.04.01 Sumatriptan 
08.01.05 Sunitinib Sutent®

Advanced and/or metastatic renal cell carcinoma in line with NICE TA169 

Gastrointestinal stromal tumours in line with NICE TA179 .

Commissioned by NHSE 

13.08.01 Sunscreens - Borderline Substances 

The British Association of Dermatology (BAD) recommend amongst their top sun safety tips for EVERYONE as standard that:

    • Skin should be protected with clothing, including a hat, t-shirt and sunglasses
    • Time should be spent in the shade between 11am and 3pm when it’s sunny
    • A ‘high protection’ sunscreen of at least SPF 30 which also has high UVA protection should be used, making sure it is applied generously and frequently when in the sun.

Most people prevent symptoms of sunburn developing with the routine use of sun protection with products that can easily be bought over the counter (OTC) in a pharmacy or supermarket.   The Medicines and Prescribing Committee does not support the prescribing of sunscreen preparations for routine use for the protection against the harmful effects of ultraviolet radiation.

A prescription for sun protection should not routinely be offered in primary care as the condition is appropriate for self-care.  Patients requesting a prescription for a sunscreen should be assessed on a case by case basis following a clinical consultation and in conjunction with Advisory Committee on Borderline Substances (ACBS) criteria.  Sunscreens approved for use by the ACBS and listed in the ‘Borderline Substances’ section of the British National Formulary (BNF) may ONLY be prescribed for skin protection against UV radiation in abnormal cutaneous photosensitivity.  Certain medicines may cause photosensitivity, however not all patients taking these medications will have photosensitivity and need sunscreen routinely prescribed. 

09.03 Supplementary Preparations Additrace®
09.03 Supplementary Preparations Cernevit®
09.03 Supplementary Preparations Dipeptiven®
09.03 Supplementary Preparations Peditrace®
09.03 Supplementary Preparations Solivito N®
09.03 Supplementary Preparations Vitlipid N®
19.15 Surgical absorbants Xupad

Use



  • Only for use on in-patient units


Application



  • 1-7days depending on exudate.


Caution



  • Not for more moderate or exuding wounds.

  • Always consider an interactive dressing.

19.15 Surgical absorbents Gauze Swabs type 13 light BP 1988 8ply sterile

Size



  • 7.5cm x 7.5cm (pack of 5)


Use



  • For use to clean peri wound area.

  • Wound bed cleansing should be done by irrigation.


Caution



  • Not to be applied as a wound dressing.


 

19.15 Surgical absorbents  Gauze swabs type 13 light BP 1988 8ply non-sterile

Size



  • 10cm x 10cm (pack of 100)


Use



  • For use to clean peri wound area

  • Wound bed cleansing should be done by irrigation.


Caution



  • Not to be applied as a wound dressing.

15.01.05 Suxamethonium Chloride 
08.02.02 Tacrolimus Prograf®, Modigraf® & Advagraf®

To be prescribed in line with NICE TA481 and TA482

PRESCRIBE BY BRAND

Commissioned by NHS England when used post transplant. All new patients should receive treatment from the Acute Trust provider. GPs can continue to prescribe for any existing patients and this will be commissioned by the CCG.

RED For new post-transplant patients
AMBER SC For existing post-transplant patients



13.05.03 Tacrolimus ointment Protopic® ointment

In line with NICE TA82; commissioned by the CCG
On recommendation of Dermatology Specialist only; GPs may issue first prescription.

07.04.05 Tadalafil 10mg, 20mg tablets 

SLS Criteria still apply

Formulary Dose: One tablet weekly prn (on demand preparation only)

SECOND LINE OPTION - With evidence reviews showing no real benefit of one PDE-5 inhibitor over another, sildenafil coming off patent with the associated reduced cost and the revised DoH guidance removing the SLS criteria for sildenafil, sildenafil is the first line PDE-5 inhibitor.


Prescribe generically



Daily dosing is NON- FORMULARY (i.e 2.5mg and 5mg strengths are Non-Formulary).

The use of a PDE-5 inhibitor after radical prostatectomy is not supported in this unlicensed indication.

17 Talimogene laherparepvec  

In line with NICE TA410

Commissioned by NHSE

08.03.04.01 Tamoxifen 

Note link to NICE CG 164 Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer

07.04.01 Tamsulosin Hydrochloride Modified-Release Capsules 
06.01.06 Tee 2+TM 

For patients with Type 2 Diabetes

08.01.03 Tegafur with Gimeracil and Oteracil Teysuno®

The use of Teysuno® with cisplatin was supported in line with the licence, for those patients with co-morbidities which would exclude them from the gold standard treatment with ECX/ECF, as an alternative to 5-FU and cisplatin.

05.01.07 Teicoplanin 
04.01.01 Temazepam  
15.01.04.01 Temazepam 
08.01.05 Temozolomide Temodal®

For the treatment of;


Recurrent malignant glioma (brain cancer) in line with NICE TA23


Newly diagnosed high-grade glioma in line with NICE TA121


This is via other specialist secondary care providers

08.01.05 Temsirolimus Torisel®
02.10.02 Tenecteplase Metalyse®

In line With NICE TA52

05.03.01 Tenofovir and Emtricitabine Truvada®

Commissioned by NHS England.

05.03.01 Tenofovir Disproxil 

In Line With NICE TA173
For chronic Hepatitis B - Commissioned by NHS England

05.03.01 Tenofovir, Efavirenz and Emtricitabine Atripla®

Commissioned by NHS England.

07.04.01 Terazosin 
13.10.02 Terbinafine Hydrochloride 1% cream Lamisil®

Patients with conditions appropriate for self-care should be advised to buy over the counter, in line with NHSE&I guidance.

05.02.05 Terbinafine tablets 
03.01.01.01 Terbutaline Sulphate 

Inhaler device (Pulmicort Turbohaler®), nebules 

07.01.03 Terbutaline Sulphate 
08.02.04 Teriflunomide Aubagio®

For treating relapsing-remitting multiple sclerosis in line with NICE TA303

Commissioned by NHS England

06.06.01 Teriparatide 

In line with NICE TA161 

06.05.02 Terlipressin acetate 

  • Solution for injection


 

06.01.06 Test strips Combur5®
06.01.06 Test strips Multistix 8SG®
06.01.06 Test strips Multistix SG®
06.01.06 Test strips Clinitest®

Pathology lab only

06.01.06 Test strips - glucose Diastix®
06.01.06 Test strips - glucose and ketones Keto-Diastix®
06.01.06 Test strips - ketones Ketostix®
06.04.02 Testosterone decanoate, isocaproate, phenylpropionate and propionate 

  • Sustanon® intramuscular injection


 

06.04.02 Testosterone enantate  

Intramuscular injection


 

06.04.02 Testosterone undecanoate 

  • Nebido® 250mg/ml intramuscular injection


Only to be prescribed for its licensed indication where frequent administration of an alternative intramuscular preparation is required and/or there are supply issues with the more affordable preparations.

14.05.02 Tetanus immunoglobulin 
04.09.03 Tetrabenazine 

Specialist initiation

15.02 Tetracaine (Amethocaine) Ametop®

Paediatrics only.

11.07 Tetracaine Hydrochloride [Amethocaine Hydrochloride] Minims®

Diagnostic use

06.05.01 Tetracosactide 

 




    • Synacthen® and Synacthen Depot®



 

08.02.04 Thalidomide Celgene®

Recommended option for specified people with multiple myeloma in line with NICE TA228.

Specialist haematologist use only - Following approved safety and therapeutic protocols only. Seek pharmacy advice, a high-cost drug application is required for some indications.

Commissioned by NHS England

03.01.03 Theophylline Uniphyllin Continus® & Nuelin SA®

Modified-release tablets


PRESCRIBE BY BRAND

09.06.02 Thiamine 
15.01.01 Thiopental Sodium 
08.01.01 Thiotepa 
04.08.01 Tiagabine 

MHRA Category 3 - It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors

06.04.01.01 Tibolone 

For persistent breakthrough bleeding only


 

02.09 Ticagrelor 
05.01.03 Tigecycline 

Consultant microbiologist or infectious disease initiation only.

13.05.03 Tildrakizumab Ilumetri®

In line with NICE TA575; commissioned by the CCG

11.06 Timolol Maleate 0.25% and 0.5% eye drops 
11.06 Timolol Maleate 0.25% and 0.5% Once -daily eye drops  

More expensive formulation - reserve for patients where compliance a problem

08.01.03 Tioguanine (Thioguanine) 
03.01.02 Tiotropium Spiriva Respimat®

For COPD & asthma


COPD:To be considered as a daily option when initiating treatment for a new patient where a dry powder inhaler is not suitable.


Asthma:Recommended as adjunctive treatment at BTS specialist therapies step.  


PRESCRIBE BY BRAND

03.01.02 Tiotropium Spiriva Handihaler®

Restricted for existing patients only


PRESCRIBE BY BRAND

03.01.02 Tiotropium Braltus Zonda®

Braltus Zonda® Inhaler - Preferred alternative for existing Spiriva Handihaler® patients only.


PRESCRIBE BY BRAND

03.01.04 Tiotropium & olodaterol Spiolto® Respimat

 LAMA/LABA option for COPD  patients unable to use dry powder inhalers


 PRESCRIBE BY BRAND

05.03.01 Tipranavir 

Commissioned by NHS England.
Third or fourth line to other HIV therapy

02.09 Tirofiban Aggrastat®
08.01.05 Tivozanib Fotivda®

For treating advanced renal cell carcinoma, in line with NICE TA512. 


 

10.02.02 Tizanidine 
05.01.04 Tobramycin 

In line with NICE TA276; commissioned by NHS England.

Nebulised solution for Cystic Fibrosis patients only.

RED New Patients to this treatment should be managed by the cystic fibrosis centre.
AMBER GPs should continue to prescribe for existing patients, which are commissioned by the CCG (when delivered via nebulisation/inhalation). GPs should not take on any new prescribing of this drug. 
10.01.03 Tocilizumab 

In line with NICE TA 238, 247(Replaced TA 198) and 375


Subcutaneous tocilizumab was approved for patients who fall in line with NICE TA 247 or the prescribing committee approved indication as monotherapy in case of intolerance to methotrexate or where continued treatment with methotrexate is inappropriate.
 
In line with NICE TA373-Commissioned by NHS England
people 2 years and older whose disease has responded inadequately to previous therapy with methotrexate.
 
In line with NICE TA375 (partially updates NICE TA247)

02.05.01 Tolazoline 
06.01.02.01 Tolbutamide 
07.04.02 Tolterodine Tartrate Immediate Release 
07.04.02 Tolterodine tartrate sustained release capsule 

Preferred brands are  NeditoXL and Mariosea® XL

06.05.02 Tolvaptan 

  • Jinarc® only


In line with NICE TA 358:Tolvaptan for treating autosomal dominant polycystic kidney disease



  • Samsca® for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion is NHS England commissioned and should only be prescribed by specialist centres.


Drug safety update: tolvaptan (Samsca) -risk of liver injury


NHS England commissioning policy for tolvaptan (Samsca) for the treatment of hyponatraemia secondary to SIADH in patients requiring chemotherapy

04.08.01 Topiramate 

Only through specialist recommendation (for adults) or specialist initiation(for children).

MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history.

08.01.05 Topotecan Hycamtin®

 


For relapsed small-cell lung cancer in line with NICE TA184 


For recurrent and stage IVB cervical cancers in line with NICE TA183 

08.01.05 Trabectedin Yondelis®


For the treatment of advanced soft tissue sarcoma in line with NICE TA185 

04.07.02 Tramadol Hydrochloride 

Capsules

04.07.02 Tramadol Hydrochloride SR 

Use non modified release preparation as first choice 


Preferred brands - Tramulief® and Marol®

08.01.05 Trametinib Mekinist®

In line with NICE TA396:
Trametinib in combination with dabrafenib is recommended as an option for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation

02.11 Tranexamic Acid Injection 
02.11 Tranexamic Acid Tablets 
08.01.05 Trastuzumab Herceptin®

For advanced breast cancer in line with NICE TA34

 

For early-stage HER2-positive breast cancer in line with NICE TA107

 

HER2-positive metastatic gastric cancer in line with NICE TA208 

11.06 Travoprost 
11.06 Travoprost with Timolol DuoTrav®
04.03.01 Trazodone Hydrochloride 
08.01.01 Treosulfan 
13.06.01 Tretinoin 0.025%, clindamycin 1% gel Treclin®
06.03.02 Triamcinolone acetonide 
10.01.02.02 Triamcinolone Acetonide Adcortyl® & Kenalog®

For intra-articular indications only

12.02.01 Triamcinolone Acetonide Nasal Spray
06.01.01.03 TriCareTM pen needles 
04.02.01 Trifluoperazine 
17 Trifluridine and tipiracil  Lonsurf®

In line with NICE TA405


Commissioned by NHSE

04.09.02 Trihexyphenidyl Hydrochloride [benzhexol] 

Specialist initiation

05.01.08 Trimethoprim 
05.01.13 Trimethoprim 
06.07.02 Triptorelin Decapeptyl®

  • Decapeptyl SR - 3mg (monthly)

  • Decapeptyl SR - 11.25mg (3 monthly)

  • Decapeptyl SR - 22.5mg (6 monthly)

08.03.04.02 Triptorelin 11.25mg Decapeptyl® SR

3-monthly injection

08.03.04.02 Triptorelin 22.5mg Decapeptyl® SR

6-monthly injection [Same price as 2 x 3-monthly (11.25mg) injection]

08.03.04.02 Triptorelin 3mg Decapeptyl® SR

4-weekly injection

11.05 Tropicamide 0.5% and 1% single use eye drops 

Diagnostic use

07.04.02 Trospium Chloride 
14.04 Typhoid Live Oral vaccine Vivotif®
19.17 UCS® debridement Pad 

Use



  • Acute or chronic wounds with surface debris eg. pressure ulcers, leg ulcers, diabetic foot ulcers.

  • Especially good with hyperkeratosis but thick hyperkeratosis may take more than one treatment.


Application



  • At each dressing change or as required.


Caution



  • Heavy slough and necrotic tissue may need autolytic debridement to soften prior to use.

07.03.05 Ulipristal Acetate EllaOne®

APC Nov 13: As an option for Emergency Hormonal Contraception (EHC) after unprotected sexual intercourse (UPSI) up to 120 hours after UPSI if copper containing intra-uterine device (IUD) is contraindicated or refused.


Available in most pharmacies following consultation with a pharmacist

13.02.01 Ultrabase® cream 
03.01.02 Umeclidinium  

Approved for the maintenance treatment of COPD; to be considered as a daily option when initiating treatment for a new patient.


 PRESCRIBE BY BRAND

03.01.04 Umeclidinium & vilanterol  Anoro® Ellipta.

Approved for the maintenance treatment of COPD; to be considered as a once daily LAMA/LABA option when initiating treatment for a new patient.


PRESCRIBE BY BRAND

01.07.02 Uniroid HC® 
01.09.01 Ursodeoxycholic acid 
13.05.03 Ustekinumab infusion / subcutaneous Stelara®

In line with NICE TA180 and TA340; commissioned by the CCG

Commissioned by NHSE when used for Paediatric indications.

19.18 V.A.C.® KCl Medical Ltd Negative Wound Pressure Therapy system 

Trust contract - SECONDARY CARE ONLY (Must send a referral form to TV for unding approval.


Use



  • Required components: Pump, dressings, foam or gauze, tubing and cannister.

  • Acute, chronic and traumatic wounds.

  • Can be used as an adjunct to surgery and for salvage procedures such as wound dehiscence.

  • Benefits are that it removes excess fluid that may contain bacterial pathogens, reduces soft tissue oedema, promotes granulation and provides a moist wound healing environment. 


Application



  • Canister change determined by exudate levels.

  • Different canister sizes available.

  • Dressings changed every three days.


Caution



  • It should not be used on:

    • Grossly infected or bleeding wounds

    • Malignancy

    • Exposed blood vessels

    • Organs

    • Unexplored fistulae

    • Extensive necrotic wounds.



  • Caution with foam - document the number inserted and ensure all pieces are retreived.


Tips



  • The use of sub atmospheric pressure to promote or assist wound healing or to remove fluids froma site.

  • Required components: pump, dressings foam or gauze, tubing and canister.

05.03.02.01 Valaciclovir 

To be used only by Sexual Health Clinic and Ophthalmology.

05.03.02.02 Valganciclovir 

Commissioned by NHS England.
Cytomegalovirus infection

04.02.03 Valproic Acid Depakote®

  • Only through specialist initiation and annual review

  • As valproate semisodium

02.05.05.02 Valsartan 
05.01.07 Vancomycin (oral) 

On microbiologist advice for C difficile if no response to metronidazole, in line with Herefordshire & Worcestershire antimicrobial prescribing guidelines.

19.04 Vapour permeable dressing Tegaderm® + pad dressing

Sizes



  • 5cm x 7cm

  • 9cm x 10cm

  • 9cm x 15cm

  • 9cm x 20cm

  • 9cm x 25cm

  • 9cm x 35cm


Use



  • Post- operative closed surgical wounds.


Application



  • Up to 7 days


Cautions



  • Clinically infected wounds bleeding or exiting exuding wounds


 

19.04 Vapour permeable dressing IV3000®

Sizes



  • 5cm x 6cm (ported)

  • 6cm x 7cm

  • 7cm x 9cm (ported)

  • 9cm x 12cm (ported)

  • 10cm x 12cm

  • 11cm x 14cm (ported)


Use



  • A sterile film for fixation over intravenous catheter sites


Application



  • Do not apply under tension


Cautions



  • Not for use on deep cavity wounds

19.04 Vapour permeable film Hydrofilm® dressing

Sizes



  • 6cm x 7cm

  • 10cm x 12.5cm

  • 10cm x 15cm

  • 10cm x 25cm

  • 12cm x 25cm

  • 15cm x 20cm

  • 20cm x 30cm


Use



  • Dry non-infected wounds, retention of lines fixation as secondary dressings protection of intact skin, post-operative wounds, protection of skin against friction, protection of newly epithelialized wounds.


Application



  • Up to 7 days


Cautions



  • Clinically infected wounds bleeding or exiting exuding wounds


 

07.04.05 Vardenafil 

SLS Criteria still apply

Formulary Dose: One tablet weekly prn

With evidence reviews showing no real benefit of one PDE-5 inhibitor over another, sildenafil coming off patent with the associated reduced cost and the revised DoH guidance removing the SLS criteria for sildenafil, sildenafil is the first line PDE-5 inhibitor.

The use of a PDE-5 inhibitor after radical prostatectomy is not supported in this unlicensed indication.

14.05.02 Varicella-Zoster vaccine 

  • Brands include: Varilrix® and Varivax®.

15.01.05 Vecuronium Bromide 
01.05.03 Vedolizumab Entyvio®

In line with NICE TA342 and TA352
Approved for the use of vedolizumab for both Crohn’s and ulcerative colitis.
(See guidance for further details)

Commissioned by NHS England when used for IBD in Children

08.01.05 Vemurafenib Zelboraf®

Recommended as an option for treating BRAF V600 mutation-positive unresectable or metastatic melanoma only if the manufacturer provides vemurafenib with the discount agreed in the patient access scheme, in line with NICE TA269.


Commissioned by NHSE

08.01.05 Venetoclax  Venclyxto®

For treating chronic lymphocytic leukaemia as per NICE TA487 

For previously treated chronic lymphocytic leukaemia in combination with Rituximab as per NICE TA561 

04.03.04 Venlafaxine 
04.03.04 Venlafaxine modified-release 

First choice should be a non modified-release preparation but where a modified release preparation is required Vensir® XL capsules should be the first choice modified release preparation.


Venlalic® XL tablets available if an alternative product is required e.g. due to availability issues.

02.06.02 Verapamil Hydrochloride 
11.08.02 Verteporfin Visudyne® In Line With NICE TA68
04.08.01 Vigabatrin 

For use in Paediatrics
 
Supported with a ESCA

MHRA Category 3 - It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors

08.01.04 Vinblastine Sulphate 
08.01.04 Vincristine Sulphate 
08.01.04 Vindesine Sulphate 
08.01.04 Vinorelbine  
A2.01.02.01 Vital 1.5kcal 

for tube fed patients under care of dietitian

09.06.02 Vitamin B Tablets (Compound Strong) 

• Oral thiamine is recommended by both NICE and the Scottish Intercollegiate Guidelines Network (SIGN) for patients who have a chronic alcohol problem and whose diet may be deficient.
• NICE recommends prescribing prophylactic oral thiamine for harmful or dependent drinkers if they are malnourished, at risk of malnourishment, they have decompensated liver disease, are in acute withdrawal or before and during a planned medically assisted alcohol withdrawal.
• The guidelines recommend prescribing thiamine in doses toward the upper end of the BNF dosage (for mild deficiency 25–100 mg daily and for severe deficiency, 200–300 mg daily in divided doses).
• They DO NOT RECOMMEND the prescribing of vitamin B complex preparations.
If it is considered that the prescribing of a vitamin B complex preparation is justifiable the vitamin B compound strong tablets represent a more cost effective option that vitamin B compound tablets.

05.02.01 Voriconazole 

Commissioned by NHS England.

04.03.04 Vortioxetine 

In line with NICE TA367
 

A2.05.01 VSL#3 (probiotic) 

Probiotic bacteria for the treatment of chronic, frequently-recurring pouchitis where remission is induced by antibiotics. GI consultant recommendation only

02.08.02 Warfarin Sodium 
09.02.02.01 Water for Injection 
06.01.06 Wavesense JAZZTM Duo blood glucose test strips 

For patients with Type 2 Diabetes

19.02 Wound contact - Super absorbent cellulose and ploymer primary dressing Zetuvit Plus ®

Sizes



  • 10cm x 10cm

  • 10cm x 20cm

  • 15cm x 20cm

  • 20cm x 25cm

  • 20cm x 40cm


Use



  • Moderate to heavily exuding acute and chronic wounds secondary dressing only.


Application



  • 1-7 days.

  • If changing daily review if needs more highly absorbent dressing.

  • If lasting 7 days step down to Zetuvit E


Cautions



  • Known product or component sensitivity.


Tips



  • Do not cut or tear

19.02 Wound contact layer - absorbent perforated Softpore ®

Sizes



  • 6cm x 7cm

  • 10cm x 10cm

  • 10cm x 15cm

  • 10cm x 20cm

  • 10cm x 25cm

  • 10cm x 30cm

  • 10cm x 35cm


Use



  • Low to moderately exuding wounds

  • Superficial wounds (closed)

  • Light amounts of exudate

  • As a protective dressing for sutured post-operative wounds or for newly epithelialized wounds and minor traumatic wounds.


Application



  • Leave for maximum 7 days. Review dressing type if changing daily.


Cautions



  • Known product or component sensitivity.


Tips



  • Use alone without other products

19.02 Wound contact layer absorbent cellulose Zetuvit E® sterile & non-sterile dressing

Sizes for non sterile & sterile



  • 10cm x 10cm

  • 10cm x 20cm

  • 20cm x 20cm

  • 20cm x 40cm


Use



  • Moderate exudating wounds as a secondary dressing.

  • Only sterile to be used in wound care.  

  • Non-sterile can be used in wet leaky legs where no leg ulcer is present

  • Can be used under compression.


Application



  • 1-7 days

  • Usually 1-2 days or when wet

  • If using daily, consider Zetuvit Plus®


Cautions



  • Do not cut or tear.


 

19.16 Wound drainage pouch Option® wound manager bag (Oakmed Ltd)

Size



  • Various sizes


Use



  • Complex abdominal wounds, moderate to large fistulas, orthopaedic wounds or fungating wounds with high levels of exudate that are unmanaged with conventional dressings.

  • For highly exuding wounds where conventional dressings cannot manage exudate.


Application



  • Empty drainage bag asrequired.

  • If no port for drainage, change as required.

  • To be used as long as adhesive remains.


Caution



  • Known product component sensitivity to hydrocolloid, (gelatin and pectin)

  • Any wound where a conventional dressing cannot manage the exudate levels.

12.02.02 Xylometazoline Hydrochloride Otrivine®

  • Short term use only.

  • Adult and paediatric

  • Patients with conditions suitable for self care should be advised to buy over the counter, in line with NHSE&I guidance.

01.07.02 Xyloproct® 
04.01.01 Zaleplon 

In Line With NICE TA77

05.03.04 Zanamivir Relenza®

In Line With NICE TA158 (Replaces TA67) and TA168 (Replaces TA15 and TA58)

05.03.04 Zanamivir aqueous solution 10mg/mL (GSK) 

Treatment is recommended within Public Health England (PHE) guidance on the use of antiviral agents for the treatment and prophylaxis of seasonal influenza.

For the treatment of critically ill adults and children having a life-threatening condition due to suspected or confirmed pandemic A(H1N1)v infection or infection due to seasonal influenza A or B virus and answering to the following criteria:

·  Patients not responding to either oral or inhaled authorised antiviral medicinal products or

·  Patients for whom drug delivery by a route other than IV (e.g. oral oseltamivir or inhaled zanamivir) is not expected to be dependable or is not feasible, or

·  Patients infected with documented oseltamivir-resistant influenza virus and not suitable for therapy with inhaled zanamivir.

13.02.01 ZeroAQS® Cream 

Similar to Aqueous Cream. SLS free.

13.02.01 Zerobase® Cream 

Similar to Diprobase®

13.02.01 Zeroderm® Ointment  

Similar to Epaderm® and Hydromol® ointments

13.02.01 Zerodouble® Gel 

Equivalent to Doublebase® Gel

05.03.01 Zidovudine 

Commissioned by NHS England.

05.03.01 Zidovudine and Lamivudine 

Commissioned by NHS England.

09.05.04 Zinc Sulphate Solvazinc®

To treat deficiency only

06.06.02 Zolendronic acid 
04.07.04.01 Zolmitriptan 
04.01.01 Zolpidem Tartrate Tablets 

In Line With NICE TA77

04.08.01 Zonisamide 

MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history

04.01.01 Zopiclone Tablets 

In Line With NICE TA77

04.02.01 Zuclopenthixol Acetate Injection 
04.02.02 Zuclopenthixol Decanoate Clopixol®
04.02.02 Zuclopenthixol Decanoate Clopixol® Conc.
04.02.01 Zuclopenthixol Dihydrochloride Tablets 
Herefordshire & Worcestershire